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Abstract 
Ovarian cancer is usually diagnosed in the advanced stages when the cancer has 
metastasised making it one of the most common gynaecological cancers with a high 
mortality rate. The development of drug resistance in such cancers is unfavourable. The 
aim of this study was to produce biomarkers of drug resistance in ovarian cancer, which 
can be used to identify a drug-resistant phenotype in patients allowing for alternative 
treatments besides the first-line choices of carboplatin and paclitaxel.  
Various methods were used in the study from western blotting to analyse protein 
expression, epithelial antigen staining to assess epithelial state of cell, scratch assays to 
determine drug-resistant phenotype, MTT assays to assess drug-inhibitor responses, 
Annexin V-FITC apoptosis detection assay for cell viability assessment, gene silencing 
assays to assess drug sensitivity on gene silencing and qPCR array led approach to 
identify genes upregulated in drug-resistant cell lines.   
Using an EMT-led approach, analysis of five common EMT markers led to the 
determination of SLUG as a probable biomarker with E-CADHERIN and β-CATENIN as 
possible biomarkers. Examination of the downstream signalling proteins of the MET 
receptor revealed RAC1 could be another possible biomarker. Using the qPCR-led 
approach, a list of upregulated genes in drug-resistant cell lines was produced with further 
protein analyses revealing ZEB1, STAT3 and WNT proteins as possible biomarkers. As 
EMT was used as a starting point to identify markers of drug resistance, to determine its 
association with drug resistance, a drug-resistant cell line model was produced through the 
induction of EMT.  
In conclusion, this study has produced a list of possible biomarkers of drug resistance in 
ovarian cancer fulfilling its aims. Further investigation of the biomarkers beyond the use of 
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cell models could determine their reliability as biomarkers of drug resistance in ovarian 
cancer in the clinical setting. 
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1.1 CANCER 
A collection of cells that have grown out of control is termed a tumour (National Cancer 
Institute, 2015). There are two main types of tumours: benign and malignant. Benign 
tumours are incapable of invading other tissues. In contrast, malignant tumours are 
capable of invading other tissues and migrating to distant sites. It is this type of tumour that 
gives rise to cancer. Cancer is defined as an uncontrollable growth of cells capable of 
invading neighbouring tissues (Figure 1.1) (World Health Organisation, 2018).  
 
 
 
 
 
 
 
 
 
It is considered a genetic disease as cells begin to grow abnormally out of control due to 
defects in the genes that govern the body’s cells (National Cancer Institute, 2015). As a 
result, in some cases, cancer can be inherited due to the passing down of faulty genes 
from parent to child. However, cancer can also occur in a person with no family history of 
cancer. This can be due to errors that occur during cell division or damage to the cell’s 
DNA via exposure to environmental agents (e.g. tobacco smoke and radiation). While 
 Figure 1.1: Cancer cells are capable of uncontrolled proliferation 
unlike non-cancerous cells [Original Figure] 
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research has advanced and survival rates are better than they were 50 years ago, cancer 
is still a leading cause of mortality worldwide (World Health Organisation, 2018).   .   
In 2012, there were approximately 14 million new cancer cases diagnosed with 8 million 
associated deaths worldwide. In addition to this, around 32 million people were living with 
cancer within 5 years of diagnosis (World Health Organisation: International Agency for 
Research on Cancer, 2018, Ledermann et al., 2013). In England, in 2016, 303,135 new                      
cases of cancer were registered (Figure 1.2). This is approximately equal to about 830 
cases being diagnosed every day in 2016. 148,116 of the cases were diagnosed in women 
of which 6430 of the cases were for ovarian cancer (Office for National Statistics, 2016).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: National statistics for cancer in England in 2016 
The statistical data available on the different types of cancers that were 
registered in 2016 in England (Office for National Statistics, 2016). 
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1.2 OVARIAN CANCER 
 
In 2015, ovarian cancer was listed as the sixth most frequent type of cancer in women and 
the second most frequent gynaecological cancer in the UK with 7270 new recorded cases 
(Figure 1.3) (Cancer Research UK, 2015).  
 
 
 
  
 
 
 
 
 
 
 
 
 
        
 
The reason for ovarian cancer being one of the most frequent gynaecological cancers with 
a high mortality rate is that it is commonly diagnosed in the late stages when the disease 
has metastasised. Data collected from ovarian cancer patients from the former Anglia 
Cancer Network between 2002 and 2006 showed that while the five-year survival rate for 
patients diagnosed at stage one was approximately 90%, the five-year survival rate for 
those diagnosed at stage four was only 4% (Figure 1.4) (Cancer Research UK, 2016). On 
a global scale, data showed that there was a 80% survival chance with early stage 
Figure 1.3: Number of new cases for the ten most common cancers in females 
in the UK in 2015 
 (Cancer Research UK, 2015) 
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diagnoses (non-metastasised) and a 30% survival chance with late stage diagnoses 
(metastasised cancer) (Matz et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Classification of Ovarian Cancer 
The stages of ovarian cancer have been determined by various classification systems, 
which are based on characteristics exhibited by the tumour. There are three main 
classification systems used to classify ovarian cancer: the FIGO (International Federation 
of Gynaecology and Obstetrics) system is based on the assessment of architectural 
features, the World Health Organisation system is based on the assessment of both 
architectural and cytological features and the Shimizu/Silverberg system is based on the 
assessment of architectural features, the degree of atypical cytological features as well the 
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Figure 1.4: Percentage of women surviving ovarian cancer at five years 
Percentage of women surviving ovarian cancer at five years decreases as 
the stage of ovarian cancer increases [Original figure produced from 
information taken from Cancer Research UK, 2016] (Cancer Research UK, 
2016). 
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mitotic index. The most common system in use is the FIGO classification system (Roy and 
Cowden Dahl, 2018).  
There are four stages of ovarian cancer designated by the FIGO system. The first stage is 
cancer confined to one or both of the ovaries. The second stage involves cancer in one or 
both ovaries with spread to the pelvic region or primary peritoneal cancer. The third stage 
is when the cancer involves one or both ovaries with metastasis to the peritoneum outside 
the pelvis and/or to the retroperitoneal lymph nodes. The fourth and last stage is 
metastasis to distant organs/locations. Each of the four stages are then divided into further 
sub-stages (Table 1.1) (Society for Gynecologic Oncology, 2014). 
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Stage Sub-
stage 
 Description 
I IA  Tumour limited to one ovary, capsule intact, no tumour on 
surface, negative washings. 
IB  Tumour involves both the ovaries, capsule intact, no tumour 
on surface, negative washings. 
IC IC1 Tumour limited to one or both ovaries, surgical spill. 
IC2 Tumour limited to one or both ovaries, capsule rupture before 
surgery or tumour on ovarian surface. 
IC3 Tumour limited to one or both ovaries, malignant cells in the 
ascites or peritoneal washings. 
II IIA  Extension and/or implant on uterus and/or fallopian tubes. 
IIB  Extension to other pelvic intraperitoneal tissues. 
III IIIA IIIA1 Positive retroperitoneal lymph nodes only, metastasis ≤ 
10mm. 
Positive retroperitoneal lymph nodes only, metastasis > 
10mm. 
IIIA2 Microscopic, extrapelvic (above the brim) peritoneal 
involvement ± positive retroperitoneal lymph nodes. 
IIIB  Macroscopic, extrapelvic, peritoneal metastasis ≤ 2 cm ± 
positive retroperitoneal lymph nodes. Includes extension to 
capsule of liver/spleen. 
IIIC  Macroscopic, extrapelvic, peritoneal metastasis > 2 cm ± 
positive retroperitoneal lymph nodes. Includes extension to 
capsule of liver/spleen. 
IV IVA  Pleural effusion with positive cytology. 
IVB  Hepatic and/or splenic parenchymal metastasis, metastasis 
to extra abdominal organs (including inguinal lymph nodes 
and lymph nodes outside of the abdominal cavity). 
 
 
 1.2.2 Subtypes of Ovarian Cancer 
Besides being divided into four stages, ovarian cancer is also divided into non-epithelial 
and epithelial subtypes based on histological features (Bast Jr and Romero, 2012). Non-
epithelial ovarian cancers account for 10% of all ovarian cancer cases. The majority of 
cases diagnosed are epithelial ovarian cancers (EOC).   
 
 TABLE 1.1: FIGO Classification for Ovarian Cancer 
(Society of Gynecologic Oncology, 2014). 
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1.3 EPITHELIAL OVARIAN CANCER (EOC) 
Epithelial ovarian cancer (EOC) is divided into several subtypes: serous (high grade and 
low grade), endometroid, mucinous, clear cell, transitional cell (Brenner), mixed epithelial 
tumours, mixed mullerian tumours (MMT), undifferentiated and unclassified (Ledermann et 
al., 2013, Gore et al., 2014, Scully et al., 1999).  
The four major subtypes of EOC are serous, endometroid, mucinous and clear cell (Figure 
1.5) (Bast Jr and Romero, 2012). Serous EOC originates from the epithelial lining of the 
fallopian tubes, endometroid EOC arises from the endometrium, mucinous EOC arises 
from the endocervix and clear cell EOC arises from the vagina (Cho and Shih, 2009).  80% 
of diagnosed EOC cases comprises of serous EOC and it is the most common subtype of 
ovarian cancer (Ledermann et al., 2013).   
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Figure 1.5: Main histotypes of epithelial ovarian cancer 
The above figures represent the four main histotypes of epithelial ovarian 
cancer. Serous is divided into low grade and high grade and arises from the 
lining of the fallopian tubes, endometroid from the endometrium, mucinous 
from the endocervix and clear cell from the vagina [Figure adapted from Cho 
& Shih (2009)].  
  6278156 
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1.3.1 Type I and Type II Epithelial Ovarian Cancer 
In 2004, Shih & Kurman (2004) proposed a tumour progression model for EOC (Shih and 
Kurman, 2004). By looking at both clinical and molecular studies, they devised a system 
based on two main pathways of tumourigenesis in EOC. Based on this model, they divided 
the EOC subtypes into Type I and Type II categories. Since the proposal of this model, 
they have gone onto revise and expand the said model (Kurman and Shih, 2016). The new 
updated model is summarised in Table 1.2. 
Table 1.2 Revised dual pathogenesis model proposed by Kurman and Shih 
Characteristic type Type I Type II 
Stage Mostly early stage Mostly advanced stage 
Tumour grade Low grade High grade 
Proliferation rate Low High 
Chemotherapy response Fair Good (recurrence later) 
Early detection Possible Difficult 
Progression rate Slow and indolent Rapid and Progressive 
Overall clinical outcome Good Poor 
TP53 mutations Infrequent Frequent  
Homologous 
recombination repair 
Rarely defective Frequently defective 
(Selective information adapted into table from Kurman & Shih (2016) 
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Based on the new revised model, the subtypes of EOC are divided as follows: 
TYPE I TYPE II 
Low grade serous High grade serous 
Endometroid Undifferentiated 
Mucinous  
Clear cell  
Mixed Mullerian Tumours (MMT)  
Transitional cell (Brenner)  
       (Kurman and Shih, 2016) 
        
Type I EOC tends to have mutations in several genes such as KRAS, BRAF and ARID1A 
among others (Table 1.3) (Jayson et al., 2014). TP53 and BRCA1 & 2 genes are not 
usually mutated in this particular group (Bast Jr and Romero, 2012).  Type II cancers all 
tend to have p53 gene mutations and most also have mutations in the BRCA1 & 2 genes. 
ERBB2 overexpression can also occur (Roy and Cowden Dahl, 2018). There are no 
distinctive differences in the genetic mutational makeup between the different Type II 
tumours unlike with the Type I tumours and they also do not have genetic mutations of 
commonly mutated genes in Type I tumours such as KRAS and PI3KCA. These type II 
tumours, while initially responsive to chemotherapy, will eventually become resistant with 
each recurrence episode (Jayson et al., 2014).   
 
Table 1.3: Genetic mutations in the different types of Type I epithelial ovarian 
cancer 
The table below lists the different genetic mutations that affect the different types 
of Type I epithelial ovarian cancers [Data in table adapted from (Jayson et al., 
2014)]. 
Low-grade 
serous 
Low-grade 
endometroid 
Clear cell Mucinous 
BRAF ARID1A ARID1A KRAS 
KRAS PI3KCA PI3KCA ERBB2 amplification 
NRAS PTEN PTEN  
ERBB2 PPP2R1A CTNNB1  
  PP2R1A  
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1.4 CHEMOTHERAPY IN OVARIAN CANCER 
The common treatment strategy used for ovarian cancer is surgery and chemotherapy 
(Jayson et al., 2014). Standard first line-chemotherapy treatment for ovarian cancer for the 
last 20 years has consisted of a platinum-based drug (carboplatin) and a taxane 
(paclitaxel). With platinum drug treatment, a relapse within 6 months of the last platinum-
based treatment is considered platinum-resistant no longer responding to platinum-based 
treatment. 
1.4.1 Platinum drugs 
The first platinum drug to be used in the treatment of ovarian cancer was cisplatin 
(Rosenberg, 1980). Cisplatin enters the cells via copper transporters present on the cell 
membrane and once inside the cell, it undergoes a hydrolysis reaction, where its chloride 
atoms were replaced by water molecules (Tapia and Diaz-Padilla, 2013). This activated 
form of cisplatin would then exert its cytotoxic effects by binding to the nitrogen of 
guanosine bases of adjacent DNA strands (Figure 1.6).  
 Figure 1.6: Formation of adducts in the DNA by platinum drugs 
Here, cisplatin forms adducts through the nitrogen atoms of the guanosine 
bases of the adjacent DNA strands. This prevents the DNA from uncoiling and 
undergoing replication and later, transcription. The consistent damage caused 
by the adduct formation eventually leads to the induction of cell death (Costi et 
al., 2011). [Original Figure] 
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However, the use of cisplatin led to the development of serious side effects including 
kidney damage (Connors et al., 1972). Due to the toxic side effects experienced, a search 
of platinum-based compounds led to the discovery of carboplatin with a much less serious 
side effects profile.   
Carboplatin has now become the first-line treatment for patients with ovarian cancer (Di 
Pasqua et al., 2012). Its structure differs to cisplatin by the absence of the chloride atoms. 
Instead, it consists of a platinum atom forming a complex with two ammonia groups and a 
cyclobutane-dicarboxyl residue (Figure 1.7). It works the same way cisplatin does (Sousa 
et al., 2014). It undergoes a hydrolysis reaction once it enters the cell where its 
cyclobutane-dicarboxyl residue is replaced by water molecules. It will then bind to the 
purine bases of the DNA forming DNA adducts. 
 
 
 
 
 
  
 
 
 
 
 
Cisplatin Carboplatin 
Figure 1.7: Structure of cisplatin and carboplatin 
Carboplatin, replacing cisplatin as the main platinum-based treatment in 
ovarian cancer, consists of a platinum atom connected to two ammonia 
groups and a cyclobutane-dicarboxylate. This form was found to be much 
less neurotoxic and nephrotoxic than its parent form, cisplatin. The 
cyclobutane-dicarboxylate ring structure made carboplatin more stable 
than cisplatin with its two chloride atoms (Di Pasqua et al., 2012). [Original 
Figure] 
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Platinum drugs can form both intra- and inter-strand adducts and the formation of these 
adducts prevents the DNA strands from separating as required during replication and the 
consistent inhibition of replication and transcription eventually leads to DNA damage and 
cell death (Sousa et al., 2014). Around 70% of adducts formed are intra-strand adducts 
and these damages are then recognised by DNA-binding proteins, which will either signal 
for the repair of the damage or mark the cell for apoptosis (Tapia and Diaz-Padilla, 2013).   
1.4.2 Paclitaxel 
Better known by its trade name ‘Taxol’, Paclitaxel is the first-line choice for a taxane in the 
treatment of ovarian cancer (Figure 1.8) (Jayson et al., 2014). It is also used in the 
treatment of other cancers such as breast and lung cancer (Weaver, 2014). Extracted from 
the bark of a Pacific yew tree, it works by preventing cell division.   
 
 
 
 
 
 
Paclitaxel works by targeting the microtubule assembly that forms during cell division 
(Kampan et al., 2015). Tubulin dimers form this assembly and paclitaxel binds to the 
tubulin stabilising the structure. The binding of paclitaxel to the microtubule structure 
prevents the depolymerisation of the structure, which is necessary for the process of cell 
division to proceed. This inhibits cell division triggering cell death. It can also trigger 
apoptosis by binding to and causing the phosphorylation of anti-apoptotic Bcl-2 protein, 
preventing it from exerting its anti-apoptotic effects.  
Figure 1.8: Structure of 
Paclitaxel 
Paclitaxel, also known by its 
trade name Taxol, is a taxane 
that is used to treat various 
cancers such as ovarian and 
breast cancer (Brody, 2012) 
(Weaver, 2014).  
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In ovarian cancer, survival probability and a positive prognosis is dependent on both the 
stage at diagnosis as well as the possibility of the onset of drug resistance (Norouzi-
Barough et al., 2018). Around 75% of ovarian cancer patients who achieve complete 
remission with initial chemotherapy will suffer a relapse within two years failing to respond 
to subsequent drug treatment due to the development of drug resistance. Therefore, due 
to the high number of drug-resistant cases, a better understanding of drug resistance in 
ovarian cancer is required to provide effective treatment. 
 
1.5 DRUG RESISTANCE IN CANCER 
Chemotherapy plays a very important role in cancer treatment and management. 
Therefore, the onset of drug resistance is a serious issue affecting the outcome of 
treatment. Pharmacokinetic factors such as the solubility, systemic distribution, 
metabolism and the elimination of a drug may affect the concentration of the drug reaching 
its final target and therefore, its effectiveness (Holohan et al., 2013). The onset of cellular 
drug resistance will only serve to weaken the already affected pharmacodynamics of the 
drug. 
Drug resistance can be divided into two types: intrinsic and extrinsic (Holohan et al., 2013). 
Intrinsic drug resistance is when the tumours being targeted in the treatment are already 
resistant to the drug. Extrinsic drug resistance is resistance that eventually develops in 
initially sensitive tumours during treatment.  
Intrinsic drug resistance 
Intrinsic drug resistance, also known as de novo drug resistance, refers to drug resistance 
that exists before the delivery of chemotherapeutic treatment (Liu et al., 2012). In many 
cancers, patients can respond poorly to chemotherapy from the beginning of their 
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treatment (Nikolaou et al., 2018) and this is due to intrinsic drug resistance. For example, 
patients whose tumours exhibit high levels of drug metabolising enzymes will be 
intrinsically resistant to drug treatment (Cummings et al., 2003). One such example is the 
UDP-glucuronosyltransferse (UGT) enzyme. The expression of UGTs in colon cancer 
biopsies were at a higher level when compared to the normal colon. Due to their high 
expression levels, SN-38 and NU/ICRF 505 (two topoisomerase I inhibitors used in colon 
cancer treatment) were inactivated through glucuronidation displaying a mechanism of intrinsic 
drug resistance in this cancer. Another mechanism of intrinsic drug resistance is seen in renal 
cancer, where multidrug resistance protein 1 (MDR1) was found to be expressed in high levels 
in the normal kidney and in renal cancer cell lines (Fojo et al., 1987). MDR1 is an ATP Binding 
Cassette (ABC) transporter capable of transporting substrates across the cell membrane and 
therefore, plays a role in drug efflux resulting in drug resistance (Hristos et al., 2004). However,  
intrinsic drug resistance can exist due to more than one factor due to tumour heterogeneity 
as the cancer cells that make up a tumour have their own genetic profiles (Gottesman, 
2002).  This heterogeneity can be contributed to by the varying populations of cancer stem 
cells within the tumour as well as differences in gene expression levels, which can lead to 
varying levels of particular proteins (Liu et al., 2012), all of which can affect drug 
resistance. Cancer stem cells can contribute to drug resistance by the increased 
expressions of transporter proteins and detoxification enzymes, the enhanced inhibition of 
apoptotic pathways (such as those mediated by TP53) and the increased activity of DNA 
damage response pathways (Nikolaou et al., 2018). Factors such as drug metabolism, 
changes to the drug target and changes to cellular transport of the drug (drug influx and 
efflux) (Nikolaou et al., 2018) affected by differential protein expression levels are other 
intrinsic drug resistance mechanisms (Liu et al., 2012). DNA damage response 
mechanisms, which exist in all cells, are another example of intrinsic drug resistance 
(Curtin, 2012). 
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Extrinsic drug resistance 
Extrinsic drug resistance, also known as acquired drug resistance, refers to drug 
resistance that develops after chemotherapy treatment has begun (Nikolaou et al., 2018). 
Patients with extrinsic drug resistance will respond well to chemotherapy initially, but begin 
to respond poorly with time due to the development of drug resistance. Extrinsic drug 
resistance is brought about by genetic and tumour microenvironmental changes that occur 
due to repeating chemotherapy (Nikolaou et al., 2018, Liu et al., 2012). This indicates the 
drug resistance is acquired rather than intrinsic. Tumours, initially responsive to 
chemotherapy, can gain DNA mutations over time which affect various mechanisms such 
as drug inactivation, DNA damage response and apoptosis leading to acquired (extrinsic) 
drug resistance (Housman et al., 2014).  Growing tumours are generally characterised by 
an abnormal vasculature and increasing interstitial fluid pressure (Nikolaou et al., 2018). 
Abnormal vasculatures and the increasing fluid pressure can affect the distribution of 
oxygen and nutrients as well as impeding the removal of metabolites. These situations can 
lead to hypoxic and acidified conditions (unfavourable for drug activity) which can lead to 
extrinsic drug resistance.  
Recently, epithelial-mesenchymal transition (EMT) has come to be associated with drug 
resistance (Housman et al., 2014). It is a process that involves changes in the expression 
levels of various genes and therefore, proteins, which can play a role in drug resistance 
through differential activations of various signalling pathways associated with cell survival 
and the inhibition of apoptosis.   
Ultimately however, a patient’s drug resistance is complex and may be contributed to by 
not just one factor, but several, which makes it a multi-drug resistance phenomena (Gillet 
and Gottesman, 2010). Therefore, an understanding of the various drug resistance 
mechanisms (both intrinsic and extrinsic) is vital in order to combat drug resistance.  
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1.5.1 Mechanisms of Drug Resistance 
There are several mechanisms a cell can adopt to resist a drug’s effects (Figure 1.9). 
These include inactivating the drug, altering the target of the drug, drug efflux, the repair of 
damaged DNA (caused by drug) and inhibiting cell death initiated by the drug (Housman et 
al., 2014). 
Figure 1.9 Mechanisms of drug resistance in cancer 
 
1.5.1.1 Inactivation of drug 
Some drugs are administered in its inactive form becoming active only when it interacts 
with other contents present inside a cell’s cytoplasm (Housman et al., 2014). These 
interactions will lead to a modification of the drug’s structure activating it (e.g. platinum 
drug activation by hydrolysis within the cell (Tapia and Diaz-Padilla, 2013)).  Cells can 
develop drug resistance to the drug by preventing such activation (Figure 1.10).  
Cytarabine (AraC), a nucleoside drug, used to treat acute myelogenous leukaemia, 
becomes active on phosphorylation. By targeting the phosphorylation pathway, drug 
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resistance is developed due to decreased phosphorylation resulting in a reduced 
concentration of activated drug (Sampath et al., 2006).  
Drug-metabolising enzymes are overexpressed in drug-resistant cancers and these 
enzymes can detoxify chemotherapeutic drugs (Norouzi-Barough et al., 2018). Their 
detoxification actions will reduce the intracellular concentration of the active form of the 
drug, which will reduce the efficacy of the treatment. The glutathione-S-transferase (GST) 
superfamily consists of enzymes involved in such detoxification (Housman et al., 2014).  
An upregulation in the expression of these enzymes can lead to an increased 
detoxification of chemotherapeutic drugs such as cyclophosphamide resulting in inefficient 
cytotoxic effects (Peters and Roelofs, 1997). GSH-S-transferase π (GSTPi) enzyme 
mediates the conjugation of glutathione (present in the cytoplasm) to cisplatin rendering 
the cisplatin inactive (Tew, 1994). Sakamoto et al. (2001) found that levels of GSTPi 
increased as the level of resistance to cisplatin increased in ovarian cancer (Sakamoto et 
al., 2001). Knocking down GSTPi resulted in an increased sensitivity towards cisplatin and 
carboplatin (Sawers et al., 2014). These show how detoxification systems within the cell 
can contribute to drug resistance.  
The UGT superfamily are a family of enzymes that catalyses glucuronidation, which is a 
part of the metabolism process (Housman et al., 2014). The glucuronidation process can 
lead to the inactivation of chemotherapeutic drugs. Irinotecan is used in the treatment of 
colon cancer (Gagnon et al., 2006). Its active form, SN-38, is subjected to glucuronidation 
through the activity of the metabolising enzyme, UGT1A1. Demethylation of the UGT1A1 
gene promoter in HT-29 colon cancer cells exhibited increased formations of the inactive 
SN-38-glucurodnide complexes decreasing the amount of the active form of the drug 
necessary for cytotoxic effects.  These colon cancer cells (HT-29) are abundant in 
UGT1A1, which makes this an intrinsic form of drug resistance. Their presence in colon 
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cancer biopsies at a higher level compared to the normal colon (Cummings et al., 2003), 
further highlights the role of UGT enzymes in intrinsic drug resistance in colon cancer.  
1.5.1.2 Alteration of the drug target 
The drug target and any changes to it will determine the effectiveness of the drug 
(Housman et al., 2014). Therefore, specific changes to the drug target site will induce drug 
resistance (Figure 1.10). Some chemotherapeutic drugs function by targeting the enzyme, 
topoisomerase II. Topoisomerase II prevents the DNA from becoming either super-coiled 
or under-coiled (Hofmann and Mattern, 1993). These drugs will stabilise the DNA-
topoisomerase II complex, which will result in DNA damage preventing the continuation of 
mitosis. The effectiveness of the drug is dependent on the amount of the active enzyme 
present and therefore, a decrease in the amount of the active enzyme can induce a drug-
resistant nature due to the reduced efficacy of the drug. Cells can also induce resistance 
to such drugs by mutating the topoisomerase II gene (Hinds et al., 1991). On analysing the 
genetic sequence of the topoisomerase II gene of a drug-resistant leukaemia cell line and 
comparing the sequence with that of a drug-sensitive leukaemia cell line, a single base 
change was identified in the resistant cell line that contributed to the drug-resistant 
phenotype. This makes amascrine, used to treat leukaemia and which works by targeting 
topoisomerase II, less effective.  
Another method of drug resistance is signalling proteins, which are important drug targets 
in chemotherapy. Many signalling proteins tend to be overactive in cancers and inhibiting 
such kinases is one chemotherapeutic aim (Montaser and Coley, 2018). Montaser & Coley 
(2018) showed that the induction of tamoxifen resistance in breast cancer cells was 
accompanied by an upregulation in the expression levels of the HER2 receptor, indicating 
a mechanism of extrinsic (acquired) drug resistance to tamoxifen in breast cancer. The 
use of tyrosine kinase inhibitors increased the cells’ sensitivity to drug treatment showing 
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the role signalling protein kinases play as drug targets in drug resistance. Such a method 
of drug resistance was also observed with trastuzumab in HER2-positive breast cancer 
(O'Brien et al., 2010). Here, the induction of drug resistance to trastuzumab was also 
accompanied by an increase in HER2 protein expression levels indicating an acquired 
drug resistance mechanism to trastuzumab in breast cancer. Trastuzumab works by 
inhibiting the PI3K/AKT signalling pathway resulting in the inhibition of cell growth and 
proliferation (Vu and Claret, 2012). The increased phosphorylation of the downstream AKT 
protein was obsverved to play a role in trastuzumab resistance (O'Brien et al., 2010). 
Other mechanisms of trastuzumab resistance was identified as phosphotidylinositol 3-
kinase (PI3KCA) mutations and the loss of tumour suppressors such as Phosphatase and 
Tensin homolog (PTEN), which are other components of the downstream signalling part of 
the pathway. These actions would lead to the constitutive activation of the PI3K/AKT 
pathway blocking cell death (O'Brien et al., 2010). Both these studies indicate that HER2 
receptor overexpression is a possible mechanism of extrinsic drug resistance in breast 
cancer. 
Changing drug target enzyme levels can also contribute to drug resistance (Housman et 
al., 2014). Fluorouracil, when activated, forms a complex with the enzyme, thymidylate 
synthase, which results in the reversible inactivation of the enzyme (Zhang et al., 2008). 5-
fluorouracil is an anticancer drug used in the treatment of colon and breast cancer 
amongst others. When this drug inactivates thymidylate synthase, it stops the production 
of deoxythymidine mono-phosphate (dTMP). dTMP is needed for DNA replication and its 
repair and therefore, the lack of dTMP results in cell cytotoxicity. Drug resistance can be 
induced through the overexpression of the target enzyme, thymidylate synthase, through 
gene amplification and/or mutations (Wang et al., 2001, Kitchens et al., 1999).  
Drug resistance can also be induced through the amplification of the drug target resulting 
in an inability of the treatment drug to inhibit all the target receptors (Housman et al., 
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2014). Amplification of androgen receptors was seen in recurrent prostate cancer tumours. 
The amplification was absent in tumours taken from the same patients before therapy 
(Visakorpi et al., 1995) indicating that such amplification of the receptors is probably an 
example of extrinsic drug resistance in prostate cancer. A recurrent tumour from a patient 
undergoing androgen-deprivation therapy with the use of bicalutamide displayed amplified 
androgen receptor targets compared to the before-treatment tumour (Palmberg et al., 
1997). Paclitaxel works by binding to β-tubulin subunits stabilising the microtubule complex 
arresting cells in the G2/M phase of the cell cycle leading to apoptosis (Kampan et al., 
2015). Cells can exhibit resistance towards paclitaxel by targeting the β-tubulin (Kamath et 
al., 2005). Paclitaxel-resistant cells have increased expression levels of β-III tubulin, which 
reduces the ability of paclitaxel to prevent microtubule depolymerisation. Point mutations in 
β-I tubulin were also identified in two paclitaxel-resistant ovarian cancer cell lines 
(Giannakakou et al., 1997).Therefore, such changes in the paclitaxel target will reduce 
efficacy of the drug making the cell more resistant to it.   
1.5.1.3 Changes to drug transporters – drug efflux and influx  
Transporter proteins present on the cell membrane can play a role in the development of 
drug resistance (Housman et al., 2014). The binding of a substrate to one of these 
transporters leads to a conformational change in its structure, which pumps the substrate 
in or out of the cell. In cancer, such transporters can increase the amount of drug pumped 
out of the cells or decrease the amount of drug pumped into the cells (Figure 1.10). The 
decreased intracellular drug concentration will contribute to a decreased drug efficacy.  
There are three well studied such transporters called ABC proteins associated with drug 
resistance: multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 
1 (MRP1) and breast cancer resistance protein (BCRP). 
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Increased expression levels of MDR1 were seen in lung cancer cells with doxorubicin 
treatment, while no such increase was observed in the normal lung counterparts 
(Abolhoda et al., 1999) displaying an extrinsic drug resistance mechanism in lung cancer. 
The overexpression of p-glycoprotein (also known as MDR1) was seen in paclitaxel-
resistant ovarian cancer (Zhang et al., 2016). The use of a p-glycoprotein inhibitor with 
paclitaxel to treat p-glycoprotein-overexpressing paclitaxel-resistant ovarian cancer cells 
saw a decrease in cell viability making these cells more sensitive to the effects of 
paclitaxel. Similarly, paclitaxel-resistant cells were also found to have a high expression of 
this transporter in another study (Vaidyanathan et al., 2016). When treated with inhibitors 
for this transporter, a reversal in the drug resistance was observed indicating that 
paclitaxel was pumped out in these drug-resistant cell lines. 
A mechanism of intrinsic dug resistance is seen in a study of neuroblastoma where high 
levels of MRP1 were seen in untreated neuroblastoma samples, which was associated 
with poor clinical outcomes (Haber et al., 2006). MRP1 also exhibited intrinsic drug 
resistance in non-small cell lung cancer, where it is overexpressed (Berger et al., 2005). 
Here too, it was associated with poor overall survival rates.  
A study which used Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor that 
blocks BCRP, found that in myelogenous leukaemia cells transfected with BCRP, there 
was an increased accumulation of topotecan in the presence of Gefitinib compared to 
transfected cells not treated with the inhibitor (Yanase et al., 2004). The actions of various 
signalling pathways can also contribute to drug resistance through the regulation of such 
transporters, as is the case with the Hedgehog signalling pathway’s effect on p-
glycoprotein and BCRP in ovarian cancer (Chen et al., 2014). Chen et al. (2014) looking at 
the transcription factor GLI1, which is part of the hedgehog signalling pathway, showed 
that an overexpression of GLI1 was associated with a higher expression of the gene 
encoding the BCRP protein in EOC. It also showed that the cell line with the increased 
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BCRP protein expression was more resistant to cisplatin. They also looked at resistance to 
paclitaxel in EOC. The cell line that had an overexpression of the GLI1 transcription factor 
and an associated higher expression of BCRP was resistant towards paclitaxel treatment. 
Other components can also indirectly contribute to the transporter-associated drug 
resistance (Katayama et al., 2007). For example, the overexpression of downstream 
signalling components of the MAPK pathway, such as c-RAF and ERK1/2, increased the 
expression of p-glycoprotein.   
Copper transporter 1 is a transporter used by platinum drugs to enter a cell (Holzer et al., 
2006, Tapia and Diaz-Padilla, 2013). The deletion of the gene encoding this transporter 
resulted in increased resistance towards cisplatin and carboplatin and a reduction in the 
accumulation of the drug within the cell (Holzer et al., 2006). ATP7A and ATP7B are two 
copper efflux transporters which have been associated with resistance towards cisplatin 
(Tapia and Diaz-Padilla, 2013). ATP7A and ATP7B are overexpressed in ovarian cancer 
cells and patients expressing these proteins have been shown to have low survival rates 
(Nakayama et al., 2002, Samimi et al., 2003). 
The presence of the organic anion transporter protein 1B3 (OATP1B3), an influx 
transporter, results in an increased uptake of cisplatin into the cell (Lancaster et al., 2013). 
It has an increased expression in ovarian cancer cells and the high expression was 
correlated to better cisplatin efficacy in a number of cancer cell lines. Cells with a lower 
expression of this transporter were less sensitive to cisplatin.   
1.5.1.4 Repair of DNA damage 
A mechanism of action of chemotherapeutic drugs is to damage the DNA, which will result 
in the activation of apoptotic pathways leading to cell death (Housman et al., 2014). For 
example, cisplatin works by forming crosslinks within the DNA causing DNA damage and 
eventual cell death (Tapia and Diaz-Padilla, 2013). However, the body does have DNA 
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repair mechanisms in place and the normal response of these repair mechanisms to such 
DNA damage can result in drug resistance (Figure 1.10) (Housman et al., 2014). 
Therefore, the efficacy and resistance to such drugs is also dependent on the efficacy of 
the DNA repair mechanisms. Certain tumours tend to have increased levels of O6-
methylguanine DNA methyltransferase (MGMT) enzyme (Blanc et al., 2004). When 
chemotherapeutic drugs alkylate O6-guanine, MGMT converts it back to guanine 
preventing mismatch of DNA bases (Maier et al., 2009). This results in resistance towards 
certain types of alkylating chemotherapeutic agents. In a study looking at MGMT gene 
silencing in glioblastoma, methylation of the gene promotor resulted in better response to 
temozolomide treatment in glioblastomas (Hegi et al., 2005). In tumours with no 
methylation of the promotor, there was a poorer response to the alkylating agent.   
The nucleotide excision repair (NER) pathway is a repair pathway responsible for the 
repair of damage induced by platinum drugs (Hassan et al., 2014). An increase in a few 
rate-limiting proteins of this pathway can determine the efficacy of platinum drugs. Of 
these proteins, the Excision repair cross-complementation group 1 (ERCC1) protein plays 
an important role. A study comparing mRNA levels between platinum-resistant patients 
and patients who were yet to receive platinum therapy showed that the platinum-resistant 
group had higher mRNA levels of ERCC1 (Dabholkar et al., 1994) and the downregulation 
of ERCC1 was shown to sensitise resistant cells to cisplatin (Selvakumaran et al., 2003).  
As mentioned before, platinum drugs act by forming DNA adducts, which lead to DNA 
double strand breaks (Tapia and Diaz-Padilla, 2013). Double strand breaks are toxic to 
DNA as they damage both strands resulting in the absence of at least one intact strand, 
which could act as a template in repair mechanisms. Cells with such unrepaired breaks will 
be signalled for apoptosis. The homologous recombination (HR) pathway is the main 
pathway to repair double strand breaks. BRCA1 and BRCA2 genes are commonly 
mutated in ovarian cancer and the proteins of these two genes play an important role in 
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the HR pathway. Their binding to other proteins is essential for HR pathway activity and 
mutated BRCA1 and BRCA2 proteins means they cannot bind to the required proteins to 
initiate DNA strand repair. Patients with mutated BRCA in their tumours are said to have a 
better prognoses possibly because they are more sensitive towards drug treatment as 
DNA double strand breaks have a lesser chance of undergoing repair (Mylavarapu et al., 
2018).    
1.5.1.5 Inhibition of apoptosis 
Another method of drug resistance is to target pro-apoptotic proteins (Housman et al., 
2014). Chemotherapeutic drugs promote cell death. Genes of apoptosis-related proteins 
such as tumour suppressor protein p53 (TP53) can be mutated or downregulated inducing 
drug resistance (Figure 1.10) (Hientz et al., 2016). Jun N-terminal kinases (JNKs) promote 
apoptosis by the upregulation of pro-apoptotic genes via the extrinsic apoptotic pathway 
and/or by regulation of other apoptosis-related proteins related to the intrinsic apoptotic 
pathway (Dhanasekaran and Reddy, 2008). The JNK proteins are located downstream of 
the MAPK pathway and the inhibition of this pathway preventing the action of JNKs 
promotes drug resistance (Housman et al., 2014).   
Drug resistance can also be induced by the overexpression of anti-apoptotic proteins such 
as BCL2 (Figure 1.10) (Sartorius and Krammer, 2002). Ovarian cancer patients whose 
tumours expressed the anti-apoptotic protein, BCL-xL (B cell lymphoma-extra large), at the 
time of their diagnoses, had shorter disease-free periods compared to patients who did not 
express the protein (Williams et al., 2005). 88% of recurrent tumours had high expression 
of this protein, which indicates that the expression of protein was increased as a response 
towards chemotherapy treatment (extrinsic drug resistance). The same study also found 
that the overexpression of this protein was associated with a poor response towards 
platinum treatment in an ovarian cancer cell line compared to control cells. Levels of BCL-
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xL was significantly higher and levels of pro-apoptotic proteins, BAX (Bcl-2-associated X) 
and FAS, were significantly lower in platinum-resistant ovarian tumours compared to 
platinum-sensitive ovarian tumours in another study (Chaudhry et al., 2009).  
The upregulation of anti-apoptotic proteins or the downregulation of pro-apoptotic proteins 
can contribute to paclitaxel treatment as well (Norouzi-Barough et al., 2018). 
Overexpression of BCL-xL in an ovarian cancer cell line showed a decreased response 
towards paclitaxel treatment when compared with its control counterpart (Williams et al., 
2005). In the same study, which also looked at ovarian tumours, patients whose tumours 
expressed BCL-xL had decreased periods of disease-free states compared to patients 
whose tumours lacked BCL-xL expression. The expression of another anti-apoptotic 
protein, SURVIVIN, is also associated with paclitaxel resistance in ovarian cancer 
(Zaffaroni et al., 2002). While SURVIVIN expression appeared to have no effect on 
cisplatin treatment, it did have a marked effect on paclitaxel treatment. Drug sensitivity 
profiling showed that two ovarian cancer cell lines transfected with SURVIVIN cDNA 
exhibited decreased sensitivity to paclitaxel treatment compared to the control cell lines.  
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1.5.1.6 Resistance due to epigenetic alterations  
Long non-coding RNA 
Long non-coding RNAs are regulatory RNAs, which have been found to play a role in drug 
resistance in some cancers (Özeş et al., 2016). HOX transcript antisense intergenic RNA 
(HOTAIR) is overexpressed in ovarian cancer. A study examining the role of HOTAIR in 
DNA damage found that it contributed to consistent DNA damage response activation in 
platinum-treated ovarian cancer through the activation of the NF-κB pathway. Platinum-
resistant ovarian tumours exhibited increased levels of HOTAIR compared to primary 
tumours. Increased expression levels of another long non-coding RNA, urothelial cancer 
 Figure 1.10 Mechanisms of drug 
resistance employed by a cancer 
cell 
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associated-1 (UCA1), in SKOV3 ovarian cancer cells was associated with cisplatin 
resistance as well (Wang et al., 2015).  
MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs that are involved in gene regulation and 
depending on their function, they can act as tumour suppressors or tumour promotors in 
cancer (Norouzi-Barough et al., 2018).  Studies have shown that the downregulation or 
upregulation of various miRNAs can induce drug resistance in ovarian cancer through their 
effects on various signalling pathways. The upregulation of miR-186 increased cell 
sensitivity towards cisplatin through decreased TWIST1 expression in ovarian cancer cells 
(Zhu et al., 2015).  miR-124 was found to induce resistance towards cisplatin through the 
PI3K/AKT pathway (Yang et al., 2008). Increased miR-124 levels were seen in ovarian 
cancer cells compared to normal ovarian surface epithelial cells. Such increased levels 
were associated with a decrease in PTEN protein levels, which led to the activation of the 
AKT pathway. AKT is a PTEN target and the AKT pathway is associated with cell survival 
(Xu and Mo, 2012) Therefore, the activation of this pathway increased cell survival. Here, 
the high levels of miR-124 in ovarian cancer cells (unexposed to drug treatment) could 
highlight this as an intrinsic drug resistance mechanism. Furthermore, when ovarian 
cancer cell lines were transfected with miR-124, the cells became resistant to the effects of 
cisplatin enhancing cell survival (Yang et al., 2008). Levels of miR-141 were significantly 
increased in a platinum-resistant ovarian cancer cell line compared to its platinum-
sensitive counterpart (Ying et al., 2015).  The increased expression levels of miRNAs in 
drug-resistant ovarian cancer cells indicate their role in platinum resistance.  
As with platinum resistance, upregulation of some miRNAs are also capable of inducing 
resistance towards agents like paclitaxel (Norouzi-Barough et al., 2018). Conversely, miR-
31 was found to be downregulated in a paclitaxel-resistant ovarian cancer cell line 
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compared to its paclitaxel-sensitive counterpart (Mitamura et al., 2013). This 
downregulation was associated with an increase in the hepatocyte growth factor (HGF) 
receptor protein levels. When miR-31 was overexpressed in this paclitaxel-resistant cell 
line, the cells became more sensitive to paclitaxel. Upregulated miR-106a and 
downregulated miR-591 were also associated with paclitaxel resistance in ovarian cancer 
(Huh et al., 2013). The downregulation of miR-106a and the upregulation of miR-591 was 
associated with the re-sensitisation of cells towards paclitaxel. With the downregulation of 
miR106a, pro-apoptotic factors such as CASPASE-7 and BCL10 were increased 
enhancing cell apoptosis. The upregulation of miR-591 decreased ZEB1 levels. The ZEB 
family is associated with epithelial-mesenchymal transition (EMT), which is being 
increasingly linked to drug resistance (Lamouille et al., 2014).  
DNA methylation 
DNA methylation is a form of epigenetic modification that involves the addition of methyl 
groups to cytosines in CpG islands (Kulis and Esteller, 2010). DNA methylation can be of 
two types: hypermethylation or hypomethylation of gene promotors. Whilst 
hypermethylation leads to gene silencing, hypomethylation will lead to the transcription of 
genes. In cancer, the hypermethylation of tumour suppressor genes and the 
hypomethylation of oncogenes result in carcinogenesis. DNA methyltransferases catalyse 
the methylation of genes and the aforementioned MGMT gene silencing in glioblastoma 
(Hegi et al., 2005), which resulted in a better drug response is an example of the role of 
DNA methylation in drug resistance. However, in ovarian cancer, Polo-like kinase 2 (PLK2) 
functions as a tumour suppressor gene and to this effect, the methylation of its gene was 
associated with increased resistance towards paclitaxel (Syed et al., 2011).   
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1.5.1.7 Cancer stem cells 
Tumours are composed of differing populations of cells with varying genetic signatures, 
which is what contributes to the heterogeneity nature of a tumour (Egeblad et al., 2010). 
The cancer stem cell hypothesis states that a subpopulation of cancer cells exhibiting the 
properties of stem cells exist within the tumour microenvironment (Tan et al., 2006). These 
cells termed cancer stem cells (CSCs) possess the ability to form a tumour identical to the 
primary tumour from which they are derived (Rycaj and Tang, 2015, Singh et al., 2004). 
CSCs are considered capable of initiating drug resistance as they exhibit several 
mechanisms of drug resistance described earlier: the upregulation of protein transporters, 
changes to drug targets and changes to apoptosis-initiating pathways (Doherty et al., 
2016). Stem cells do exist in tumours prior to chemotherapy. However, it now appears that 
chemotherapy itself can also lead to the transformation of non-CSCs to CSCs. The 
mechanism behind this transformation is unclear, but epithelial-mesenchymal transition 
(EMT) (to be discussed in detail later) is considered a probable candidate (Mani et al., 
2008).  
Breast cancer stem cells are characterised by a CD44high/CD24low phenotype (Al-Hajj et al., 
2003). Analyses of breast cancer cells surviving post-treatment were found to be possess 
the stem cell phenotype of CD44high/CD24low as well as an EMT signature (Creighton et al., 
2009) highlighting these cells as CSCs and by surviving treatment, their drug-resistant 
nature. The ability of CSCs to evade therapy-induced apoptosis is attributed to well-
established DNA damage response mechanisms (Bao et al., 2006). Surviving neural stem 
cells post-radiation treatment had lower rates of apoptosis and this particular cell 
population was found to have reduced levels of CASPASE-3. The activation of DNA 
damage checkpoint proteins (RAD17, CHK1 and CHK2) were also elevated in the neural 
stem cell population post-radiation treatment highlighting the heightened response to DNA 
damage in these stem cells. CSCs also express increased expression levels of ABC 
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transporter pumps such as MDR1 (Chaudhary and Roninson, 1991) and BCRP (Kim et al., 
2002) indicating other mechanisms employed by such stem cells to induce drug 
resistance.   
The existence of such CSCs prior to treatment indicate the presence of an intrinsic drug 
resistance mechanism. However, recent evidence regarding the conversion of non-CSCs 
to CSC-like cells point to an extrinsic drug resistance mechanism as well. Carboplatin 
therapy increased levels of transcription factors, SOX2 and OCT4 (which play a role in the 
induction and the maintenance of pluripotent stem cells) converting non-CSCs to cells with 
CSC-like properties (Hu et al., 2012). However, it was also observed that this particular 
stem cell state of these cells was only transitory. The knockdown of these transcription 
factors were marked by an increase in the sensitivity of these cells towards carboplatin. 
The transitional nature of such cells with an acquired ‘stem-cell nature’ could be a valuable 
target in combating drug resistance issues. SOX2 and OCT4 are also inducers of EMT 
(Dai et al., 2013, Han et al., 2012). With EMT being a possible driver of the stemness 
factor in non-CSCs, its role in drug resistance becomes important as CSCs exhibit drug-
resistant phenotypes. If the stem-like nature is transitory and is driven to by EMT (itself an 
impermanent state), EMT becomes a possible target in combating drug resistance. 
  
1.6 EPITHELIAL-MESENCHYMAL TRANSITION (EMT) 
Epithelial-mesenchymal transition (EMT) was first described by Elizabeth Hay in the 1990s 
in the primitive streak of chicken embryos (Hay, 1990, Hay, 1995). It involves a change in 
the cell phenotype from an epithelial phenotype to a motile mesenchymal phenotype 
(Kalluri and Weinberg, 2010). A cell undergoing EMT will lose its epithelial characteristics 
such as apical-basal polarity and its attachment to the basement membrane. Its 
cytoskeleton will be rearranged and cell-cell contact will be lost. The mesenchymal 
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phenotype it obtains will be spindle-like in shape and consist of migratory and invasive 
phenotypes (Figure 1.11). 
 
 
 
 
 
 
 
 
 
 
 
When Elizabeth Hay described EMT for the first time, she used the term ‘transformation’ 
rather than the term ‘transition’ (Kalluri and Weinberg, 2010).  However, since then, the 
term ‘transition’ has been adopted as it signifies the transient nature of the process. After 
undergoing EMT, a cell is capable of moving to a different location and undergoing its 
reverse process, mesenchymal-epithelial transition (MET), where it sheds its 
mesenchymal characteristics and re-acquires epithelial characteristics (Nieto et al., 2016). 
Currently, EMT is divided into three phases in which it plays a central role: 1. 
embryogenesis, 2. wound injury and inflammation and 3. cancer (Dongre and Weinberg, 
2018). The purpose of EMT in all three situations is unique to that particular situation, 
 Figure 1.11: A cell undergoing EMT 
The figure shows a cell undergoing EMT. When in its epithelial phenotype, the 
cell has apical-basal polarity, where the cell is immobile through its attachment 
to the basement membrane as well as to its neighbouring cells. When changing 
into a mesenchymal phenotype, the cell will lose its polarity and therefore, its 
attachment to the basement membrane as well as its neighbouring cells. It will 
obtain a spindle-like shape and be capable of motility [Original figure adapted 
from (Kalluri and Weinberg, 2010)].  
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while the actual process of EMT remains the same in that it allows an immobile cell to 
become motile (Kalluri and Weinberg, 2010). EMT and its reverse process of MET are 
solid pieces of evidence of a cell’s plasticity and this could be the reason for the plasticity 
exhibited by CSCs discussed before.  
Due to the focus of this PhD thesis being on cancer, only EMT in cancer will be discussed. 
Further information on the other two types of EMT can be found in the review by Kalluri & 
Weinberg (2010). 
1.6.1 EMT in cancer 
The development of a cancerous tumour begins with uncontrolled cell proliferation and 
angiogenesis (Kalluri and Weinberg, 2010). As these processes continue, the cancer cells 
gain the malignant characteristics of invasion and metastasis (Figure 1.12). This 
progression of a cancer cell from uncontrolled proliferation and growth to gaining invasive 
and migratory capacities is now commonly associated with the process of EMT. Once a 
cell migrates to a distant site, it will undergo the reverse process of MET and shed its 
mesenchymal characteristics (Dongre and Weinberg, 2018, Kalluri and Weinberg, 2010). It 
will then go onto form a metastatic epithelial tumour similar to the primary tumour in the 
new site.  
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1.6.2: EMT characteristics  
EMT is commonly characterised by the loss of cell polarity and dissociation of the cell-cell 
junctions followed by the development of invasive and migratory characteristics (Dongre 
and Weinberg, 2018). 
Epithelial cells form tight sheets of interconnecting cells through tight junctions, adherens 
junctions, desmosomes and gap junctions (Figure 1.13). During EMT, these junctional 
proteins are removed where they are either relocated or degraded (Lamouille et al., 2014) 
and the loss of the cell junctional proteins lead to the loss of the cell polarity (Dongre and 
Weinberg, 2018). E-CADHERIN (a junctional protein) levels are downregulated and levels 
of other proteins associated with the mesenchymal state such as N-CADHERIN and 
VIMENTIN are increased. EMT transcription factors, SNAIL and ZEB, inhibits the 
transcription of polarity complexes (responsible for the apical-basal polarity of a cell) 
(Thiery et al., 2009). They can also activate the transcription of metalloproteases, which 
will degrade the basement membrane, giving cells their invasive phenotype (Dongre and 
Weinberg, 2018, Thiery et al., 2009).  
Figure 1.13 
Junctional 
complexes present 
between cells 
A cell is connected 
to its neighbouring 
cell through various 
junctional protein 
complexes: tight 
junctions, adherens 
junctions, 
desmosome and 
gap junctions. 
These junctional 
proteins are 
subjected to 
relocation or 
degradation during 
EMT. 
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During EMT, the actin cytoskeleton of a cell reorganises itself to form membrane 
protrusions rich in actin (Figure 1.14) (McNiven, 2013). These membrane protrusions 
(lamellipodia and filopodia) give a mesenchymal cell the ability to move. The formation of 
protrusions such as invadopodia gives the mesenchymal cells an invasive ability 
(McNiven, 2013) allowing cells to invade neighbouring tissues. 
The cytoskeletal rearrangements resulting in cell shape changes with cell elongation and 
membrane protrusions with the development of front-rear polarity are important steps in 
EMT, which marks the beginning of EMT-associated invasion and migration (Lamouille et 
al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Cytoskeletal rearrangements occurring in a cell undergoing EMT 
A cell undergoing EMT will lose its apical-basal polarity losing its epithelial cell 
shape. Actin, a cytoskeletal protein, will reorganise its structure so that the cell is 
capable of forming protrusions in the form of lamellipodia and filopodia. The 
expression of matrix metalloproteases (MMPs) is increased which degrades the 
extracellular matrix proteins. All these structural changes allow a mesenchymal 
cell to form, which is capable of motility (Lamouille et al., 2014) 
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1.6.3 Signalling pathways related to EMT 
There are several signalling pathways implicated in EMT. TGF-β, tyrosine kinase, Wnt, 
Notch and Hedgehog are some of the major signalling pathways active in EMT. The 
activation of these pathways leads to the transcription of various genes commonly 
associated with EMT.   
Though these signalling pathways have other active functions outside of cancer, the 
pathways will only be discussed here in relation to EMT and cancer.  
1.6.3.1 TGF-β signalling pathway 
TGF-β is linked to EMT-associated wound healing, fibrosis and cancer (Xu et al., 2009). In 
cancer, TGF-β can induce the change in cell phenotype from an epithelial to a 
mesenchymal state, which is important for metastatic purposes. TGFβ can activate two 
pathways: SMAD-dependent and SMAD-independent (Du and Shim, 2016). The pathways 
can regulate the expression of several important EMT-related transcription factors: SNAIL 
factors (SNAIL and SLUG), bHLH factors (TWIST1 and TWIST2) and ZEB factors (ZEB1 
and ZEB2). Upregulation of SNAIL will repress the expression of junctional protein E-
CADHERIN (Cano et al., 2000). Other cell junctional proteins besides E-CADHERIN, such 
as OCCLUDINS, CLAUDINS and DESMOPLAKINS, are targeted for gene repression as 
well and cytoskeletal-associated proteins such as VIMENTIN, FIBRONECTIN and MMPs 
are targeted for gene activation (Du and Shim, 2016). 
The SMAD-dependent pathway, on activation, leads to the formation of the SMAD 
complex, which will translocate to the nucleus and work to either activate or repress the 
transcription of genes (Lamouille et al., 2014). The SMAD-independent pathway involves 
TGF-β initiating effects through PI3K/AKT pathway and Rho GTPases leading to 
translational regulation, cell junction dissociation and cytoskeletal changes. Inhibition of 
the AKT protein will decrease the expression levels of SNAIL, which will lead to an 
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increase in the E-CADHERIN expression levels as the E-cadherin gene will no longer be 
repressed (Xu et al., 2015). AKT, however, is also capable of exerting its effects by 
inhibiting the activity of GSK-3β, which will increase SNAIL expression repressing the 
transcription of E-cadherin. TGF-β activation also activates several other downstream 
signalling pathways such as p38, JNK and ERK (Derynck and Zhang, 2003). ERK MAPK 
signalling represses E-CADHERIN expression and elevates EMT-associated N-
CADHERIN and MMP expression levels (Lamouille et al., 2014). P38 and JNK activities 
aid in TGF-β-induced transcriptional activity through SMAD3 and SMAD4. Activations of 
RHO, RAC and CDC42 lead to actin cytoskeletal changes and the formation of 
aforementioned lamellipodia and filopodia. The TGF-β receptor, on activation, 
phosphorylates and activates PAR6 protein, which will lead to the ubiquitylation and 
subsequent degradation of RHO-A at tight junctions, which leads to destruction of cell-cell 
tight junctions (Figure 1.15).  
The TGF-β pathway activates various transcription factors and proteins associated with 
EMT playing a role in the induction of EMT characteristics such as cell junctional 
dissociations and cytoskeletal rearrangements highlighting its importance as a signalling 
pathway in EMT. 
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1.6.3.2: Tyrosine kinase signalling 
The activation of tyrosine kinase signalling is associated with cell proliferation, motility and 
survival (Porter and Vaillancourt, 1998). The binding of growth factors causes 
phosphorylation of tyrosine sites on intracellular domains activating various downstream 
signalling pathways such as ERK, P38 and JNK mentioned earlier (Figure 1.16).   
The hepatocyte growth factor binds to the HGF receptor, which is a tyrosine kinase 
receptor (Baldanzi and Graziani, 2014). The binding of HGF to its receptor activates the 
ERK MAPK pathway, which induces the transcription of the SNAIL or SLUG genes, which 
are key EMT-inducing genes. Epidermal growth factor (EGF) binds to the epidermal 
growth factor receptor (EGFR) leading to increases in SNAIL and VIMENTIN levels with 
 Figure 1.15: TGF-β signalling pathways in EMT 
TGF-β signalling activates the SMAD-dependent and SMAD-independent 
pathways. The SMAD-dependent pathway involves the formation of a 
SMAD2/SMAD3/SMAD4 complex, which can translocate to the nucleus to regulate 
gene expression. The SMAD-independent pathways are the PI3K-Akt pathway, 
ERK pathway as well as the activation of RAC. The SMAD-independent pathways 
can regulate transcriptional activities, cell junctional dissociations and 
cytoskeletal rearrangements. 
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decreases seen in the levels of E-CADHERIN (Kim et al., 2016a, Yang et al., 2014). The 
platelet-derived growth factor (PDGF) binding to its receptor (PDGFR) causes the 
destabilisation of the adherens junctions, localisation of β-CATENIN to the nucleus and the 
repression of E-cadherin gene transcription (Figure 1.16) (Lamouille et al., 2014, Kong et 
al., 2008). The regulation of EMT-inducing genes and the activation of various cell 
processes (associated with EMT) by tyrosine kinase signalling highlights the importance of 
this pathway in EMT.  
 
 
 
 Figure 1.16 Tyrosine kinase signalling 
There are different tyrosine kinase receptors. HGFR activation leads to the 
upregulation of SLUG and SNAIL genes; EGF activation leads to the 
upregulation of SNAIL and VIM genes and the downregulation of the CDH1 gene 
(encoding for E-cadherin); PDGFR activation leads to the dissociation of 
adherens junctions and the localisation of β-catenin to the nucleus and the 
downregulation E-cadherin expression.  
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1.6.3.3 Wnt signalling pathway 
The activation of the WNT signalling pathway through WNT ligand binding to Frizzled 
receptors leads to the inhibition of glycogen synthase kinase-3β (GSK-3β) (Lamouille et 
al., 2014). The inhibition of GSK-3β prevents the degradation of β-CATENIN in the 
cytoplasm allowing it to translocate to the nucleus where it regulates the transcription of 
various EMT-associated genes such as SNAIL. Human adipose stem cells treated with 
WNT3A or with GSK3 inhibitors exhibited increased expression levels of the gene coding 
for β-CATENIN compared to their control counterparts (Huang et al., 2017). There was 
also an increase in the nuclear localisation of β-CATENIN in all the treated cells compared 
to the untreated controls, which points to an increased upregulation of EMT-associated 
genes. The activation of non-canonical pathways, which do not involve β-catenin, leads to 
cytoskeletal changes and cell migratory activity. The association of WNT/β-CATENIN 
signalling pathway with EMT is well documented in cancer (Figure 1.17) (Vincan and 
Barker, 2008, Ford et al., 2013, Xiao et al., 2016). 
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1.6.3.4 Notch signalling pathway 
The binding of JAGGED or DELTA ligands to the Notch receptors leads to the release of 
the Notch intracellular domain (Shao et al., 2015). The Notch intracellular domain 
regulates EMT-associated SLUG gene expression. When Notch was silenced in a breast 
cancer cell line, the cells appeared to undergo a reversal of EMT adopting a more 
spherical shape (epithelial-like). Expression levels of E-CADHERIN were increased, whilst 
mesenchymal markers such as N-CADHERIN and VIMENTIN were decreased (Shao et 
al., 2015).   
1.6.3.5 Hedgehog signalling pathway 
In the Sonic Hedgehog (SHH) signalling pathway, the binding of the ligand to the Patched1 
receptors activates SMOOTHENED (SMO), which in turn activates GLIOMA (GLI)  
 Figure 1.17 WNT signalling in EMT 
The activation of the Wnt signalling pathway leads to the regulation of genes 
involves in cell adhesion, cytoskeletal rearrangements and cell migration.  
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transcription factors, which regulate the transcription of the SNAIL gene (Du and Shim, 
2016, Lamouille et al., 2014). The activation of the SHH pathway can also activate the 
PI3K/AKT pathway upregulating MMP9 and SNAIL levels, which are EMT-associated 
genes involved in matrix destabilisation and E-CADHERIN suppression (Yoo et al., 2011). 
In addition to this, it upregulates many other EMT-associated genes (ZEB1, ZEB2, 
TWIST2 and BMP4) (Katoh and Katoh, 2009). 
These various signalling pathways also contribute to cell stemness, where the activation of 
these pathways leads to the maintenance of the stem cell phenotype. (Roy and Cowden 
Dahl, 2018).  For example, drug-resistant ovarian cancer displayed elevated levels of 
activated AKT, which maintained the pool of stem cell markers: OCT4, SOX2, ALDH1 and 
ABCG2 (Seo et al., 2016). In another ovarian cancer study, drug resistance was seen 
when treatment with paclitaxel led to the activation of the STAT3 signalling pathway and 
increased expression levels of stem cell markers such as OCT4 and CD117 (Abubaker et 
al., 2014a). Hedgehog signalling was found to be an important step in the maintenance of 
colon cancer stem cells (Regan et al., 2017). Colon cancer stem cells were found to have 
activated Hedgehog and WNT signalling in them. The knocking down of an enzyme 
required for SHH signalling led to a decrease in colon stem cell marker: ALDH (aldehyde 
dehydrogenase).  
Not only do these signalling pathways play an important role in the induction of EMT, but 
their contribution to cell stemness highlights the importance of CSCs and EMT in drug 
resistance.  
1.6.3.6 Tumour microenvironmental factors affecting EMT 
Other than the binding of ligands, which activate various signalling pathways, the 
surrounding environment of a cell can also initiate EMT-related pathways (Lamouille et al., 
2014). Growing tumours experience hypoxic conditions and hypoxia can activate hypoxia 
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inducible factor-1α (HIF-1α). HIF-1α will induce the transcription of SNAIL and TWIST 
gene expressions downregulating E-CADHERIN expression (Yang and Wu, 2008). 
Colorectal cancer cells transfected with HIF-1α displayed a spindle morphology with 
increased N-CADHERIN and VIMENTIN levels and decreased E-CADHERIN levels 
(Zhang et al., 2015). The release of inflammatory cytokines such as IL-6 (Interleukin-6) 
can also contribute to EMT (Zhou et al., 2017). Cells treated with increasing levels of IL-6 
showed a decrease in E-CADHERIN levels and an increase in VIMENTIN levels. The 
expression of IL-6 activates the signal transducer and activator of transcription 3 (STAT3) 
transcription factor (Gyamfi et al., 2018). STAT3 can increase SNAIL gene expression. 
The activation of IL-6 not only results in a decrease in E-CADHERIN levels, but also leads 
to an increase in N-CADHERIN, VIMENTIN and TWIST levels resulting in an invasive cell 
phenotype.  
EMT-related transcription factors can be activated by more than one pathway and ligand 
binding can lead to the activation of more than one signalling pathway (Lamouille et al., 
2014). This is strong evidence of cross-talk between EMT-associated signalling pathways. 
Having established the importance of EMT in cancer progression, one’s attention next 
needs to be diverted to the possible role EMT could play in a devastating issue in cancer: 
drug resistance.  
1.6.4 Association of EMT with drug resistance in cancer 
EMT has been increasing been linked to drug resistance in recent times in various 
cancers: pancreatic cancer, breast cancer and lung cancer to name a few  (Arumugam et 
al., 2009, Zheng et al., 2015, Huang et al., 2015, Fischer et al., 2015).  
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1.6.4.1 EMT and drug resistance in ovarian cancer 
Ovarian cancer is a fatal gynaecological cancer where the onset of drug resistance will 
drastically affect the prognoses of affected patients. Therefore, exploration of EMT and its 
contribution to drug resistance in ovarian cancer is worthy of investigation.  
In ovarian cancer, Dual-specificity tyrosine-regulated kinase 2 (DYRK2) was found to be 
reduced in two cisplatin-resistant cell lines compared to their drug-sensitive counterparts 
(Yamaguchi et al., 2015). DYRK2 regulates the expression of the SNAIL transcription 
factor and true to this fact, the two cisplatin-resistant cell lines showed increased SNAIL 
expression levels. Knocking down DYRK2 led to an increase in SNAIL expression levels 
and a decrease in E-CADHERIN levels, which are characteristics of EMT. In the same 
study, mouse tumour xenografts with DYRK2 knockdown had higher levels of SNAIL 
expression and were resistant to cisplatin effects (Yamaguchi et al., 2015).  
SNAIL and SLUG are transcription repressors that contribute to cancer drug resistance 
through EMT. Kurrey et al. (2009) demonstrated paclitaxel resistance driven by SNAIL and 
SLUG in ovarian cancer. SNAIL and SLUG levels were overexpressed in paclitaxel-
resistant ovarian cancer cells and the resistance to paclitaxel-induced apoptosis was 
induced through the inhibition of various proteins of the p53-mediated apoptotic pathway 
(Kurrey et al., 2009).  
In another study, cisplatin-resistant ovarian cancer cells had a morphology associated with 
EMT and gene expression analysis of the resistant cells displayed increased levels of the 
EMT-associated transcription factors: SNAIL, SLUG, TWIST2 and ZEB2 (Haslehurst et al., 
2012). There was an increase in VIMENTIN levels and a decrease in E-CADHERIN levels, 
which are both characteristics of EMT. These resistant cells also had increased migratory 
and invasive capacities. Knocking down SNAIL and SLUG genes reversed the EMT 
phenotype reducing migratory and invasive capacities of the cells, but also increased 
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sensitivity towards cisplatin. The study concluded that resistant cells could be identified by 
the expression levels of EMT-associated genes, such as SNAIL, SLUG, TWIST and ZEB, 
which forms the basis for this PhD.   
All these studies associate EMT-related factors with drug resistance, which implies the 
idea that the establishment of a panel of such factors will aid in the identification of drug-
resistant cells and or the identification of cells gearing towards the acquisition of a drug-
resistant phenotype. 
All studies conducted so far talked about the association of EMT with cancer metastasis 
and drug resistance i.e.: the association of the mesenchymal phenotype with cancer 
metastasis and drug resistance. Interestingly, however, a report by Jolly et al. (2016) 
suggested this might not be entirely accurate. They suggested the notion of a partial EMT 
state contributing to metastasis and drug resistance instead of the complete EMT state 
(Jolly et al., 2016). A cell, which has undergone partial EMT, will exhibit both epithelial and 
mesenchymal properties thus allowing cells to participate in collective migration, which 
incidentally makes them more resistant to toxic drug effects. A study in breast cancer 
showed that the co-expression of both epithelial- and mesenchymal-associated genes 
predicted a poorer survival outcome than with the expression of mesenchymal-associated 
genes only (Grosse-Wilde et al., 2015) suggesting the possibility that the partial EMT state 
could be more important than a complete EMT state. The partial EMT state is ideally 
recognised as a transient state that a cell is in when undergoing EMT to completion. 
However, Jolly et al. (2016) identify ‘phenotypic stability factors’ (PSFs), which are capable 
of stabilising the partial EMT state making this state not a transitory state, but a stable cell 
phenotype of its own.  
Jolly et al. (2016) identified such a stable partial EMT state in a lung adenocarcinoma cell 
line showing that such a partial state can be maintained stably at a single-cell level. 
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Mathematical model analysis identified OVOL, GRHL2 and miR-145 as possible PSFs. To 
support this, the knockdown of OVOL and GRHL2 led to the completion of EMT in the cell 
line with a stable partial EMT state. The levels of these PSFs were correlated with poorer 
survival rates, metastasis-free and relapse-free periods in various tissues. Low levels of 
these factors were correlated with better survival and as low levels of these factors 
indicated a complete EMT state or the reverse state of MET, it puts forward the idea that 
perhaps the partial EMT state is more aggressive and likely contributes to aggressive 
metastasis and poor response to drug treatment.  
Despite this, published studies show that EMT-related factors are capable of contributing 
to the induction of drug resistance. This in turn can possibly serve to indicate the possibility 
of a drug resistant phenotype. This thought brings attention to biomarkers that could play a 
role in identifying a drug-resistant phenotype in cancer.  
 
1.7 BIOMARKERS OF DRUG RESISTANCE IN OVARIAN CANCER 
The use of a panel of biomarkers for the detection of a drug-resistant phenotype in cancer 
does not currently exist. The use of such biomarkers to personalise medication regimens 
and to avoid treating patients with drugs that may be rejected by their bodies is an 
important avenue to consider. The existence of such a pool of biomarkers could also help 
focus research on the development of drugs to circumvent drug resistance issues better as 
well as to help understand drug resistance by studying the identified proteins.  
In the present, there are some studies looking at such biomarkers in ovarian cancer in the 
literature. Silencing RTF1, CSDE1, CNOT8 and MEK1 genes increased sensitivity towards 
carboplatin in EOC cells (Penzvalto et al., 2014). Silencing MEK1-encoding gene also 
resulted in significantly enhanced apoptosis compared to the silencing of other genes. The 
absence of MEK1 protein leads to the decreased activation of the anti-apoptotic protein, 
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BCL-xL, leading to increased apoptosis  (Jazirehi et al., 2004). Further, the examination of 
patient tissue samples showed that a low MEK1 level was associated with a better 
progression-free survival rate (Penzvalto et al., 2014). Therefore, MEK1 could be a 
possible biomarker of drug resistance.  
CD147 protein was found to have significantly higher expression levels in drug-resistant 
ovarian cancer tissue samples compared to drug sensitive samples (Gao et al., 2014). 
CD147 is an extracellular MMP inducer present in high levels on membranes of cancer 
cells (Yan et al., 2005) and it is responsible for drug-resistant characteristics of cell 
metastasis and invasion. Zou et al. (2007) found that inhibiting CD147 led to increased 
sensitivity towards paclitaxel (Zou et al., 2007), making CD147 another possible marker of 
drug resistance.  
Teng et al. (2014), in an effort to identify biomarkers that could predict drug resistance, 
conducted a study of platinum-sensitive and platinum-resistant cell lines and secreted 
proteins were analysed for their drug resistance-evaluating nature. The authors identified 
13 upregulated proteins, which included three MMPs (MMP1, MMP3 and MMP10) that 
warrant further investigation as possible drug resistance-associated markers.  
The expression of NANOG, a transcription factor associated with poor prognosis and drug 
resistance in ovarian cancer, contributed to platinum resistance in ovarian cancer (Qin et 
al., 2017). Its expression was associated with increased expression levels of 
mesenchymal markers: VIMENTIN, FIBRONECTIN and N-CADHERIN. Looking at ovarian 
cancer tissue samples, samples with NANOG expression were linked to drug resistance 
while the samples lacking NANOG expression had no history of drug resistance. Drug 
resistance was possibly mediated by STAT3, which is a downstream target of NANOG (Liu 
et al., 2016). STAT3 activation leads to the activation of anti-apoptotic proteins: BCL-2 and 
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BCL-xL inducing drug resistance (Alas and Bonavida, 2003). This makes NANOG a 
possible protein of interest as a biomarker of drug resistance.  
Annexins are phospholipid-binding membrane proteins. Yan et al. (2010) found that 
annexin A3 was associated with platinum resistance. Platinum-resistant ovarian cancer 
tissue samples had high annexin A3 expression levels compared to platinum-sensitive 
tissue samples (Yan et al., 2010). With high levels of annexin A3, intracellular 
concentrations of platinum were reduced indicating that the resistance could be associated 
with a reduced cellular uptake of platinum. Cisplatin induces the pro-apoptotic p53 
pathway and the overexpression of annexin A3 was also correlated with a decrease in p53 
levels. Therefore, annexin A3 appears to mediate platinum resistance through reduced 
platinum intracellular concentrations, which in turn decreased the p53-mediated apoptosis 
induced by the platinum (as evidenced in the study by the low amount of DNA-bound 
platinum in the Annexin A3-overexpressing cells). This makes annexin A3 another 
possible protein of interest as a drug-resistant biomarker.  
Despite these studies, there is still very limited information available in the literature that 
focuses on biomarkers that could be specifically used to identify a drug-resistant 
phenotype in ovarian cancer patients. Having a pool of possible proteins that could be 
used to identify a possible drug-resistant phenotype could be of beneficial use to patient, 
clinician and researcher. As highlighted before, the development of drug resistance is a 
major issue in ovarian cancer, which generally has a good response rate to the first-line 
treatment drugs. The onset of drug resistance in a disease that is commonly diagnosed in 
the late stages with a low chance of survival proves an obstacle to improving survival 
rates. If biomarkers can be identified that can be used to identify patients who may resist 
the first-line chemotherapy drugs (carboplatin and paclitaxel), patients could be directed 
towards other chemotherapeutic options. 
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The work in this thesis, therefore, focuses on identifying possible biomarkers that might aid 
in the identification of a drug resistant phenotype in EOC patients. In order to approach 
this, the process of EMT was used. As EMT has shown to play a role in drug resistance, 
this thesis begins with investigating whether EMT itself can be associated with a drug-
resistant phenotype (Chapter 3). Then, whether drug resistance could be reversed by 
targeting specific EMT-associated markers was investigated. An in-vitro model of EMT 
was also produced and this model was compared to the in-vitro derived drug-resistant 
model to understand the association of EMT with drug resistance. After the investigation 
on EMT, other possible biomarkers are investigated such as the HGF receptor protein 
(also known as the MET receptor not to be confused with the mesenchymal-epithelial 
transition process: MET) (Chapter 4). The possible role the HGF receptor plays in drug 
resistance (and therefore, its usefulness as a biomarker of drug resistance) was 
investigated through gene silencing (downregulation of the HGF receptor), western blotting 
(analyses of downstream signalling pathways) and MTT assays (receptor inhibition 
effects). Chapter 5 concludes the work by identifying more biomarkers of drug resistance 
in ovarian cancer by carrying out a more comprehensive search for genes associated with 
EMT (and therefore, drug resistance) through PCR.   
Hypotheses 
Overall hypothesis: The expression of specific cellular proteins and/or genes can predict 
the sensitivity of epithelial ovarian cancer to chemotherapeutic agents 
 EMT markers can be used as biomarkers of drug resistance in ovarian cancer 
(Chapter 3). 
 The induction of EMT can lead to the production of an in-vitro derived cellular 
model of drug resistance. (Chapter 3). 
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 The MET receptor protein could be a biomarker of drug resistance in ovarian 
cancer (Chapter 4). 
 Analyses of EMT-related genes in drug-resistant cell lines could provide a panel of 
genes that could serve as biomarkers of drug resistance in ovarian cancer.  
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Cell lines and Reagents 
2.1.1 Cell lines used 
Several cell lines were used (Table 2.1). The main two cell lines chosen were OVCAR3 
and SKOV3 cell lines (Figure 2.1), whose general characteristics are provided in table 2.3. 
These two cell lines were chosen as the main cell lines as they are commonly used cell 
lines in ovarian cancer studies and they were both readily available in the drug-resistant 
forms (paclitaxel- and carboplatin-resistant) necessary for this study. Images of the control 
and drug-resistant OVCAR3 and SKOV3 cells are provided in figure 2.2. The drug-
resistant cell lines were developed through periodic treatment of each cell line with the 
appropriate drug until a drug-resistant phenotype was obtained. These drug-resistant cell 
lines were developed and provided for use in this PhD by Dr H.M. Coley (of the University 
of Surrey). The SKOV3 cell line was made resistant to carboplatin and the OVCAR3 cell 
line was made resistant to paclitaxel. The maintenance drug doses for the drug-resistant 
cell lines used are provided in Table 2.2. 
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Table 2.1: List of cell lines used 
 
 
Table 2.2 List of drug-resistant cell lines used 
Cell line Resistant towards Maintenance dose Nomenclature 
name used 
SKOV3 Carboplatin 10µM SKOV3 CR 
OVCAR3 Paclitaxel 5nM OVCAR3 TaxR 
PEO1 Carboplatin 2µM PEO1 CR 
CaOV3 Carboplatin 4µM CaOV3 CR 
 
 
Cell line Type of cell line Where it was obtained from Culture 
medium 
used 
OVCAR3  Ovarian cancer ATCC (distributed by LGC 
Promochem, Teddington, UK) 
RPMI-1640 
SKOV3  Ovarian cancer ECACC (European Collection of 
Authenticated Cell Cultures), Porton 
Down, UK 
DMEM 
CaOV3  Ovarian cancer Kindly provided by Professor Fran 
Balkwill (formerly of ICRF, Lincoln’s 
Inn, London) 
RPMI-1640 
PEO1  Ovarian cancer Kindly provided by Professor Fran 
Balkwill (formerly of ICRF, Lincoln’s 
Inn, London) 
RPMI-1640 
HuH7 Liver cancer Kindly provided by Dr Rohini Sharma 
of Imperial College, London.  
DMEM 
MCF7 Breast cancer ATCC (distributed by LGC 
Promochem, Teddington, UK) 
DMEM 
SKBR3 Breast cancer ATCC (distributed by LGC 
Promochem, Teddington, UK) 
DMEM 
A375 Melanoma ATCC (distributed by LGC 
Promochem, Teddington, UK) 
DMEM 
MB231 Breast cancer ATCC (distributed by LGC 
Promochem, Teddington, UK) 
DMEM 
Hela Cervical cancer ATCC (distributed by LGC 
Promochem, Teddington, UK) 
DMEM 
3T3 Fibroblast ECACC (European Collection of 
Authenticated Cell Cultures), Porton 
Down, UK 
DMEM 
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A) 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
 
Figure 2.1: Morphology of the OVCAR3 and SKOV3 cells 
A) Left: Image of OVCAR3 cells used in this study obtained with Nikon Eclipse TS100 
microscope at 10x magnification. Right: Image of OVCAR3 cells at low density 
provided by ATCC (HTB-161). 
B) Left: Image of SKOV3 cells used in this study obtained with Nikon Eclipse TS100 
microscope at 10x magnification. Right: Image of SKOV3 cells at low density 
provided by ATCC (HTB-77). 
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A)  
 
 
 
 
 
B) 
 
 
 
 
 
Figure 2.2 Morphology of control and drug-resistant OVCAR3 and SKOV3 cells 
A) Left: Image of parental OVCAR3 cells used in this study. Right: Image of paclitaxel-
resistant OVCAR3 cells used in this study. 
B) Left: Image of parental SKOV3 cells used in this study. Right: Image of carboplatin-
resistant SKOV3 cells used in this study.  
[All images obtained with Nikon Eclipse TS100 microscope at 10x magnification] 
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Table 2.3 Characteristics of the two main cell lines 
        (Beaufort et al., 2014)  
2.1.2 Cell culture medium 
Culture media used were that used by others for each cell line and also used in-house and 
are appropriate choices of media for the cell lines being studied.  
RPMI-1640 (Product code: R5886) was obtained from Sigma-Aldrich (Poole, UK). 50ml of 
heat-inactivated foetal bovine serum (FBS) (PAN-Biotech, Germany) was added to 450ml 
of RPMI-1640 medium to produce 500ml of RPMI-1640 medium with 10% FBS. In 
addition, 5ml of 200mM L-glutamine solution (glutaMAX from Invitrogen, Paisley, UK) was 
added to the medium plus FBS. The media was then stored at 4ºC. 
Dulbecco’s Modified Eagle Medium (DMEM) (Product code: D6171) was obtained from 
Sigma-Aldrich (Poole, UK). 50ml of heat-inactivated FBS (PAN-Biotech, Germany) was 
added to 450ml of DMEM medium to produce 500ml of DMEM medium with 10% FBS. In 
addition, 10ml of 200mM L-glutamine solution (glutaMAX from Invitrogen, Paisley, UK) 
was added to the medium plus FBS. The media was stored at 4ºC. 
Heat inactivation of the FBS was carried out in a water bath at 55ºC for 30 minutes. 
 OVCAR3 SKOV3 
Morphology Epithelial Epithelial 
Histology High grade serous Serous 
Origin Ascites Ascites 
Protein 
Markers 
CD44 Low expression High expression 
CD24 Moderate expression Moderate expression 
EpCAM Moderate expression Low expression 
Gene Mutations TP53 TP53, NF1, PIK3CA, 
HRAS, ARID1A 
Gene Amplification High CCNE1 High ERBB2 
Mutated genes in 
pathways 
One mutated gene in HRR 
pathway 
Three mutated genes in 
Wnt/β-catenin pathway 
and two mutated genes in 
HRR pathway 
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Trypsin-EDTA solution (Product code: T3924) was obtained from Sigma-Aldrich (Poole, 
UK) and stored at 4ºC. 
In order to induce a mesenchymal phenotype in the OVCAR3 cells, epidermal growth 
factor (EGF), interleukin-6 (IL-6) and transforming growth factor-β (TGF-β) were used and 
they were all from R&D Systems (Abingdon, UK) (Table 2.4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  6278156 
 
87 
 
Table 2.4 Information on the growth factors and cytokine used 
 Original 
form 
Working 
concentration 
Reconstitution method 
Recombinant 
Human EGF 
(Product 
code:236-EG-
200) 
Obtained in 
powder form 
(200μg).  
20μg/ml A stock concentration of 200μg/ml 
was obtained by dissolving 200μg 
of the EGF powder in 1ml of sterile 
phosphate-buffered saline (PBS) in 
a sterile Eppendorf. A working 
concentration of 20μg/ml was then 
made by pipetting 100μl of the 
stock concentration into an 
Eppendorf. Five working 
concentration Eppendorf tubes 
were prepared as aliquots to avoid 
repeat freeze-thaw issues. Stock 
and working concentrations were 
stored at -20°C for three months.  
Recombinant 
Human IL-6 
Rα (Product 
code: 227-SR-
025) 
Obtained in 
powder form 
(25μg). 
100μg/ml 50mg bovine serum albumin (BSA) 
was dissolved in 50ml PBS. 25µg 
IL-6 was dissolved in 250μl of the 
prepared BSA-PBS solution to get 
a final concentration of 100μg/ml. 
Reconstituted solution was then 
pipetted into four 20μl aliquots. 
Stock and aliquots were stored at -
20°C for three months.  
Recombinant 
Human TGF-
β1 
(Product 
code: 240-B-
002/CF) 
Obtained in 
powder form 
(2μg). 
20μg/ml A 1.2M HCL solution was prepared 
with 100μl of 12M HCL and 900μl 
of RO water. 75mg BSA was 
dissolved in 1000µl RO water as a 
BSA stock. A reconstitution 
solution was prepared with 160μl of 
the prepared BSA stock, 40μl of 
the prepared 1.2M HCL solution 
and 11.8ml of RO water. The 
solution was filter sterilised by 
passing it through a 0.22μm filter 
unit (Millex, Germany). 100μl of the 
reconstituted solution was added to 
2μg TGF-β powder as a stock 
solution. Three 20μl aliquots were 
prepared in Eppendorf tubes. The 
reconstituted solution, stock 
solution and aliquots were stored at 
-20°C for three months.  
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Freezing medium for cell storage 
Cells were frozen in the appropriate media with 10% dimethyl sulfoxide (DMSO). The 
freezing medium was prepared fresh each time cells were frozen.  
 
2.1.3 Western Blotting 
2.1.3.1 Protein Extraction 
Lysis buffer solution 
The following were added to a labelled 2ml Eppendorf tube to produce the working lysis 
solution, which was prepared fresh each time protein extraction was done: 
 1000μl RIPA buffer (RIPA buffer solution was stored at 4°). 
 10μl PMSF (PMSF solution was stored at -20°C). 
 2μl Aprotonin (10mg/ml aq. stock solution).  
[Aprotonin was obtained as a 5mg powder. 500μl of RNase-free water was added 
to the 5mg powder to obtain the 10mg/ml stock concentration. 6μl aliquots were 
prepared and the stock and working aliquots were stored at -20°C for the duration 
of the study]. 
 2μl Leupeptin (10mg/ml aq. stock solution). 
[Leupeptin was obtained as a 5mg powder. 500μl of RNase-free water was added 
to the 5mg powder to obtain the 10mg/ml stock concentration. 6μl aliquots were 
prepared and the stock and working aliquots were stored at -20°C for the duration 
of the study]. 
 10μl Na3VO4 (sodium orthovanadate) (100mM aq.). 
[Sodium orthovanadate was provided as a 10g powder. Stock concentration of 
100mM was made up with RO water as instructed by the manufacturer. Stocks 
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were made up in Eppendorf tubes and stored at -20°C for the duration of the 
study]. 
All of the above were obtained from Sigma-Aldrich (Poole, UK). Once the working lysis 
solution was prepared at the beginning of each protein extraction, it was placed on ice till 
needed and discarded after use.  
2.1.3.2 Bradford Protein Assay – Measurement of protein content in samples 
Serial dilutions of bovine serum albumin (BSA) 
Using a 5mg/ml BSA stock (Sigma Aldrich, Poole, UK), the following BSA concentrations 
were prepared in labelled Eppendorf tubes: 
Table 2.5 Preparation of the standard BSA series 
BSA Final Concentration 
(mg/ml) 
Volume of RO Water (μl) Volume of BSA Stock 
(5mg/ml) 
0.0 1000 0 
0.2 960 40 
0.5 900 100 
0.7 860 140 
1.0 800 200 
1.2 760 240 
1.5 700 300 
 
The solutions were vortexed for several seconds and stored at -20°C. Each time they were 
used, they were thawed at RT and then vortexed for 10 seconds.  
Working Reagent 
20μl Reagent S (Bio-Rad, USA) and 1000μl Reagent A (Bio-Rad, USA) were added to a 
labelled Eppendorf tube.  
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2.1.3.3 Electrophoresis 
MOPS SDS Running Buffer (X1) 
50ml MOPS SDS running buffer (Manufacture strength: X20) (Invitrogen, Paisley, UK) was 
made up to 1000ml with RO water in a 1L measuring cylinder.  
Tris-Acetate (TA) SDS Running Buffer (X1) 
50ml TA SDS running buffer (Manufacture strength: X20) (Invitrogen, Paisley, UK) was 
made up to 1000ml with RO water in a 1L measuring cylinder.  
 
2.1.3.4 Transfer 
Transfer Buffer (X1) containing 10% methanol per gel 
50ml transfer buffer (Manufacture strength: X20) (Invitrogen, Paisley, UK) and 100ml 
methanol (Sigma-Aldrich, Poole, UK) per gel were made up to 1000ml with RO water in a 
1L measuring cylinder. 
 
2.1.3.5 Blocking, Primary and Secondary Antibody Solutions 
1X PBS solution 
Five PBS tablets (Oxoid, UK) were dissolved in 500ml RO water as per the manufacturer’s 
instructions (pH 7.4) 
10X TBS solution 
24g Tris-base powder (Fisher Scientific, UK) and 88g sodium chloride powder (Fisher 
Scientific, UK) were dissolved in 900ml of RO water. The pH was adjusted to 7.6 with 12M 
HCL (Fisher Scientific, UK). The total volume was made up to 1L with RO water.  
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1X TBS solution 
50ml 10X TBS solution was added to 450ml RO Water (pH 7.6). 
PBS:Tween 20 solution 
500μl Tween 20 (Sigma Aldrich, Poole, UK) was added to 500ml 1X PBS solution to make 
a 0.1% (v/v) final solution. 
TBS:Tween 20 solution 
500μl Tween 20 (Sigma Aldrich, Poole, UK) was added to 500ml 1X TBS solution to make 
a 0.1% (v/v) final solution. 
Blocking solution 
5% milk solution: 0.5g of dried skimmed milk powder (Marvel, Dublin, Ireland) was 
measured into a universal tube and 10ml TBS:Tween 20 was added. The universal tube 
was then placed on a roller to allow the solution to become homogeneous.  
5% BSA solution: 0.5g of BSA powder (Sigma, Poole, UK) was measured into a universal 
tube and 10ml TBS:Tween 20 was added. The universal tube was then placed on a roller 
to allow the solution to become homogeneous.  
Primary antibody solution 
The appropriate antibody volume (Table 2.6) was added to a solution of 0.5g of BSA 
powder dissolved in 10ml of TBS:Tween 20 solution. This was the dilution solution used 
for all antibodies except for the β-catenin, TCF4 and WNT5A antibodies. The appropriate 
volume of any of these four mentioned antibodies was added to a solution of 0.5g of dried 
skimmed milk powder dissolved in 10ml of PBS:Tween 20 solution.  
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Table 2.6: Types of primary antibodies used 
Antibody Type of antibody Concentration 
used at 
Obtained from 
MET Rabbit Polyclonal 1:1000 Cell Signalling, UK 
Phospho-MET 
(Tyr1349) 
Rabbit monoclonal 1:500 Cell Signalling, UK 
E-CADHERIN Mouse monoclonal 1:1000 Cell Signalling, UK 
β-CATENIN Mouse monoclonal 1:100 Santa Cruz 
Biotechnology, USA 
VIMENTIN Rabbit monoclonal 1:1000 Cell Signalling, UK 
SLUG Rabbit monoclonal 1:1000 Cell Signalling, UK 
TWIST Rabbit polyclonal 1:1000 Cell Signalling, UK 
STAT3 Rabbit monoclonal 1:1000 Cell Signalling, UK 
Phospho-
STAT3 (Ser727) 
Mouse monoclonal 1:1000 Cell Signalling, UK 
AKT Rabbit polyclonal 1:1000 Cell Signalling, UK 
Phospho-AKT 
(Thr308) 
Rabbit Polyclonal 1:1000 Cell Signalling, UK 
P44/42 MAPK Rabbit monoclonal 1:1000 Cell Signalling, UK 
Phospho-
P44/42 MAPK 
(Thr202/Tyr204) 
Rabbit monoclonal 1:1000 Cell Signalling, UK 
RAC1 Rabbit polyclonal 1:1000 Cell Signalling, UK 
Phospho-RAC1 
(Ser71) 
Rabbit polyclonal 1:1000 Cell Signalling, UK 
ZEB1 Rabbit monoclonal 1:1000 Cell Signalling, UK 
TCF4 Mouse monoclonal 1:100 Santa Cruz 
Biotechnology, USA 
WNT5A Mouse monoclonal 1:100 Santa Cruz 
Biotechnology, USA 
GAPDH Mouse monoclonal (1:3000) Sigma Aldrich, UK 
 
Secondary antibody solution 
2μl of appropriate secondary antibody (LICOR Biosciences, UK) (Table 2.7) was added to 
a solution of 1g of dried skimmed milk powder dissolved in 20ml TBS:Tween 20 solution.  
Table 2.7: Types of secondary antibodies used 
Antibody 
Donkey anti-mouse IR Dye 800CW 
Donkey anti-rabbit IR Dye 800CW 
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2.1.4 Epithelial Antigen Staining 
Monoclonal mouse anti-human epithelial antigen conjugated to FITC (clone Ber-EP4) 
(Product code: F0860) was obtained from Dako, Denmark. 100μl of Ber-EP4 antibody 
solution was prepared for every four samples: 90μl PBS and 10μl antibody solution in an 
Eppendorf tube. 
1X PBS solution 
Prepared as detailed in section 2.1.3.5. 
PBS with 2% BSA 
100mg of BSA was dissolved in 5ml PBS (1X) in a universal tube on a roller at RT. 
 
2.1.5 Annexin V-FITC Apoptosis Detection 
1X PBS solution 
Prepared as detailed in section 2.1.3.5. 
1X Binding Buffer 
8ml RO water was added to 2ml 5X Binding buffer (Calbiochem, UK) in a universal tube 
and placed on ice till needed. This solution was prepared fresh each time.  
Annexin V-FITC  
Annexin V-FITC in liquid form was obtained from Calbiochem, UK and stored at 4°C. 
Propidium Iodide (PI) 
Propidium Iodide in liquid form was obtained from Calbiochem, UK and stored at 4°C.  
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2.1.6 MTT Assay 
Carboplatin  
Carboplatin was obtained from Sigma Aldrich (UK) in powder form. It was made up in 
sterile saline (0.9% (w/v) NaCl) as a 50mM stock solution and stored at -20°C.  
Paclitaxel 
Paclitaxel was obtained from Sigma Aldrich (UK) in powder form. It was made up in sterile 
saline (0.9% (w/v) NaCl) as a 1mM stock solution and stored at -20°C.  
Foretinib 
Foretinib was obtained from Selleck Chemicals (USA). Stock solutions of 20mM were up in 
DMSO and stored at -20°C. 
MTT solution (5mg/ml) 
The MTT powder was obtained from Sigma Aldrich (Poole, UK). 1g MTT powder was 
dissolved in 200ml 1X PBS.  
Dimethyl Sulfoxide (DMSO) 
500ml bottle of DMSO (analytical grade) was obtained from Fisher Scientific, UK (Product 
code: D/4121/PB08). 
 
2.1.7 Gene Silencing Assay 
All the reagents for the gene silencing work was obtained from Dharmacon, Horizon 
Discovery, UK. The SiRNA reagents each have four target sequences as each reagent is 
a collection of four siRNAs targeting the required gene allowing for optimal gene 
knockdown.  
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 ON-TARGETplus Human Met siRNA (MET) [Product code: 4233] 
[Target sequences: GAACUGGUGUCCCGGAUAU, 
GAACAGCGAGCUAAAUAUA, GAGCCAGCCUGAAUGAUGA and 
GUAAGUGCCCGAAGUGUAA] 
 ON-TARGETplus Human SNAI2 siRNA (SLUG) [Product code: 6591] 
[Target sequences: UCUCUCCUCUUUCCGGAUA, 
GCGAUGCCCAGUCUAGAAA, ACAGCGAACUGGACACACA and 
GAAUGUCUCUCCUGCACAA] 
 SiGENOME Non-Targeting siRNA (Scramble Control) [Product code: D-001206-
13-20] 
[Target sequences: UAGCGACUAAACACAUCAA, UAAGGCUAUGAAGAGAUAC, 
AUGUAUUGGCCUGUAUUAG and AUGAACGUGAAUUGCUCAA] 
 Dharmafect Transfection Reagent (DharmaFECTTM1 – Product code: T-2001-02).  
 5X siRNA Buffer (Product code: B-002000-UB-100) 
 RNase-free water.  
 
All siRNA were constituted in the same manner. Briefly, the tube was centrifuged for one 
minute at 0.5 r.c.f. Then, 50ul 5X siRNA buffer and 200μl RNase-free water were added to 
the siRNA pellet in the tube to make a 20μM stock. The solution was pipetted up and down 
three times. Then, the tube was placed in a shaker for 30 minutes at RT. Following this, 
the tube was centrifuged at 0.5 r.c.f. for two minutes. Aliquots of 50μl were made up in 
1.5ml Eppendorf tubes and stored at -20°C.  
The Transfection reagent, siRNA buffer and RNase-free water were stored at 4°C in their 
original form.  
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2.1.8 PCR Array 
2.1.8.1 Extraction of RNA 
RNA was extracted using the RNeasy Mini kit (Product code: 74104) from Qiagen,UK. 
 2.1.8.2 Conversion to cDNA 
 cDNA was prepared using QuantiTect Reverse Transcriptase kit (Product code: 205311) 
from Qiagen, UK. 
The Master mix was prepared as instructed in the QuantiTect Reverse Transcription 
handbook (detailed in Table 2.8) 
Table 2.8 Reagents used in the master mix 
 
 
 
2.1.8.3 PCR Array  
All the reagents listed below were purchased from Qiagen (UK). They were all stored at -
20°C. 
 RT2 SYBR Green qPCR Mastermix (Product no: 330500) [contained tubes of 
nuclease-free water] 
 RT² Profiler™ PCR Array Human Epithelial to Mesenchymal Transition (EMT) 
(Product no: 330231) 
 
 
 
Master mix components Volume per 
reaction (µl) 
Quantiscript Reverse 
Trancriptase 
1 
Quantiscript RT Buffer 4 
RT Primer Mix 1 
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2.1.9 General labware 
Eppendorf tubes used in this study were 1.5ml tubes. For gene silencing, 2ml tubes were 
used. Universal tubes used were 20ml tubes, falcons were 50ml tubes and the centrifuge 
tubes were 14ml tubes.  
 
2.2 Methods 
 
2.2.1 General handling of cell lines 
All cell culture work was done in a laminar flow hood. The work area was always cleaned 
with 70% IMS (Industrial methylated spirit - made up with RO water) before and after work.  
2.2.1.1 Maintenance of cell lines 
The appropriate media for each cell line used is listed in Table 2.1 and section 2.1.2 
explains how each type of media was made up. All cells were grown in T25 or T75 culture 
flasks in a single monolayer attached to the flask surface in a humidified incubator at 37°C 
with 5% CO2. 
2.2.1.2 Thawing of frozen cells 
As a general rule, all cell lines were stored in liquid nitrogen. When needed, cells (present 
in a cryotube) were allowed to thaw at 37°C in a water bath until a small frozen pellet 
remained. The cryotube was then removed from the water bath and the remaining frozen 
pellet was allowed to thaw at RT. The tube was then wiped down with 70% IMS. The cell 
suspension was transferred from the cryotube into a universal tube. 10ml of appropriate 
media was then added dropwise to the suspension. The solution was centrifuged at 300xg 
for five minutes at RT. The media was removed and the cell pellet was suspended in 10ml 
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of the appropriate fresh media. The cell suspension was transferred to a labelled T25 
culture flask and placed in a humidified incubator at 37°C with 5% CO2. 
2.2.1.3 Freezing cells for storage 
Cells were grown to approximately 80% confluency in a T25 culture flask. Cells were then 
trypsinised with 2ml trypsin-EDTA for five minutes in a humidified incubator at 37°C with 
5% CO2 to ensure complete cell detachment, which was confirmed with a light microscope. 
The action of trypsin-EDTA was neutralised by the addition of 8ml of appropriate media. 
The cell suspension was transferred to a universal tube and centrifuged at 300xg for five 
minutes. The media was removed and the cell pellet was suspended in 1ml of freezing 
medium. The cells suspended in the freezing medium were transferred to a labelled 
cryotube. The cryotube was then placed in a freezing jar at -80°C and then transferred to 
liquid nitrogen afterwards for long term storage. 
2.2.1.4 Cell culture 
Cells were grown, trypsinised and media was added to neutralise the trypsin-EDTA as 
described in section 2.2.1.3.  
For drug resistant cell lines, the appropriate volume of the specific drug was added to 
maintain the required concentration shown in in Table 2.2 each time the drug-resistant 
cells were passaged.  
The in-vitro drug-resistant OVCAR3 cell line was passaged as described above (Section 
2.2.1.3). The appropriate volumes of EGF, IL-6 and TGF-β were added to the media 
containing the cells to obtain final concentrations of 20ng/ml, 50ng/ml and 10ng/ml 
respectively.  
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2.2.2 Western Blotting 
2.2.2.1 Extraction of protein 
The lysis buffer was made up as described in section 2.1.3.1 (lysis buffer) and the 
Eppendorf was placed on ice till needed. Cells were cultured in T75 flasks till they reached 
80%-90% confluency. They were then trypsinised and suspended in media. The cell 
suspension was transferred to a universal tube and centrifuged at 300xg for five minutes. 
The media was removed, the cell pellet was suspended in 5ml PBS and centrifuged at 
300xg for five minutes. This last step was repeated twice. The PBS was then removed and 
the cell pellet was immersed in the prepared lysis buffer. The tube was placed on ice for 
10 minutes. After 10 minutes, the solution was transferred to an Eppendorf. The solution 
was lysed with a 25-gauge needle and the lysed solution was placed on ice for 30 minutes. 
After 30 minutes, the lysed solution was centrifuged at 0.5 r.c.f. for 10 minutes at 4°C. The 
supernatant was transferred to a labelled Eppendorf tube and stored at -20°C till needed.  
2.2.2.2 Quantification of total protein concentration 
In order to determine the total protein concentration in the prepared cell lysate, the Bio-
Rad protein assay based on the Bradford method was used. The assay depends on the 
colour change of the blue Coomassie dye, whose colour change is based on the amount 
of protein in the sample being tested. 
50μl of each serial standard BSA dilution (Table 2.5) was added in duplicate to a 96-well 
plate. For the control, 50μl of RO water was added in duplicate to the plate. 5μl of the 
sample was added in duplicate to the 96-well plate. The samples were diluted in 45μl of 
RO water for a 1/10 sample dilution. 25μl working reagent was pipetted to each control, 
standard and sample well. This was followed by the addition of 200μl of reagent B to each 
well. The plate was left for five minutes and the absorbance was read at 690nm in an 
ELISA plate reader. The total protein concentration was calculated using the obtained 
absorbance values and the standard curve.  
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2.2.2.3 Sample preparation 
For western blotting, a protein quantity of 30μg per lane was used. The protein amount 
was taken from the sample into an Eppendorf. 5μl NuPAGE LDS Sample buffer (X4) and 
2μl NuPAGE Reducing Agent (X10) were added to the Eppendorf tube. The reducing 
agent dentures the secondary and tertiary protein structures and the sample buffer aids to 
maintain the polypeptides in their denatured state. The LDS is negatively charged and this 
allows the proteins to move towards the positive electrode during electrophoresis. The 
total volume was made up to 25μl with RO water. The prepared samples were then heated 
at 70°C for 10 minutes. The samples were cooled on ice for three minutes and vortexed for 
5 seconds before being centrifuged for 10 secs at RT. 
2.2.2.4 Electrophoresis 
For electrophoresis, NuPAGE Bis-Tris (10%) gels or Tris-Acetate (7%) pre-cast gels 
(Invitrogen, Paisley, UK) were used. The type of gel being used depended on the protein 
of interest. The Bis-Tris gels were used for proteins with low molecular weights. The Tris-
Acetate gels were used for proteins with high molecular weights. The gels were placed into 
the gel tank (Invitrogen, Paisley, UK) and locked into place. The tank was then filled with 
running buffer (X1) until the wells were covered completely. Two types of running buffers 
were used: Tris-Acetate SDS running buffer was used with the Tris-Acetate gels and 
MOPS SDS running buffer was used with Bis-Tris gels. 24μl of a sample was loaded into a 
well. 3μl of the ladder marker (Novex Sharp pre-stained protein standard, Invitrogen 
Paisley, UK) was loaded into another well. The ladder marker contained a mixture of 
stained proteins at defined molecular weights, which allowed the determination of the 
location of protein of interest (with its known molecular weight) in the samples. 24µl of an 
appropriate positive sample was also added to a well. The positive sample was used to 
validate the specificity of the antibodies used and was a cell line that was determined to be 
positive for the protein being tested for. The lid was secured onto gel tank and 
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electrophoresis was carried out at 240V for approximately 45 minutes (or till the dye 
reached the edge of plate).  
2.2.2.5 Transfer 
After the separation of the proteins on the gel, the gel was prepared for the transfer 
process during which the separated proteins are transferred onto a nitrocellulose 
membrane for protein detection. The gel was carefully removed from the gel tank. Filter 
paper, blotting pads and nitrocellulose membrane were soaked in Transfer buffer (X1) 
containing 10% methanol for 5 minutes. Then, the membrane was placed onto the gel and 
the gel/membrane assembly was sandwiched between filter paper and blotting pads. This 
sandwich was then placed on a blotting module which was inserted into a gel tank 
(Invitrogen, Paisley, UK). The tank was filled with transfer buffer (X1) and the transfer of 
proteins was carried out at 45V for two hours. As the voltage used is low, ice packs are not 
required as heat generated is less. 
2.2.2.6 Blocking of membrane 
After transfer, the gel was discarded and the membrane was washed in RO water for five 
minutes twice. The membrane was then blocked with BSA or milk. Blocking is done to 
ensure non-specific interactions between the proteins on the membrane and the antibody 
are minimised. After washing the membrane with RO water, the membrane was placed in 
a solution of either 5% milk or 5% BSA depending on the protein of interest. Blocking was 
done for one hour at RT on a rotary shaker.  
2.2.2.7 Primary antibody incubation of membrane 
After blocking, the membrane was incubated in primary antibody solution containing the 
antibody of interest overnight on a rotary shaker at 4°C.  
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2.2.2.8 Secondary antibody incubation of membrane 
The membrane was washed with PBS:Tween 20 solution for five minutes at RT thrice. The 
membrane was then placed in secondary antibody solution with the appropriate secondary 
antibody and incubated for one hour at RT on the rotary shaker.  
2.2.2.9 Visualisation of membrane 
After secondary antibody incubation, the membrane was washed in PBS:Tween 20 
(TBS:Tween 20 was used with membranes probed for phosphorylated proteins) for five 
minutes twice followed by a single wash with PBS (or TBS) for five minutes (all steps at 
RT). The membrane was visualised with LiCOR Odyssey CLx Imaging System.  
2.2.2.10 Re-use of membrane 
Due to the risk of losing proteins with stripping methods, stripping was not done. Each 
membrane was used twice; First for specific probing for protein of interest and second for 
GAPDH. After antibody probing and membrane visualisation, the membrane was washed 
with RO water for five minutes and then with PBS for five minutes. Then, blocking followed 
by GAPDH probing (loading control) and secondary antibody probing were carried out. 
After GAPDH visualisation, the membrane was discarded. 
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Figure 2.3 Flow diagram for the western blotting process 
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2.2.3 Scratch Assay 
Scratch assays can be used to look at cell migratory behaviour under various conditions. 
In this study, cell migration was assessed between parental and drug-resistant cells and to 
determine the effects of drug treatment on cell migration.  
Cells were grown to 100% confluency (i.e. cells covered the entire floor of the well) in a 24-
well plate for 24 hours. Wells of plates with the SKOV3 cell line were then treated with 
serum-free media for 24 hours. Wells of plates with the OVCAR3 cell line were treated with 
serum-free media for 4 hours. Serum starvation was carried out to avoid the effect of cell 
proliferation on wound closure in the assays. OVCAR3 cells were found to be sensitive to 
serum starvation more than the SKOV3 cells and therefore, a decreased number of hours 
of serum starvation were used. After serum starvation, a scratch was made in each well 
with a 1000μl pipette tip. The media was replaced with 100% serum-containing media and 
appropriate drug treatment was carried out (SKOV3 - 100µM; OVCAR3 – 5nM and 10nM). 
The scratches were then photographed with an EVOS FL Microscope (Life Technologies). 
SKOV3 scratch assays were analysed for 24 hours and the OVCAR3 assays were 
analysed for 48 hours. With the OVCAR3 assay, since the analysis was carried out for 48 
hours, the media was changed at the 24-hour time point (after the first drug treatment at 0 
hours when the scratches were made) and drug treatment was carried out and wells were 
photographed at the 48-hour end point. The changes in the widths of the scratches were 
then analysed using Cell Profiler software.  
 
2.2.4 Epithelial Antigen Staining   
Cells were cultured in T25 flasks until they were 60%-70% confluent. Cells were then 
harvested using trypsin-EDTA and suspended in culture media. The cell suspension was 
centrifuged at 500xg for five minutes. The media was removed and the cell pellet was 
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suspended in 5ml PBS. The solution was centrifuged again at 500xg for five minutes. The 
PBS was removed and the cell pellet was resuspended in 200μl PBS. This solution was 
then split into two Eppendorfs (100μl in each) and labelled blank sample and test sample. 
To the test sample tube, 25μl of the prepared antibody solution was added. To the blank 
sample tube, 25μl PBS was added. Both the blank and test samples were then incubated 
in the dark at RT for 30 minutes. After 30 minutes, each sample was washed with 200μl 
PBS. The samples were centrifuged at 1000xg for 10 minutes. The PBS was then 
removed and the samples were suspended in 500μl PBS containing 2% BSA and 
analysed on the flow cytometer.   
This method was used to determine the epithelial natures of parental and drug resistant 
cell lines. Ber-EP4 is a monoclonal antibody that binds to specific cell surface 
glycoproteins present on epithelial cells. Therefore, it does not detect any non-epithelial 
cells and is useful in the differentiation between epithelial and mesenchymal cells (Latza et 
al., 1990).  
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Figure 2.4 Flow diagram for the epithelial antigen staining process 
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2.2.5 Annexin V-FITC Apoptosis Detection 
When cells undergo apoptosis, one of the first steps is the translocation of cell membrane-
bound phosphatidylserine (PS) to the outer surface of the membrane. The detection of this 
protein allows the identification of cells undergoing apoptosis. Annexin V is a protein with a 
high affinity to PS. Conjugated to FITC (a fluorescent probe), Annexin V can be used in 
apoptosis detection assays. The loss of membrane integrity is a characteristic of late stage 
apoptosis and this is detected by a dye such as Propidium Iodide (PI). Therefore, viable 
healthy cells will be both Annexin V and PI negative, cells that are in early apoptosis will 
be Annexin V positive, but PI negative. Cells that are in late apoptosis will be both Annexin 
V and PI positive (Figure 2.5) (Hingorani et al., 2011). 
Figure 2.5: Identification of viable and apoptotic cells by Annexin V and PI 
Healthy viable cells contain PS on the inner surface of the membrane. 
Therefore, Annexin V cannot bind to it. In early stage apoptosis, PS 
translocates to the outer surface of the membrane allowing Annexin V 
detection and binding. In late stage apoptosis, membrane disintegration 
occurs, which allows PI dye to enter and stain the cell (Hingorani et al., 
2011). [Original Figure] 
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Cells were grown in T25 flasks till they were 80% confluent. The media they were in was 
saved in a universal tube. The cells were harvested with trypsin-EDTA and suspended in 
their saved culture media. The solution was then centrifuged at 500xg for four minutes. 
The media was removed and the cell pellet was suspended in 500μl cold PBS. This 
solution was transferred to an Eppendorf tube and centrifuged at 0.5 r.c.f. for five minutes 
at 4°C. The PBS was removed and the cell pellet was suspended in 500μl 1X Binding 
buffer. To this solution, 2μl Annexin V-FITC was added. The solution was mixed in a 
vortexer and incubated in the dark at RT for 30 minutes. After 30 minutes, the solution was 
centrifuged at 0.5 r.c.f for five minutes at 4°C. The solution was removed and the pellet 
was suspended in 500μl 1X Binding buffer. To this solution, 10μl PI was added and the 
solution was mixed in the vortexer. The sample was then analysed by flow cytometry, 
which separates the cells into groups (viable cells, early apoptosis and late apoptosis).  
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Figure 2.6 Flow diagram for the cell apoptosis detection assay 
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Flow cytometer 
A flow cytometer (consisting of a fluidic system, an optic system and an electronic system) 
allows analysis of single cell suspensions. In short, a single cell suspension is taken into 
the flow cytometer. In order for each cell to be analysed, the cells are sorted into a single 
file. Each cell of this single cell file will pass through a laser beam. The laser beam will hit 
the cell and excite any fluorophores attached to the cell (e.g. FITC) and this will emit a 
fluorescence light. The fluorescence light is detected by the detector and the information is 
processed (Figure 2.7) (Thermo Fisher Scientific).  
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Figure 2.7: Flow cytometer analysis of single cell suspensions 
A single cell suspension is taken into the machine and the cells are 
sorted into a single cell file by the fluidic system of the flow 
cytometer. The laser beam passes through the cell and light is 
scattered when it hits components in the cell (optical system). The 
light hitting the cell will also excite any fluorophores in the cells, 
which will emit fluorescence light, which will then be detected and 
processed by the detector (electronic system). The information can 
then be analysed on a computer connected to the flow cytometer 
(Thermo Fisher Scientific).  
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The data produced by a flow cytometer is presented in a cytogram (Figure 2.8). Cytograms 
consist of four quadrants each representing a specific state of a cell (viable, early 
apoptotic, late apoptotic and necrosis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Necrosis Late apoptosis 
Viable 
Early apoptosis 
FL3 
(PI) 
FL1 
(Annexin V-
FITC) 
Figure 2.8: Typical cytogram produced by a flow cytometer 
There are four quadrants in each cytogram. E1 represents necrotic cells (PI 
positive only), E2 represents cells in late apoptosis stage (both PI and 
Annexin V-FITC positive), E3 represents viable cells (both PI and Annexin V-
FITC negative) and E4 represents cells in early apoptosis stage (Annexin V-
FITC positive only).  
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2.2.6 Cell Viability Assay 
To measure cell viability in response to various doses of drug treatment, the MTT assay 
was used. The MTT assay is a colourimetric assay that depends on the activity of 
NAD(P)H –dependent cellular oxidoreductase enzymes. These enzymes reduce the 
yellow MTT dye to insoluble purple formazan crystal. The insoluble formazan is solubilised 
by the addition of DMSO and the absorbance reading is taken. The absorbance value is a 
reflection of the amount of viable cells.  
Cells (parental and drug-resistant) were set up in a 96-well plate and allowed to reach 40-
50% confluency overnight. The appropriate drug concentration (Table 2.9) was added to 
the appropriate wells and the plate incubated at 37ºC and 5% CO2 for 72 hours. The 
chosen drug ranges were obtained from previous laboratory work. At 72 hours, 20μl of 
MTT solution (5mg/ml) was added to each well. The cells were incubated for four hours 
with the MTT solution to allow for the development of the purple formazan crystals. After 
four hours, the liquid in the wells were aspirated and the purple crystals were solubilised 
by the addition of 200μl of DMSO. The plate was left for five minutes and the absorbance 
was read at 570nm in a plate reader (Thermo Scientific – Labsystem Multiskan RC).  
 
Table 2.9: Concentration ranges of drugs used in MTT assays 
Type of Cell Line Drug Concentration Range 
OVCAR3 Paclitaxel 3nM - 160nM 
SKOV3 Carboplatin 2μM - 64μM 
SKOV3 Foretinib 0.1μM – 3.2μM 
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Figure 2.9 Flow diagram for the cell viability assay 
 
2.2.7 Gene Silencing Assay 
Proteins identified as being significantly more expressed in the resistant cells (through 
western blotting) were chosen for gene silencing. The genes of these proteins were 
silenced for 72 hours in the parental and drug-resistant cells of the appropriate cell line 
and were then drug treated to observe for re-sensitisation of the cells to the drug. 
Cells were plated to 50%-60% confluency in a 6-well plate for overnight. Then, cells were 
treated with the appropriate target siRNA (Table 2.10) or a scrambled siRNA (control). 
Firstly, for each well, the following tubes were set up: 
Cells were plated in 
a 96-well plate and 
left to reach 50% 
confluency 
overnight. The first 
four rows consisted 
of parental cells 
and the bottom four 
rows consisted of 
drug-resistant cells. 
Increasing doses of drug 
Cells were treated 
with increasing doses 
of drug. The red 
circles represent 
control wells with no 
drug treatment. 
72 hours 
Cells were incubated 
for four hours in MTT 
solution. 
200µl DMSO was 
added to each cell to 
dissolve the purple 
formazan crystals 
formed.  
Absorbance readings 
were taken using a 
plate reader at 570nm. 
  6278156 
 
115 
 
 Tube 1: 10μl 20μM stock siRNA + 90μl RNase-free water +100μl serum-free media 
(SFM). 
 Tube 2: 3μl DharmaFect reagent + 200μl SFM. 
 
The tubes were left at RT for five minutes and then mixed together and left at RT for 20 
minutes. The media was removed from the wells and wells were washed with sterile PBS 
twice. Then, 400μl of the appropriate siRNA mix (target siRNA or scrambled siRNA) was 
added to the appropriate well and the cells incubated for four hours in a humidified 
incubator at 37°C with 5% CO2. At the end of the four hour incubation, 400μl of culture 
media containing 20% FBS was added. The cells were incubated overnight in a humidified 
incubator at 37°C with 5% CO2. The next day, the media was replaced with 100% FBS-
containing culture media. Cells were incubated for a total of 72 hours (from the day of 
silencing) and then harvested to set up cells for western blotting and flow cytometry 
analyses.  
                   Table 2.10: Type of gene silenced for each particular cell line 
 
2.2.7.1 Setting up siRNA-treated cells for flow cytometry analyses 
Cells were harvested from the siRNA-treated 6-well plate. They were then plated into wells 
of a fresh 6-well plate. Following the cell plating, cells were allowed to attach to the well 
bottom for two hours and then treated with different drugs (paclitaxel for OVCAR3 and 
carboplatin for SKOV3) and incubated for 48 hours in a humidified incubator at 37°C with 
5% CO2. After 48 hours, cells were harvested for Annexin V-FITC Apoptosis Detection 
Assay (Section 2.2.5). 
OVCAR3 paclitaxel-sensitive and 
resistant cells and EMT-induced cell 
model 
SKOV3 carboplatin-sensitive 
and resistant cells 
Slug Met 
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Figure 2.10 Flow diagram for the gene silencing assay 
Cells are harvested 
and set up in fresh 
6-well plate for drug 
treatment.  
Cells plated in a 6-
well plate to reach 
60% confluency. 
Overnight 
10µl stock siRNa (either 
target or scrambled 
siRNA) + 90µl RNase-
free water + 100µl SFM 
3µl Dharmafect 
reagent + 200µl 
SFM 
Allowed to stand 
for five minutes at 
RT and then 
mixed together. 
Allowed mixture to stand 
for 20 minutes at RT. 
Culture media was 
removed from the wells 
and the cells were 
washed with sterile PBS 
twice. 
Target 
siRNA 
Scrambled 
siRNA 
400µl of appropriate 
siRNA was added 
to appropriate well. 
Four hours 400µl 20% FBS-
containing culture media 
added to siRNA-
containing well.  
Overnight 
Culture media in 
siRNA-treated wells 
replaced with 100% 
FBS-containing 
culture media.  
After 72 
hours 
(from day 
of 
silencing) 
Target 
siRNA 
Scrambled 
siRNA 
No drug Drug added 
48 
hours 
Cells are harvested 
and processed for 
Annexin V-FITC 
apoptosis analysis.  
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2.2.8 qPCR Array 
2.2.8.1 Extraction of RNA 
The detailed protocol for RNA extraction is provided in the RNeasy Mini Handbook by 
Qiagen. In short, cells were harvested from a T25 flask and lysed and homogenised with 
350µl of Buffer RLT (containing 10 µl ß-Mercaptoethanol per 1 ml Buffer RLT for effective 
inactivation of RNases in the sample). Then, 70% ethanol was added and 700µl of the 
sample was added to an RNeasy spin column placed in a collection tube. The sample was 
centrifuged at 8000xg for 15 seconds. RNA is collected in the spin column and the flow 
through in the collection tube is discarded. 700µl Buffer RW1 (washing buffer to remove 
molecules such as carbohydrates and proteins etc.) was added to the spin column and the 
tube was centrifuged at 8000xg for 15 seconds. 500µl Buffer RPE (washing buffer for the 
removal of salts) was added to the spin column and centrifuged at 8000xg for 15 seconds. 
500µl Buffer RPE was added to the spin column again and centrifuged at 8000xg for two 
minutes. 30µl RNase-free water was added to the spin column and centrifuged at 8000xg 
for a minute to elute the RNA.  
The RNA quantity and quality was determined using the Thermo Scientific NanoDrop 2000 
spectrophotometer and the Agilent 2100 Bioanalyser respectively.  
2.2.8.2 Conversion to cDNA 
The detailed protocol for the conversion of the RNA to cDNA is given in the QuantiTect 
Reverse Transcriptase Handbook by Qiagen. In short, the RNA was incubated with gDNA 
Wipeout Buffer (to eliminate genomic DNA) and RNase-free water at 42ºC for two minutes. 
Then, the master mix (Table 2.8) was added to the RNA-containing solution and incubated 
at 42ºC for 15 minutes. The sample was then incubated at 95ºC for three minutes to 
inactivate the Reverse Transcriptase enzyme.  
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2.2.8.3 Setting up PCR Plate for qPCR analyses 
The RT2 Profiler PCR array was chosen because it enabled the simultaneous analysis of 
84 genes related to EMT (the process of interest in the PhD study). The array also 
contained assays for housekeeping genes, a genomic DNA control (to detect DNA 
contamination of sample), a reverse transcription control (to determine the efficiency of the 
reverse transcription reaction) and a positive PCR control (to determine the efficiency of 
the PCR process).  
Detailed information on the protocol followed is provided in the RT2 profiler PCR Array 
Handbook from Qiagen. In short, the RT2 SYBR green master mix, the prepared cDNA 
(section 2.2.8.2), nuclease-free water (NFW) and the PCR array plate were thawed at RT. 
The PCR components mix was prepared as given below (Table 2.11) in a centrifuge tube.  
Table 2.11: Preparation of the PCR components mix 
 
[1x indicates the amount of each component for a single well and as there are 96 wells in 
the PCR array plate, a PCR components mix volume was made for 108 wells in order to 
avoid pipetting errors] 
25μl of the PCR mix was added to each well of the PCR array plate. The plate was tightly 
sealed with ABI optical adhesive film (Applied Biosystems) and centrifuged for one minute 
at 1000xg at RT. The plate was then run on the Applied Biosystems QuantStudio 7 real-
time PCR cycler according to the protocol in Table 2.12. 
Reagents 1x (μl) 108x (μl) 
RT2 SYBR Green Master mix 12.5 1350 
cDNA (5ng/well) 0.1 10.8 
NFW 12.4 1339.2 
TOTAL VOLUME 25 2700 
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Table 2.12: The PCR cycling program 
 
 
 
The CT values obtained were analysed using the SABiosciences PCR Array Data Analysis 
software. 
2.2.9 Statistical Analyses 
All statistical analyses conducted were carried out using GraphPad Prism 7 software. 
Statistical data were presented as mean ± standard deviation with P<0.05 denoting 
statistical significance. For western blotting and epithelial antigen staining assay analyses 
between parental and drug-resistant cell lines, student’s unpaired t-test was used.  For 
gene silencing assay analyses, one-way ANOVA was used. For scratch assay analyses, 
student’s unpaired t-test was used to compare between parental and drug-resistant cell 
lines with one-way ANOVA being used to compare between more than two groups (i.e. 
when drug-treated cells were compared). Parametric tests were used as the data was 
assumed to have a normal distribution.  For combination analyses, the mean absorbance 
values were run through the Compusyn software and combination index values were 
obtained. A combination index value equal to one indicates an additivity effect between the 
two drugs, a value less than one indicates synergism between the two drugs and a value 
greater than one indicates antagonism between the two drugs. PCR array analyses were 
conducted using SABiosciences PCR Array Data Analysis software available on the 
Qiagen website. CT values were uploaded onto the data analysis website on the Qiagen 
website. The online software uses the delta delta CT method to calculate fold regulation 
values.  
Cycles Duration Temperature (°C) 
1 10 mins 95 
40 15 secs 95 
1 min 60 
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Firstly, the delta CT  value is calculated as follows for each gene in each control and drug-
resistant sample: 
ΔCT = CT (gene of interest) – CT (housekeeping gene) 
Once the ΔCT values have been obtained for each gene of interest in each control group 
and drug-resistant group, the delta-delta CT calculations are performed for each gene as 
follows: 
ΔΔCT= ΔCT (drug-resistant sample) – ΔCT (control sample) 
ΔΔCT value represents the difference between the two samples for a particular gene. Fold 
change is then calculated as follows: 
Fold change = 2^-(∆∆CT) 
Fold change was used to identify genes whose expression was significantly different 
between the parental and drug-resistant cell lines. Values greater than one were 
considered to denote upregulation and values less than one were considered to denote 
downregulation. 
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CHAPTER 3 
 The role of EMT in drug resistance 
and the identification of EMT-
associated proteins for the role of 
biomarkers of drug resistance in 
ovarian cancer 
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3.1 Introduction 
 
In 1992, EMT characteristics were observed in two drug-resistant breast cancer cell lines 
(Sommers et al., 1992). A decrease in epithelial markers, KERATIN-19 and ZONA-
OCCLUDENS-1, and an increase in mesenchymal marker, VIMENTIN, (typical EMT 
characteristics) were seen in Adriamycin-resistant MCF7 and Vinblastine-resistant ZR-75-
B cell lines. Since then, there has been an accumulation of research on EMT and drug 
resistance. Du et al. (2016) and Shibue & Weinberg (2017) discuss this subject in general 
(reviews) whilst there is many literature on the subject focussed on particular cancer types 
such as pancreatic cancer (Sarkar et al., 2009, Gaianigo et al., 2017), breast cancer 
(Huang et al., 2015) and gastric cancer (Xu et al., 2017, Zhou et al., 2018) to name a few.  
Research on EMT and its association with drug resistance in ovarian cancer is limited as 
evidenced by literature searches conducted. Ovarian cancer is the 8th most common 
cancer in women worldwide and the 3rd most common gynaecologic cancer worldwide 
(International Agency for Research on Cancer, 2018). Ovarian cancer is typically 
asymptomatic in its early stages resulting in it being diagnosed in the advanced stages 
during which the cancer may have already metastasised (Reid et al., 2017). This results in 
poor prognosis and poor survival rates. Due to the low survival rates of ovarian cancer 
typically attributed to late diagnoses, the onset of drug resistance in such cases is an 
added disadvantage. Therefore, drug resistance in ovarian cancer requires a better 
understanding and an ability to recognise a possible drug-resistant phenotype in ovarian 
cancer patients could be of great help to only to the patients themselves, but to the 
healthcare system as well.  
Drug resistance can be induced by many factors such as drug inactivation, changes to the 
drug target and the increased repair of DNA damage induced by the drug (Housman et al., 
2014) (Figure 1.9). In recent times, epithelial-mesenchymal transition (EMT) has become 
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increasingly associated with drug resistance in cancer (Du and Shim, 2016, Shibue and 
Weinberg, 2017). As the process of EMT has already been described in section 1.6, only a 
brief description has been outlined here. EMT is characterised by a change from an 
epithelial to a mesenchymal cell phenotype (Kalluri and Weinberg, 2010) and this process 
is driven by regulatory changes in various transcription factors such as SNAIL, SLUG, 
TWIST and ZEB (Voon et al., 2017). As drug-resistant cells exhibit EMT characteristics 
such as upregulated SNAIL, SLUG (Kurrey et al., 2009) and VIMENTIN levels and 
decreased E-CADHERIN levels (Haslehurst et al., 2012), the idea of using such EMT-
related proteins as possible biomarkers to identify a drug-resistant phenotype in ovarian 
cancer is investigated in this chapter.  
Firstly, five proteins, commonly referred to in the associated literature with EMT, were 
chosen as EMT-markers: E-CADHERIN, β-CATENIN, VIMENTIN, SLUG and TWIST. 
Using four drug-resistant ovarian cancer cell lines (one paclitaxel-resistant cell line and 
three carboplatin-resistant cell lines) along with their drug-sensitive (parental) 
counterparts, the first part of the chapter identifies the presence of these chosen proteins 
in these cells lines to determine their possible significance in identifying a drug-resistant 
phenotype. These drug-resistant cell lines were chosen to work with as carboplatin and 
paclitaxel are the standard first-line choices as chemotherapy in ovarian cancer (Jayson et 
al., 2014).  
When a cell undergoes EMT, it loses contact with its neighbouring cells and its basement 
membrane giving it a motile phenotype (Boyer et al., 2000). Operating under the 
hypothesis that drug-resistant cells have undergone EMT, one can conclude that these 
cells might also have increased migratory capacities. This hypothesis was tested with one 
paclitaxel-resistant cell line and one carboplatin-resistant cell line.  
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The hypothesis that inducing EMT in a cell line results in the induction of drug resistance 
was next tested. EMT was induced with a cocktail of EGF (20ng/ml), IL-6 (50ng/ml) and 
TGF-β (10ng/ml) in one parental ovarian cancer cell line and the presence of the EMT 
markers and the cells’ motile capacity was measured to determine its drug-resistant 
phenotype. Finally, after studying protein markers’ expressions in the drug-resistant cell 
lines, the next avenue of research focussed on whether drug-resistant cells could be re-
sensitised to drug treatment on silencing the genes of upregulated proteins. This could 
further help determine the reliability of these proteins as possible biomarkers of drug 
resistance in ovarian cancer.  
 
Hypotheses investigated in the chapter: 
 Drug-resistant ovarian cancer cells display a more mesenchymal phenotype 
compared to their drug-sensitive counterparts (parental cells). 
 Drug-resistant ovarian cancer cells display an increased migratory capacity 
compared to their drug-sensitive counterparts (parental cells).  
 EMT-induced ovarian cancer cells display a drug-resistant phenotype.  
 Silencing EMT-marker genes can reverse the drug-resistant phenotype in drug-
resistant cells making them more sensitive to drug treatment.  
 
3.2 Methods used in the chapter 
Various methods were employed to investigate the hypotheses including western blotting 
(section 2.2.2), scratch assays (section 2.2.3), epithelial antigen staining (section 2.2.4), 
annexin V-FITC assay (section 2.2.5) and gene silencing (section 2.2.7). All methods used 
in this chapter are described in full detail in chapter 2. 
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3.3 Results 
3.3.1 Determination of the use of commonly used EMT-associated proteins as biomarkers 
of drug resistance in ovarian cancer 
 
3.3.1.1 E-CADHERIN  
E-CADHERIN expression was decreased in all but one of the drug-resistant cell lines. The 
CaOV3 CR cell line expressed significantly more E-CADHERIN compared to its parental 
counterpart (P<0.01) (Figure 3.1).  
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Figure 3.1 E-CADHERIN expression in parental 
and drug-resistant ovarian cancer cell lines 
 
E-CADHERIN protein levels were analysed 
through western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels and 
transferred onto nitrocellulose membranes. The 
membranes were then blocked and probed for 
primary and secondary antibodies and 
visualised with the LiCOR Odyssey CLx Imaging 
System.  ** P<0.01 between indicated groups 
(Unpaired T-test) n=3. 
  
 
3.3.1.2 β-CATENIN   
β-CATENIN expression was increased significantly in all of the drug-resistant cell lines 
compared to their parental counterparts (OVCAR3: P<0.05; SKOV3, PEO1 and CaOV3: 
P<0.01) (Figure 3.2).   
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Figure 3.2 β-CATENIN expression in parental and drug-resistant ovarian cancer cell 
lines 
β-CATENIN protein levels were analysed through western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging System.  
* P<0.05; ** P<0.01 between indicated groups (Unpaired T-test) n=3. 
  
 
3.3.1.3 VIMENTIN  
VIMENTIN expression was decreased in two drug-resistant cell lines (OVCAR3: P>0.05) 
and SKOV3: P<0.001)) and increased in the other two drug-resistant cell lines (CaOV3: 
P>0.05 and PEO1: P<0.0001) (Figure 3.3). 
 
β-CATENIN 
92kDa 
GAPDH 
37kDa 
Positive 
Control 
O
V
C
A
R
3
 C
o
n
tr
o
l 
O
V
C
A
R
3
 T
a
x
R
 
S
K
O
V
3
 C
o
n
tr
o
l 
S
K
O
V
3
 C
R
 
P
E
O
1
 C
o
n
tr
o
l 
P
E
O
1
 C
R
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
N
o
rm
a
li
s
e
d
 b
a
n
d
 d
e
n
s
it
y
*
* *
* *
C
a
O
V
3
 C
o
n
tr
o
l 
C
a
O
V
3
 C
R
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
N
o
r
m
a
li
s
e
d
 b
a
n
d
 d
e
n
s
it
y
* *
  6278156 
 
128 
 
A 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 VIMENTIN expression in parental and drug-resistant ovarian cancer cells 
VIMENTIN protein levels were analysed through western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging System.  
*** P<0.001; **** P<0.0001 between indicated groups (Unpaired T-test) n=3. 
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3.3.1.4 SLUG  
SLUG expression was increased in all but one of the drug-resistant cell lines. SLUG 
expression was increased in the drug-resistant cell lines of OVCAR3 (P<0.0001), SKOV3 
(P<0.0001) and PEO1 (P<0.01). In the drug-resistant CaOV3 cell line, SLUG was 
decreased compared to its parental cell line (P>0.05) (Figure 3.4). 
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Figure 3.4 SLUG expression in parental and drug-resistant ovarian cancer cells 
SLUG protein levels were analysed through western blotting. Proteins were 
electrophoresed on 10% Bis-Tris gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging System.  
** P<0.01; **** P<0.0001 between indicated groups (Unpaired T-test) n=3. 
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3.3.1.5 TWIST  
TWIST is decreased in all the drug-resistant cell lines (OVCAR3 and SKOV3: P<0.05 and 
CaOV3: P>0.05) except for the PEO1 carboplatin-resistant cell line (P<0.01). (Figure 3.5).  
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Figure 3.5 TWIST expression in parental and drug-resistant ovarian cancer cells 
TWIST protein levels were analysed through western blotting. Proteins were 
electrophoresed on 10% Bis-Tris gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging System.  
* P<0.05; ** P<0.01 between indicated groups (Unpaired T-test) n=3. 
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3.3.1.6 Epithelial antigen staining to determine the epithelial nature of a cell line 
Ber-EP4 detects a protein antigen present on epithelial cells (Latza et al., 1990). This 
protein antigen is not expressed on normal or neoplastic non-epithelial cells. Cells were 
treated with the epithelial antigen for 30 minutes (PBS used as a control) and cells were 
sorted through the flow cytometer. Graphs were produced from the flow cytometry 
analyses and the peaks of each parental and drug resistant cell line were compared to 
each other. The cell line with the greater peak value (peak is more to the right compared to 
the peak of the other cell line) meant that cell line had more cells with bound epithelial 
antigen making it more epithelial than the other cell line (Raw peak values are given in 
Appendix 7.1).  
3.3.1.6.1 Epithelial antigen staining in SKOV3 parental and carboplatin-resistant cells 
The average peak values were 5.4 units for SKOV3 control cells and 2.5 units for SKOV3 
CR cells. Here, the peak in the SKOV3 CR cells was shifted to the left (lower peak value) 
indicating there were significantly less epithelial antigens present compared to its parental 
control counterpart (P<0.05) (Figure 3.6). 
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Figure 3.6 Epithelial antigen staining in SKOV3 
parental and carboplatin-resistant cells 
Cells were incubated with either 25µl of Ber-EP4 
antibody or 25µl of PBS (Blank control)   for 30 
minutes and cells were sorted through the flow 
cytometer. * P<0.05 between indicated groups 
(Unpaired T-test) n=3.  
    
 
3.3.1.6.2 Epithelial antigen staining in OVCAR3 parental and paclitaxel-resistant cells 
The average peak values were 7.9 units for OVCAR3 control cells and 17.3 units for 
OVCAR3 TaxR cells. Here, the peak in the OVCAR3 TaxR cells was shifted to the right 
(higher peak value) indicating there were significantly more epithelial antigens present 
compared to its parental control counterpart (P<0.0001) (Figure 3.7). 
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Figure 3.7 Epithelial antigen staining in OVCAR3 parental and paclitaxel-resistant 
cells  
Cells were incubated with either 25µl of Ber-EP4 antibody or 25µl of PBS (Blank 
control)  for 30 minutes and cells were sorted through the flow cytometer. **** 
P<0.0001 between indicated groups (Unpaired T-test) n=3.  
  
3.3.1.6.3 Epithelial antigen staining in PEO1 parental and carboplatin-resistant cells 
The average peak values were 29.4 units for PEO1 control cells and 35.5 units for PEO1 
CR cells. Here, the peak in the PEO1 CR cells was shifted to the right (higher peak value) 
indicating there were significantly more epithelial antigens present compared to its parental 
control counterpart (P<0.001) (Figure 3.8). 
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Figure 3.8 Epithelial antigen staining in PEO1 parental and carboplatin-resistant 
cells 
Cells were incubated with either 25µl of Ber-EP4 antibody or 25µl of PBS (Blank 
control)  for 30 minutes and cells were sorted through the flow cytometer. *** 
P<0.001 between indicated groups (Unpaired T-test) n=3.  
  
3.3.2 Drug-resistant ovarian cancer cells display an increased migratory capacity 
compared to their parental cells 
In order to observe whether drug-resistant cells had an increased migratory capacity, 
scratch assays were carried out. SKOV3 scratch assays were conducted for 24 hours and 
OVCAR3 scratch assays were conducted for 48 hours. Cells could not be grown beyond 
these time points due to over-confluent wells and cell death in each cell line (All data 
obtained in the scratch assays are presented in Appendix 7.2).  
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3.3.2.1 Migratory capacity of carboplatin-resistant ovarian cancer cells 
The wounds in the SKOV3 CR wells closed faster than the wounds in the SKOV3 parental 
wells. The mean distance of wound closure with SKOV3 parental cells was 884.9µm ± 
42.1 and with SKOV3 CR cells, it was 1126µm ± 39.4 (P<0.001) (Figure 3.9).  
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Figure 3.9 Carboplatin-resistant cells 
exhibit an enhanced migratory capacity 
Scratches were made with a pipette tip 
in each well of a 24-well plate after cells 
had grown to 100% confluency. Wells 
were photographed and the gap widths 
were measured with Cell Profiler 
software when the scratches were 
made (0 hours) and at the 24-hour time 
point.  *** P<0.001 between indicated 
groups (Unpaired T-test) n=3. 
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In order to observe whether drug treatment has an effect on this enhanced migratory 
capacity, cells were treated with a dose of 100μM carboplatin and the scratch closure was 
examined. Drug treatment had a significant effect on migratory capacity. Drug treatment 
significantly reduced the migratory capacity of parental cells compared to untreated 
parental cells (mean distances of wound closures: 718.4µm ± 63.7 and 9884.9µm ± 42.1 
respectively   (P<0.01)). Drug treatment also significantly reduced the migratory capacity of 
carboplatin-resistant cells compared to their untreated resistant counterparts (mean 
distances of wound closures: 969.6µm ± 53.6 and 1126µm ± 39.4 respectively (P<0.05)). 
The reduction in migratory capacity seen with drug-treated parental cells was significantly 
greater when compared to the drug-treated resistant cells, in line with their relative drug 
sensitivities. Mean distance of wound closure for parental cells with drug treatment was 
718.4µm ± 63.7 and for drug-resistant cells with drug treatment, it was 969.6µm ± 53.6 
(P<0.01) (Figure 3.10). 
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3.3.2.2 Migratory capacity of paclitaxel-resistant ovarian cancer cells 
 
The wounds in the OVCAR3 TaxR wells closed faster than the wounds in the OVCAR3 
parental wells. The mean distance of wound closure with OVCAR3 parental cells was 
395.6µm ± 69.0 and with OVCAR3 TaxR cells, it was 761.9µm ± 81.1 (P<0.001) (Figure 
3.11).  
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Figure 3.10 Drug treatment affects the migratory capacity of SKOV3 cells 
Scratches were made with a pipette tip in each well of a 24-well plate after 
cells had grown to 100% confluency.  Media was replaced and for drug-treated 
wells, 100µM of carboplatin was added. Wells were photographed and the gap 
widths were measured with Cell Profiler software when the scratches were 
made (0 hours) and at the 24-hour time point.  * P<0.05; P<0.01 between 
indicated groups (One-way ANOVA) n=3. 
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Figure 3.11 Paclitaxel-resistant ovarian 
cancer cells exhibit an enhanced 
migratory capacity 
Scratches were made with a pipette tip 
in each well of a 24-well plate after cells 
had grown to 100% confluency. Wells 
were photographed and the gap widths 
were measured with Cell Profiler 
software when the scratches were made 
(0 hours) and at the 48-hour time point.  
*** P<0.001 between indicated groups 
(Unpaired T-test) n=4. 
 
 
Drug treatment had significantly reduced the migratory capacity of carboplatin-resistant 
cells (Figure 3.10) and in order to see whether this same pattern could be observed with 
paclitaxel-resistant cells, these drug-resistant cells were treated with 5nM and 10nM doses 
of paclitaxel. Treating OVCAR3 parental cells with increasing doses of paclitaxel showed 
that the greater the dose, the greater the reduction in migration capacity. Untreated 
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parental cells had the greatest migratory capacity (mean distance of wound closure: 
588µm ± 71.9) with the cells receiving the largest dose (10nM) having the slowest 
migratory rate (mean distance of wound closure: 363.6µm ± 84.1). None of these 
differences were of significance (P>0.05) (Figure 3.12).  
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Figure 3.12 Drug treatment affects the 
migratory capacity of OVCAR3 cells 
Scratches were made with a pipette tip in 
each well of a 24-well plate after cells had 
grown to 100% confluency.  Media was 
replaced and for drug-treated wells, 5nM or 
10nM of paclitaxel was added. Wells were 
photographed and the gap widths were 
measured with Cell Profiler software when 
the scratches were made (0 hours) and at 
the 48-hour time point. P>0.05 between all 
groups (One-way ANOVA) n=4. 
 
 
 
This same pattern was observed with the paclitaxel-resistant ovarian cancer cells. Treating 
paclitaxel-resistant cells with increasing doses of paclitaxel showed that the greater the 
dose, the greater the reduction in migration capacity. Untreated paclitaxel-resistant cells 
had the greatest migratory capacity (mean distance of wound closure: 1095µm ± 55.4) 
with the cells receiving the largest dose (10nM) having the slowest migratory rate (mean 
distance of wound closure: 633.4µm ± 53.4). All differences were significant (TaxR 
Control-TaxR 5nM: P<0.01, TaxR Control-TaxR 10nM: P<0.0001 and TaxR 5nM-TaxR 
10nM: P<0.05) (Figure 3.13). 
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Figure 3.13 Drug treatment affects 
the migratory capacity of paclitaxel-
resistant cells 
Scratches were made with a pipette 
tip in each well of a 24-well plate after 
cells had grown to 100% confluency.  
Media was replaced and for drug-
treated wells, 5nM or 10nM of 
paclitaxel was added. Wells were 
photographed and the gap widths 
were measured with Cell Profiler 
software when the scratches were 
made (0 hours) and at the 48-hour 
time point. * P<0.05; ** P<0.01; *** 
P<0.001 between indicated groups 
(One-way ANOVA) n=3. 
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When drug-treated OVCAR3 parental cells were compared to the drug-treated drug-
resistant cells, parental cells treated with a 5nM paclitaxel dose had a significantly greater 
reduction in their migratory capacity compared to their paclitaxel-resistant cells treated with 
the same dose (mean distance of wound closure: 408.9µm ± 100.7 vs. 798µm ± 41.3 
(P<0.01)). This same pattern was observed with the 10nM dose (mean distance of wound 
closure: parental 10nM: resistant 10nM: 363.6µm ± 84.1 vs. 633.4µm ± 53.4 (P<0.05) 
(Figure 3.14). 
Figure 3.14 Drug treatment affects 
paclitaxel-resistant cells to a lesser 
extent compared to parental cells 
Scratches were made with a pipette tip 
in each well of a 24-well plate after 
cells had grown to 100% confluency.  
Media was replaced and for drug-
treated wells, 5nM or 10nM of 
paclitaxel was added. Wells were 
photographed and the gap widths 
were measured with Cell Profiler 
software when the scratches were 
made (0 hours) and at the 48-hour 
time point. * P<0.05; ** P<0.01 between 
indicated groups (One-way ANOVA) 
n=3. 
 
 
3.3.3 EMT-induced ovarian cancer cells display a drug-resistant phenotype 
OVCAR3 cells were induced to undergo EMT with a treatment cocktail of EGF (20ng/ml), 
IL-6 (50ng/ml) and TGF-β (10ng/ml). These cells were analysed with western blotting and 
scratch assays to identify whether they displayed a drug-resistant phenotype. The cells 
were compared to the paclitaxel-resistant OVCAR3 cell line as the parental cell line was 
common to both. Western analysis done previously in section 3.3.1 has shown that 
different ovarian cancer cell lines can exhibit different protein expression panels in their 
drug-resistant states and therefore, it was deemed the proper course of action to only 
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compare the EMT-induced cell line to the cell line with which it shares the common 
parental cell line.  
3.3.3.1 EMT-induced ovarian cancer cells display a similar EMT protein expression panel 
as paclitaxel-resistant cells 
 
The obtained results showed that both the paclitaxel-resistant OVCAR3 cell line and the 
EMT-induced OVCAR3 cell line displayed similar protein expression patterns. When 
compared to the parental cells, EMT-induced cells had significantly downregulated E-
CADHERIN (P<0.01) and TWIST (P<0.01) levels and significantly upregulated β-
CATENIN (P<0.05), VIMENTIN (P=0.001) and SLUG (P<0.001) levels (Figure 3.15). This 
same pattern was seen when the paclitaxel-resistant cell line was compared to the 
parental control cell line though the significance varied among the proteins (section 3.3.1).  
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Figure 3.15 The paclitaxel-resistant OVCAR3 
cell line and EMT-induced OVCAR3 cell line 
display similar protein expression patterns in 
their EMT markers 
All protein levels were analysed through 
western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels (E-
cadherin and β-catenin) or 10% Bis-Tris gels 
(vimentin, SLUG and TWIST) and transferred 
onto nitrocellulose membranes. The 
membranes were then blocked and probed for 
primary and secondary antibodies and 
visualised with the LiCOR Odyssey CLx 
Imaging System.  * P<0.05; ** P<0.01 and *** 
P<0.001 between indicated groups (Unpaired 
T-test) n=3. 
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3.3.3.2 EMT-induced ovarian cancer cells display a less epithelial nature compared to its 
parental ovarian cancer cells   
As before in section 3.3.1.6, OVCAR3 EMT-induced cells were also treated with Ber-EP4 
to determine whether they had a less epithelial nature befitting cells that were induced to 
undergo EMT. The same principle as before applied here. The peaks of the parental and 
EMT-induced cell lines were compared to each other (Raw peak values are given in 
Appendix 7.1).  
The average peak values were 7.9 units for OVCAR3 control cells and 4.9 units for 
OVCAR3 EMT-induced cells (P<0.01). Here, the peak in the OVCAR3 EMT-induced cells 
was shifted to the left (lower peak value) indicating there were less epithelial antigens 
present compared to its parental control counterpart (Figure 3.16). 
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Figure 3.16 Epithelial antigen staining for OVCAR3 control and OVCAR3 EMT-
induced cell lines 
Cells were incubated with either 25µl of Ber-EP4 antibody or 25µl of PBS (Blank 
control)  for 30 minutes and cells were sorted through the flow cytometer. ** P<0.01 
between indicated groups (Unpaired T-test) n=3.  
  
 
3.3.3.3 EMT-induced ovarian cancer cells display increased capacity for migration as 
paclitaxel-resistant cells 
In order to observe whether EMT-induced cells displayed the drug-resistant property of an 
increased migratory capacity, scratch assays were carried out. OVCAR3 scratch assays 
were conducted for 72 hours. 72 hours was the optimised time point to observe significant 
results before wells reached confluence and cell death occurred (All data obtained in the 
scratch assays are presented in Appendix 7.2).  
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EMT-induced cells had significantly increased migratory rates compared to control 
parental cells (mean distance of wound closure: 909.2µm ± 22.9 vs. 302.4µm ± 34.6 
(P<0.0001)). This same increased migratory rate was observed between control parental 
cells and paclitaxel-resistant cells (mean distance of wound closure: 302.4µm ± 34.6 vs. 
834.6µm ± 78.1 (P<0.0001)) (Figure 3.17).  
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Figure 3.17 EMT-induced cells exhibit the same characteristic of increased 
migratory capacity as paclitaxel-resistant cells 
Scratches were made with a pipette tip in each well of a 24-well plate after cells had 
grown to 100% confluency. Wells were photographed and the gap widths were 
measured with Cell Profiler software when the scratches were made (0 hours) and at 
the 72-hour time point.  **** P<0.0001 between indicated groups (One-way ANOVA) 
n=5. 
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The EMT-induced cells were then treated with paclitaxel to determine whether they 
behaved in the same manner as the paclitaxel-resistant cells of the same cell line. The 
same behaviour as the paclitaxel-resistant cells was observed with the EMT-induced cells, 
where their migratory capacity was significantly decreased with increasing doses of drug 
treatment. Mean distance of wound closure for untreated EMT-induced cells was 909.2µm 
± 22.9, for 5nM-treated EMT-induced cells was 763.7µm ± 27.2 and for 10nM-treated 
EMT-induced cells was 633.5µm ± 53.9 (Figure 3.18).  
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Figure 3.18 EMT-induced cells have 
increased migratory capacity 
Scratches were made with a pipette tip 
in each well of a 24-well plate after 
cells had grown to 100% confluency.  
Media was replaced and for drug-
treated wells, 5nM or 10nM of 
paclitaxel was added. Wells were 
photographed and the gap widths 
were measured with Cell Profiler 
software when the scratches were 
made (0 hours) and at the 72-hour 
time point. * P<0.05; *** p<0.001 
between all groups (One-way ANOVA) 
n=5. 
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3.3.4 Silencing EMT-marker genes can reverse the drug-resistant phenotype in drug-
resistant cells making them more sensitive to drug treatment. 
From the results with protein expression analyses (section 3.3.1), SLUG was chosen for 
further investigation to determine its potential as a biomarker of drug resistance. In order to 
further analyse these marker’s usefulness as a biomarker of drug resistance in ovarian 
cancer, the gene for the protein was silenced and the effect of this silencing was analysed 
through drug treatment.  
3.3.4.1 SLUG as a potential biomarker of drug resistance – Paclitaxel   
Due to the increased expression levels of SLUG in three of the drug resistant cell lines 
(section 3.3.1.4), it was considered to be of potential use as a biomarker of drug 
resistance. Therefore, it was investigated further. For SLUG to be considered a biomarker 
of drug resistance, it was hypothesised that if it was indeed contributing to drug resistance, 
a reduction in its expression levels could re-sensitise cells to drug treatment.  
To this effect, the Slug gene in OVCAR3 parental and drug-resistant cell lines (TaxR and 
EMT-induced cells) were knocked down and the cells were treated with paclitaxel. The 
annexin V-FITC assay was used to determine the viability of these cells.  
Knocking down the Slug gene in parental cells significantly re-sensitised the cells towards 
paclitaxel treatment. Mean percentage cell viability for paclitaxel-treated  parental cells 
with no gene knockdown (scramble control - NC) was 77% ± 3.2 and for paclitaxel-treated 
parental cells with Slug gene knockdown was 67.8% ± 0.7(P<0.0001) (Figure 3.19). 
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Figure 3.19 Effect of SLUG knockdown in OVCAR3 parental control cells’ response 
to drug treatment 
Cells were then set up for annexin assay with Paclitaxel treatment (150nM) for 48 
hours. After 48 hours, cells treated with Annexin-FITC and propidium iodide and cell 
viability was analysed through flow cytometry. A) All NC and slug siRNA control 
results were corrected to 100% and all drug-treated NC and slug siRNA results were 
normalised according to their respective controls. B) Knockdown of slug was 
confirmed through western blotting. C) Graphical representation of cell viability with 
the knockdown of the slug gene, cell viability on drug treatment decreased 
drastically. **** P<0.0001 between indicated groups (One-way ANOVA) n=3. 
 
With drug-resistant cells, the re-sensitisation effect was better with gene knockdown. 
Paclitaxel-treated drug-resistant cells with no gene knockdown (scramble control - NC) 
had a mean percentage cell viability of 87.4% ± 4.8 and paclitaxel-treated drug-resistant 
cells with Slug gene knockdown had a mean percentage cell viability of 46.7% ± 3.3 
(P<0.0001) (Figure 3.20). 
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Figure 3.20 Effect of SLUG knockdown in OVCAR3 TaxR cells’ response to drug 
treatment 
Cells were then subjected to scrambled siRNA (NC) or slug siRNA treatment for 72 
hours. Cells were then set up for annexin assay with Paclitaxel treatment (150nM) 
for 48 hours. After 48 hours, cells treated with Annexin-FITC and propidium iodide 
and cell viability was analysed through flow cytometry. A) All NC and slug siRNA 
control results were corrected to 100% and all drug-treated NC and slug siRNA 
results were normalised according to their respective controls. B) Knockdown of 
slug was confirmed through western blotting. C) Graphical representation of cell 
viability with the knockdown of the slug gene, cell viability on drug treatment 
decreased drastically. * P<0.05; **** P<0.0001 between indicated groups (One-way 
ANOVA) n=3. 
 
With the EMT-induced cells, re-sensitisation towards drug treatment was achieved with 
Slug gene knockdown, but the effect was smaller when compared to the parental and 
paclitaxel-resistant cell lines. EMT-induced cells with no gene knockdown had a mean 
percentage cell viability of 97.2% ± 2.8 and EMT-induced cells with Slug gene knockdown 
had a mean percentage cell viability of 90.2% ± 0.7 (P<0.05) (Figure 3.21). 
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Figure 3.21 Effect of SLUG knockdown in OVCAR3 EMT-induced cells’ response to 
drug treatment 
Cells were then subjected to scrambled siRNA (NC) or slug siRNA treatment for 72 
hours. Cells were then set up for annexin assay with Paclitaxel treatment (150nM) 
for 48 hours. After 48 hours, cells treated with Annexin-FITC and propidium iodide 
and cell viability was analysed through flow cytometry. A) All NC and slug siRNA 
control results were corrected to 100% and all drug-treated NC and slug siRNA 
results were normalised according to their respective controls. B) Knockdown of 
slug was confirmed through western blotting. C) Graphical representation of cell 
viability with the knockdown of the slug gene, cell viability on drug treatment 
decreased drastically. * P<0.05; ** P<0.01 between indicated groups (One-way 
ANOVA) n=3. 
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3.4 Discussion 
 
The aim of this chapter was to identify biomarkers, which could help recognise a drug-
resistant phenotype in ovarian cancer patients.  
Due to the association of EMT with drug resistance in cancer, several EMT-associated 
proteins were used to identify their potential as biomarkers of drug resistance in ovarian 
cancer.  
As carboplatin and paclitaxel are the standard first-line treatment in ovarian cancer 
(Jayson et al., 2014), cell lines resistant to each drug were used. Whilst the work done in 
this thesis is focussed on two main ovarian cancer cell lines: OVCAR3 and SKOV3, the 
availability of two other ovarian cancer cell lines (CaOV3 and PEO1) allowed the 
opportunity to investigate the chosen EMT markers in them as well.  All four drug-resistant 
cell lines were derived through continuous treatment of the particular cell line with either 
carboplatin or paclitaxel until a resistant phenotype was obtained. The stable resistant 
phenotypes of PEO1 and CaOV3 cell lines were confirmed in previous works (Coley et al., 
2006). The stable resistant phenotypes were confirmed for OVCAR3 and SKOV3 during 
this PhD through MTT assays as they were the chosen cell lines for the work done. Both 
the OVCAR3 paclitaxel-resistant cell line (OVCAR3 TaxR) and the SKOV3 carboplatin-
resistant cell line (SKOV3 CR) were 2-folds resistant (resistant factor obtained by dividing 
the resistant IC50 by the control IC50) compared to their respective parental control cell 
lines.   
The first epithelial marker, E-cadherin, was downregulated in all the resistant forms of the 
cell lines, except for the CaOV3 resistant cell line, where it was significantly upregulated. 
Cells that have undergone EMT will have gained the ability to migrate and therefore, would 
need to have lost their attachments to other cells and the basement membrane. E-
cadherin, encoded by the CDH1 gene, is an anchorage protein facilitating a cell’s 
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attachment to neighbouring cells and the basement membrane (Serrano-Gomez et al., 
2016) which keeps a cell immobile. Therefore, downregulation of E-cadherin frees the cells 
of its attachments and allows it to move. This is a characteristic commonly associated with 
EMT (Du and Shim, 2016). A study on prostate cancer showed that downregulation of E-
cadherin not only increased the migratory and invasive capacity of prostate cancer cells, 
but also made them more resistant to paclitaxel treatment (Wang, 2017). Overexpression 
of E-cadherin reversed these characteristics and re-sensitised the cells to paclitaxel 
treatment. The study supports the fact that E-cadherin is downregulated in drug-resistant 
cells. However, in this present study, E-cadherin was shown to be upregulated in one of 
the drug-resistant states. In the CaOV3 carboplatin-resistant cell line, E-cadherin was 
significantly upregulated indicating that E-cadherin may contribute to drug resistance. E-
cadherin, as mentioned earlier, is a protein that initiates cells’ attachments to each other. 
Drug resistance can be exhibited by clusters of cells forming cell aggregates. Such a 
phenomena where cell aggregation induced drug resistance is described by Fadeev et al. 
(2015). Leukaemia cells grown to form cell aggregates were found to be more drug 
resistant and preventing the formation of these cell aggregates made these cells more 
susceptible to drug effects. For these cells to form aggregates would require them to form 
attachments with one another leading to an upregulation of E-cadherin. Therefore, in this 
situation drug resistance can be associated with an upregulation of this particular epithelial 
marker, which could explain the results regarding the CaOV3 carboplatin-resistant cell line. 
This theory is supported by other works where increased E-cadherin expression was 
observed to result in an increased resistance towards drug treatment (Day et al., 1999, Xu 
et al., 2014). As observed in this study, downregulation of E-cadherin could be considered 
a biomarker of drug resistance as it is downregulated in three of the drug-resistant cell 
lines.  
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The second epithelial marker to be investigated was β-catenin. It was significantly 
upregulated in all the drug-resistant cell lines compared to their parental control cell lines. 
β-catenin is a protein attached to the cytoplasmic tail portion of the E-cadherin 
transmembrane protein and via α-catenin, it is linked to the actin cytoskeleton allowing for 
cell structural stability (Tian et al., 2011).The downregulation of cadherins results in the β-
catenins localising to the cytoplasm. β-catenin cytoplasmic concentrations are maintained 
by GSK3, which phosphorylates it leading to its ubiquitination (Nakata et al., 2015, Reya 
and Clevers, 2005). However, an activated Wnt pathway can result in the phosphorylation 
of GSK3, which allows accumulation of β-catenin in the cytoplasm allowing it to translocate 
to the nucleus to act as a co-transactivator of various genes coding for proteins 
responsible for cell proliferation and cell survival. Cell proliferation and cell survival are 
characteristics of drug resistance that gives resistant cells their anti-apoptotic nature. This 
explains the upregulated levels of β-catenin observed in this PhD study.  An increase in β-
catenin was also seen in a study by Nagaraj et al. (2015) in drug-resistant ovarian cancer 
cells compared to their parental cell counterparts (Nagaraj et al., 2015). However, in 
another study, β-catenin levels were found to be decreased in drug-resistant cell lines in 
the western blot analysis (Barghout et al., 2015).  Even though the role of the Wnt pathway 
had been mentioned in other cancers before, it was in 2002, Ricken et al. raised the idea 
that the Wnt signalling axis could play a role in tumourigenesis in ovarian cancer (Ricken 
et al., 2002). The significantly elevated levels of β-catenin in the drug resistant cell lines in 
this study and the role β-catenin plays in the Wnt signalling pathway could indicate that the 
Wnt pathway plays an important role in drug resistance (of both paclitaxel and carboplatin) 
in terms of cell survival. This is confirmed by the study conducted by Nagaraj et al. (2015) 
and whilst the study by Barghout et al. (2015) shows decreased β-catenin levels, they do 
examine the reason for this and identifies that the nuclear localisation of β-catenin is high 
in the drug-resistant cell lines despite the low protein levels seen and concludes that the 
  6278156 
 
160 
 
transcriptional activity of β-catenin is high indicating an activated Wnt signalling pathway. 
Wnt signalling allows for cell survival and this could enable cells to become more resistant 
to drug-induced apoptosis. Therefore, in the light of the results, it can be concluded that 
the upregulation of β-catenin could be a potential biomarker of drug resistance in ovarian 
cancer. 
The first mesenchymal marker to be investigated was VIMENTIN. VIMENTIN, as a 
mesenchymal marker, is upregulated in EMT (Mendez et al., 2010). In this study, however, 
the results were conflicting. VIMENTIN was found upregulated in two drug-resistant cell 
lines (one paclitaxel-resistant and one carboplatin-resistant), but downregulated in the 
other two drug-resistant cell lines (both carboplatin-resistant). VIMENTINs are intermediate 
filaments that are necessary for the cell shape changes that occur in order for a cell to be 
motile (Mendez et al., 2010). With the assumption that drug-resistant cells display EMT 
characteristics, the increased expression of VIMENTIN in two of the drug-resistant cell 
lines is the expected result. Nevertheless, decreased VIMENTIN in drug-resistant ovarian 
cancer cells has been observed (Huo et al., 2016).  Huo et al. (2016) found that 
overexpressing VIMENTIN in drug-resistant cells increased their sensitivity to platinum 
drug treatment. They found an increased expression of proteins involved in exocytosis 
activity in parental control cells concluding that the drug resistance was contributed to by a 
decreased accumulation of the cytotoxic drug in the cell’s intracellular environment. 
VIMENTIN could be contributing to drug resistance by such a mechanism in the PEO1 and 
CaOV3 parental cell lines. It would be interesting to see whether these two cell lines 
express proteins involved in drug exocytosis in high quantity, which might help identify a 
mechanism of drug resistance in them. In the SKOV3 and OVCAR3 drug-resistant cell 
lines, the expression of VIMENTIN could link to the expression of β-catenin. A study found 
that β-catenin, in its role as a transcription co-activator, could contribute to upregulated 
VIMENTIN transcription (Gilles et al., 2003). Here, breast cancer cells with VIMENTIN 
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expression displayed strong β-catenin-TCF4 transcriptional activity in contrast to 
VIMENTIN-negative cells. These two cell lines previously showed significantly increased 
expression levels of β-catenin (section 3.3.1.2) and this could be the reason for the 
increased expression levels of VIMENTIN in these particular cell lines. The decreased 
VIMENTIN expression levels in the other two cells probably point to a lack of β-catenin 
involvement at the transcriptional level for VIMENTIN in those cell lines. VIMENTIN could 
also be contributing to drug resistance through the ERK signalling pathway (Virtakoivu et 
al., 2015). Downregulating VIMENTIN expression was found to decrease the activation of 
this pathway in breast cancer cells resulting in reduced tumour growth. The same study 
showed that VIMENTIN prevents the dephosphorylation of ERK and therefore, its 
inactivation and it turn, ERK regulates VIMENTIN expression (silencing ERK2 reduced 
VIMENTIN expression levels) displaying a reciprocal feedback loop. The ERK pathway 
can induce drug resistance through the regulation of proteins involved in apoptosis such 
as BAD, BIM, CASPASE-9 and BCL-2 enhancing cell survival (McCubrey et al., 2007). 
With regards to VIMENTIN’s potential as a biomarker, due its downregulated levels in two 
of the four drug-resistant cell lines, it may not be an ideal biomarker of drug resistance in 
ovarian cancer. 
The second mesenchymal marker to be investigated was SLUG. In this study, SLUG 
expression was increased in three of the drug-resistant cell lines significantly. This is 
supported by a study by Haslehurst et al. (2012). In this particular study, the contribution of 
SLUG, as an EMT marker, to cisplatin resistance in ovarian cancer was investigated. 
Carboplatin is a derivative of cisplatin differing only by the absence of the chloride atoms in 
its structure (Di Pasqua et al., 2012). The authors show that SLUG was increased in the 
drug-resistant cells and the knockdown of its gene resulted in the re-sensitisation of the 
cells to drug treatment as well as a reduction in the migratory and invasive capacities of 
the cells (Haslehurst et al., 2012). In another study, resistance to paclitaxel was associated 
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with increased SLUG expression levels in ovarian cancer (Kurrey et al., 2009) supporting 
the result seen here with the OVCAR3 paclitaxel-resistant cell line. The involvement of the 
Wnt signalling pathway with β-catenin was discussed earlier. The Wnt signalling pathway 
also happens to play a role in SLUG activity (Wu et al., 2012). SLUG is phosphorylated 
and directed towards degradation via ubiquitination by GSK3 activity in the absence of Wnt 
signalling. However, in the presence of Wnt signalling, the phosphorylation activity of 
GSK3 is inhibited and SLUG is available to translocate to the nucleus and initiate its 
actions as a transcription factor. It was found to repress E-cadherin gene transcription 
(resulting in decreased E-cadherin levels) and increase vimentin expression. SLUG was 
also found to repress the expression of the tumour suppressor gene, BRCA1 by binding to 
its promotor elements. Another study found that SLUG largely played a repressive function 
downregulating the expression of various genes more than upregulating genes’ 
expressions (Dhasarathy et al., 2011). Looking at the genes regulated by SLUG, it was 
seen that they were related to processes such as cell growth, cell proliferation and cell 
survival highlighting the mechanisms through which SLUG could induce drug resistance. 
When discussing the Wnt signalling pathway, β-catenin also comes to mind. β-catenin 
expression could also be related to the increased expression levels of SLUG seen in the 
present study. A study showed that Xenopus slug promotor contained binding sites for β-
catenin-Lef1 transcriptional co-activators (Vallin et al., 2001). In the three drug-resistant 
cell lines with the increased expression of SLUG (in this study), the increase could be 
contributed to the increased transcriptional activity of β-catenin as they all displayed 
significantly elevated levels of β-catenin. In the resistant cell line, where SLUG expression 
is decreased, β-catenin may not be a transcriptional activator for the Slug gene regardless 
of the high β-catenin expression levels in that cell line. SLUG can also be related to E-
cadherin expression. SLUG was found to bind to E-box elements of the E-cadherin 
proximal promotor region and repress the transcription of the E-CADHERIN gene leading 
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to the downregulation of the E-cadherin protein in breast cancer (Hajra et al., 2002). With 
regards to E-cadherin investigated earlier on, all three drug-resistant cell lines with 
increased expression of SLUG showed decreased levels of E-cadherin possibly pointing to 
the idea that SLUG could play a role in the repression of the E-cadherin gene in these 
three drug-resistant cell lines. This is further supported by the fact that the one drug-
resistant cell line with decreased SLUG expression displayed increased expression of E-
cadherin.  Overall, due to its high expression levels in three of the drug-resistant cells at 
significant levels, SLUG should be considered a potential biomarker of interest in drug-
resistant ovarian cancer.  
TWIST, the third and final mesenchymal marker, was found downregulated in three of the 
drug-resistant cell lines in this study. In studies of drug resistance in cancer, TWIST is 
found upregulated in drug resistant models (Wang et al., 2018, Haslehurst et al., 2012). 
While this result can be seen with one of the resistant cell lines in the present study, the 
other three displayed the opposite result and this has not been reported in the literature as 
far as this author can see. In a breast cancer study, TWIST was found to transcriptionally 
repress E-CADHERIN expression by binding to the promotor region of the E-cadherin 
gene (Vesuna et al., 2008). In the drug-resistant cell line (PEO1 carboplatin-resistant) with 
upregulated TWIST expression, E-CADHERIN levels are downregulated. In this particular 
ovarian cancer cell line, TWIST maybe another factor responsible for the E-cadherin 
downregulation in the drug-resistant state. SLUG, which was also capable of 
downregulating E-cadherin expression (Hajra et al., 2002), was increased in this particular 
cell line in its drug-resistant form. TWIST can contribute to anti-apoptotic activity, cell 
mobility and the stem cell phenotype (Feng et al., 2009), characteristics of drug resistance. 
Interestingly, a study by Miow et al. (2015) explains that, contrary to what is commonly 
believed, in an analysis of 46 ovarian cancer cell lines, a majority of the chemo-resistant 
cells were epithelial in nature (Miow et al., 2014), indicating that drug-resistant cells may 
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not be mesenchymal in nature only. This could explain why a mesenchymal marker such 
as TWIST is downregulated in three of the drug-resistant cell lines. Moreover, Jolly et al. 
(2015) gives examples of how a partial EMT state maybe more drug-resistant than a 
complete EMT state, where a complete mesenchymal phenotype has been achieved (Jolly 
et al., 2015). Whilst this association between a partial EMT state and a drug-resistant state 
is yet to be investigated thoroughly, it is suggested that the partial EMT state should be 
considered a stable cell phenotype rather than a transitory phase that occurs during EMT 
or its reverse process, MET (Jolly et al., 2016). In such a context, the downregulated twist 
expression levels could be explained. In the drug-resistant cells with decreased twist 
expression (OVCAR3, SKOV3 and CaOV3), drug resistance has been achieved without its 
contribution. Twist probably does not contribute to the induction of drug resistance in these 
cell lines. This perhaps makes twist, downregulated in three of the drug-resistant cell lines, 
not an ideal marker of drug resistance in ovarian cancer.  
Looking at the EMT marker expression levels in all the drug-resistant cell lines, the theory 
of partial EMT enabling a drug-resistant state could be valid. In the present study, three of 
the drug-resistant cell lines displayed varying levels of the mesenchymal markers and they 
were not upregulated in all of them. This indicates that a drug-resistant state can be 
achieved without the completion of EMT and with Jolly et al. (2016) identifying factors 
capable of stabilising the partial EMT state, we could support the idea that the partial EMT 
state could be a separate cell phenotype that is capable of inducing a drug-resistant state. 
The CaOV3 carboplatin-resistant cell line was unique on its own in that it showed that its 
drug-resistant state was more epithelial in nature (with downregulation of all three 
mesenchymal markers). Miow et al. (2014) reports that ovarian cancer cell lines with an 
epithelial nature were more resistant to cisplatin effects and this could be compared to the 
effect seen with the CaOV3 carboplatin-resistant cell line. This further helps develop the 
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argument that EMT (at least in the complete state) may not be a contributing factor to the 
induction or the state of drug resistance.   
Since EMT-associated markers are the focus of this work due to the association of EMT 
with drug resistance, whether EMT could be induced to bring about drug resistance was 
explored. For this, rather than relying on one factor to induce EMT (TGF-β  being the most 
common EMT-inducer), as EMT is contributed to not only by one factor but by many 
various factors, a cocktail of EGF, IL-6 and TGFβ were used in this study to better mimic 
EMT. They were chosen after a general literature search on EMT looking at various 
studies conducted, not limited to ovarian cancer only. Initially, when each of these factors 
were tested independently and in combination, it was observed that the combination 
treatment was better than individual treatments (results not included). Therefore, the 
combination approach was used to produce the cellular model of EMT-induced drug 
resistance.  
The western blot analysis revealed similar expression levels in this EMT-induced cell line 
to the same cell line, which was paclitaxel-resistant (OVCAR3 TaxR). No comparison was 
made to the carboplatin-resistant cell lines as they belonged to different ovarian cancer 
cell lines. Comparison was only, therefore, made to the OVCAR3 parental cell line from 
which the EMT-induced cell line was derived from and to the OVCAR3 TaxR cell line. The 
similar protein expression patterns could indicate that despite two different methods of 
inducing drug resistance (repeated drug treatment versus cocktail of EMT inducers), the 
same proteins are affected in the induction of drug resistance (at least in the case of 
paclitaxel). However, if this is to be compared to the carboplatin-resistant SKOV3 cell line, 
it can be demonstrated that they share similar expression patterns too and therefore, the 
same proteins could play a role in this particular cell line as well in inducing drug 
resistance. Interestingly, even in the EMT-induced cell line, TWIST levels were 
significantly lower compared to the parental cell line showing that complete EMT is not 
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necessary for the induction of drug resistance. This examination also added strength to the 
validity of β-CATENIN and SLUG as possible biomarkers of drug resistance in ovarian 
cancer. 
The objective in inducing EMT was to observe whether drug resistance could be induced 
in such a cell model. MTT assays were used to assess drug sensitivity of the EMT-induced 
cell model. MTT assays are easy to set up, produces results in a short span of time and 
are used for cell viability assessment in the presence of cytotoxic drugs (Pieters et al., 
1990, Sargent, 2003). However, when carrying analyses with the EMT-induced cells, we 
identified a disadvantage of using the MTT assay. The results were inconsistent and 
difficult to reproduce with the EMT-induced cell model. A study found that the MTT assay 
was capable of underestimating the growth inhibitory effects of interferons (Jabbar et al., 
1989). The study used cell counting and the MTT assay to compare the growth inhibitory 
effects of interferons and found that the MTT assay was reporting very low levels of cell 
inhibition compared to the cell counting method. Furthermore, TGF-β (one of the EMT-
inducers used) was shown to increase the production of reactive oxidative species, whose 
presence could lead to mitochondrial dysfunction (Guo, 2017, Ma et al., 2013). This 
showed that the MTT assay, which relied on intact mitochondrial activity, might not be the 
ideal assay for drug sensitivity in this case. Therefore, scratch assays, which have been 
used previously to investigate drug-resistant cells (Park, 2018), were used instead. 
Scratch assays are simple and cost-effective and can be carried out in various sized well-
plates. However, a major disadvantage is the reproduction of consistent scratches. In fact, 
this author started making scratches with the 10µl pipette tip and then moved to the 200µl 
pipette tip and found that it was difficult to produce approximately identical scratches. 
Fortunately, the 1000µl pipette tip turned out to be effective in helping to produce almost-
identical scratches that only varied to each other by less than 5µm. Furthermore, this 
author did not measure the size of the scratch at the end time-point of the assay, but 
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rather the distance moved by the closing scratch. In order to ensure that the wound 
closure was due to migration and not the proliferative ability of cells, the cells were always 
serum starved before the production of scratches and subsequent drug treatment.  
In order to determine the kind of phenotype that is displayed by drug-resistant cells, 
scratch assays were performed with the OVCAR3 and SKOV3 parental and drug-resistant 
cell lines first. Both assays showed that drug-resistant cells had increased migratory 
capacity and that drug treatment affected this migratory capacity decreasing it. This was 
established as the drug-resistant phenotype for scratch assay analysis and followed this 
up with scratch assay analyses on the EMT-induced OVCAR3 cell line. The EMT-induced 
OVCAR3 cell line exhibited the same behaviour patterns including a decrease in migratory 
capacity when treated with drug confirming that the EMT-induced cell model was 
successful in its replication of drug resistance. A study on mice with vimentin knockdown 
indicated that vimentin was necessary for migration as seen by the delayed wound healing 
(Eckes et al., 2000). The three cell lines (EMT-induced, paclitaxel-resistant and 
carboplatin-resistant) both had upregulated vimentin levels compared to their parental cell 
lines. Therefore, vimentin could contribute to the increased migratory rate observed in the 
drug-resistant state. Due to the increased levels of β-CATENIN and SLUG also observed 
in all three drug-resistant cell lines, it could be that the Wnt signalling pathway (discussed 
earlier for all three of the mentioned proteins) plays a role in cell migration. This pathway, 
when activated, leads to the downstream activation of different proteins, which are 
involved in various cellular processes, one of them being cell motility (Sedgwick and 
D'Souza-Schorey, 2016). Therefore, it is a signalling cascade of interest with regards to 
drug resistance.  
Other than relying on the western blot analyses of EMT markers, a monoclonal antibody 
called Ber-EP4 was also used to determine whether drug-resistant cells were more 
epithelial or not. Ber-EP4 antibody recognises a cell surface glycoprotein called EpCAM, 
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which is transmembrane adhesion molecule present on epithelial cells (Dasgeb et al., 
2013, Sunjaya et al., 2017). The results obtained in the present study further cemented the 
idea that drug-resistant cells do not have to be mesenchymal in nature.   
The PEO1 carboplatin-resistant cell line expressed significantly more epithelial antigen 
compared to its parental cell line. This same result was seen with the OVCAR3 paclitaxel-
resistant cell line compared to its parental cell line. The SKOV3 carboplatin-resistant cell 
line and the OVCAR3 EMT-induced cell line, however, were less epithelial compared to 
their respective parental cell lines. EpCAM (epithelial cell adhesion molecule), the protein 
antigen that was targeted here, is a cell adhesion molecule found to be elevated in 
expression in epithelial cancers, but not in normal epithelia (Schnell et al., 2013). Whilst it 
is considered a cell adhesion molecule, research suggests that it could be a negative 
regulator of cell adhesion (Litvinov et al., 1997). It appears to weaken adherens junctions 
by interfering with the connection the cadherins have to the cytoskeletal system 
destabilising the junctional components. An increase in Ep-CAM expression was also 
associated with increased cell proliferation. In another study, knocking out EpCAM 
expression was found to decrease the migratory capacity of epithelial cells (Schnell et al., 
2013). Taking these factors together, it may not be surprising that two of the drug-resistant 
cell lines (OVCAR3 TaxR and PEO1 CR) displayed high expression of EpCAM. Despite its 
name (as a cell adhesion molecule), the presence of EpCAM seems to give cells 
increased proliferative and migratory capacities, characteristics of drug-resistant cells. 
Furthermore, β-catenin appears to be a transcriptional activator of EpCAM via the Wnt 
signalling pathway (Yamashita et al., 2007). The drug-resistant cell lines with high EpCAM 
had significantly high levels of β-catenin, which could be inducing the high expression of 
this epithelial marker in these cell lines. With the decreased β-catenin levels in the parental 
cell lines, we would get less of the EpCAM, which might show why the parental cell lines 
appeared less epithelial. In the other two drug-resistant cell lines (SKOV3 carboplatin-
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resistant and EMT-induced OVCAR3), the high levels of β-catenin present could indicate 
that β-catenin is probably not a dominant transcriptional activator for EpCAM. It is 
important to note that these cells (SKOV3 and OVCAR3), though they had less EpCAM 
expression in them compared to their parental control counterparts, did express the 
EpCAM protein. Therefore, EpCAM possibly plays its proliferative and migratory roles in 
these drug-resistant cell lines too. However, the decrease in its levels indicate that there 
exists a signalling protein/network that has been activated and has affected the EpCAM 
levels. There is limited information available in the literature regarding the role of EpCAM, 
which makes it difficult to speculate what might be responsible for the decreased levels at 
this stage. As an epithelial marker, it shows that cells do not have to be less epithelial 
(more mesenchymal in the context of this PhD) in order to display drug-resistant 
characteristics of enhanced proliferative and migratory behaviour.  
As the focus of this research was to identify possible biomarkers of drug resistance, the 
next step was to identify how useful a chosen protein could be in this respect. To this 
effect, due to its significantly elevated expression levels in four of the drug-resistant cell 
lines (three drug-induced drug-resistant cell lines and one EMT-induced cell line), SLUG 
was chosen for further investigation. For this, we decided to silence the slug gene, SNAI2, 
and to observe the effect of the cells’ to drug treatment. 
The knockdown of the slug gene re-sensitised the cells to paclitaxel treatment. This 
indicates that SLUG should be considered a possibly ideal biomarker of drug resistance. In 
the analyses, the untreated (i.e. no drug) results were corrected to 100%, but the raw 
values showed that knocking down slug did decrease the cell viability compared to no slug 
knockdown (in both the parental and paclitaxel-resistant cell lines – NC versus slug siRNA) 
though none of these differences were large or reached levels of statistical significance. 
Therefore, SLUG should play a role in cell survival mechanisms and this is proven when 
on slug knockdown and subsequent drug treatment, cell viability is significantly decreased. 
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With regards to slug knockdown in EMT-induced cells, raw values (the uncorrected values) 
indicate that the knockdown does not affect the cell viability of the cells compared to the 
control cells (where cell viability was lower with no slug siRNA). This could be the reason 
why the difference in cell viability between EMT-induced cells with scrambled siRNA or 
with slug siRNA was of significance but much lower in significance value compared to the 
results seen with parental control cells and paclitaxel-resistant cell lines. According to 
these results, in the EMT-induced cell line, slug plays a role in cell survival as for the 
parental control cell line and the paclitaxel-resistant cell line, but to a lesser extent. Being 
induced with EGF, IL-6 and TGF-β, this cell line should have enhanced anti-apoptotic 
mechanisms activated in it. For example, EGF binds to the epidermal growth factor 
receptor and on activation, this receptor can activate various downstream targets involved 
in cell survival processes (Sibilia et al., 2000). Among the signalling pathways activated by 
the epidermal growth factor receptor are the RAS/RAF/MAPK pathway, PI3K/AKT pathway 
and the STAT pathway (Chen et al., 2016). The RAS/RAF/MAPK pathway is involved in 
cell proliferation and cell survival processes (Scaltriti and Baselga, 2006). The PI3K/AKT 
pathway is involved in cell growth, survival and migration. The STAT pathway regulates 
cell survival, proliferation and metastasis (Haura et al., 2005). The overexpression of IL-6 
in human cholangiocarcinoma cell lines resulted in increased cell growth and survival and 
cell survival appeared to be mediated via the P38 MAPK pathway (Meng et al., 2006). In a 
study on prostate cancer, IL-6 was found to activate the PI3K/AKT pathway as well as the 
MAPK/ERK pathway both involved in cell survival processes (Wegiel et al., 2008). TGF-β, 
on the other hand, can promote pro-apoptotic or anti-apoptotic pathways depending on the 
cell context (Zhang et al., 2017, Elliott and Blobe, 2005). However, in the EMT-induced cell 
model, any anti-apoptotic activity was probably dominated over by the combined action of 
EGF and IL-6. Considering the enhanced cell survival activity with the added EGF and IL-
6, it is no surprise that the EMT-induced cell has strong cell viability. As discussed earlier, 
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knocking down the slug gene alone in such a cell line would not see a drastic decrease in 
cell viability considering the cell survival mechanisms that are activated in the presence of 
EGF and IL-6.  
The overall objectives of the work reported in this chapter was to use EMT markers to 
determine their use as biomarkers of drug resistance. In this aspect, SLUG was found to 
be a putative candidate biomarker of drug resistance. The results also confirmed that the 
drug-resistant state is not dominated by a mesenchymal phenotype alone and that 
perhaps a partial EMT state could be a better phenotype for describing the drug resistant 
state. We also successfully induced drug resistance with three EMT inducers in a cell 
model. This cell model’s activity further collaborated slug’s possible effectiveness as a 
biomarker of drug resistance. Having used two cell lines, in which drug resistance was 
induced in two different ways, and seeing that slug shows similar responses in both, we 
can conclude that it requires further investigation as a biomarker of drug resistance. To 
this effect, β-catenin, here used as an epithelial marker and therefore, not investigated in 
more detail, should also require further investigation as a possible biomarker of drug 
resistance.     
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CHAPTER 4 
MET receptor protein as a biomarker 
of drug resistance 
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4.1 Introduction  
In cancer, there is an increase in the phosphorylated form of the tyrosine kinase receptor, 
MET, due to gene mutations (Schmidt et al., 1999), gene amplification (Smolen et al., 
2006, Lutterbach et al., 2007) and protein overexpression (Di Renzo et al., 1995, Ozasa et 
al., 2014). During the MSc dissertation of this author, increased expression of the MET 
protein was observed in drug-resistant ovarian cancer cell lines (HBJ Assalaarachchi, MSc 
dissertation, 2014). Furthermore, increased expression of the activated form of the MET 
receptor (phosphorylated MET – p-MET) has been observed in other cancers: gastric 
cancer (Inoue et al., 2004), breast cancer (Parr and Jiang, 2001) compared to normal 
tissue and drug-resistant pancreatic cancer (Shah et al., 2007).  
The hepatocyte growth factor (HGF), also known as the scatter factor, binds to the MET 
receptor (also called the hepatocyte growth factor receptor (HGFR)) leading to the 
phosphorylation of tyrosine residues on its intracellular kinase domain (Zhang and Vande 
Woude, 2003). The phosphorylation of two tyrosines (Y1349 and Y1356) create multiple 
docking sites to downstream signalling effectors, whose subsequent phosphorylation 
activates various downstream signalling pathways (Figure 4.1). The MET receptor and its 
ligand are involved in developmental processes (Birchmeier and Gherardi, 1998) and are 
now also associated with cancer (Peruzzi and Bottaro, 2006). The signalling pathways 
activated by the MET receptor are associated with cancer hallmark characteristics such as 
uninhibited cell proliferation, evasion of apoptosis and invasion (Hanahan and Weinberg, 
2000, Peruzzi and Bottaro, 2006): PI3K signalling pathway (cell survival and proliferation), 
STAT3 signalling pathway (cell proliferation and differentiation), MAPK signalling pathway 
(cell proliferation, motility and regulation of cell cycle progression) and FAK signalling 
pathway (cell migration) (Organ and Tsao, 2011, Trusolino et al., 2010). 
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Figure 4.1 The MET receptor and its downstream signalling pathways 
[Original Figure] 
 
 
The roles of the signalling pathways activated downstream of the MET receptor are 
associated with a drug-resistant phenotype (cell survival, cell proliferation etc.) highlighting 
the role the activation of the receptor could play in the induction of drug resistance. To this 
effect, in breast cancer, the knockdown of the MET receptor increased sensitivity towards 
daunorubicin through the upregulation of topoisomerase II (Jia et al., 2018). Gefitinib 
resistance in non-small cell lung cancer was reversed by the overexpression of miR-128 
(Jiang et al., 2016). The MET receptor is a target of miR-128 and the overexpression of 
miR-128 led to a reduction in MET protein levels. The resulting decrease in the activation 
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of the PI3K signalling pathway (a downstream signalling pathway of the MET receptor) 
was associated with an increased sensitivity towards gefitinib.  
Due to the association of the receptor with drug resistance, several inhibitors to the 
receptor have been investigated as ways of improving responses to chemotherapy.  
DE605, a MET inhibitor displayed synergistic activity when combined with sorafenib in 
hepatocellular carcinoma increasing the cytotoxicity effects of sorafenib (Jiang et al., 
2015). In ovarian cancer, the use of a MET inhibitor, PHA665752, led to synergistic activity 
with cisplatin resulting in effective cisplatin-induced apoptosis in MET overexpressing cells 
(Li et al., 2016).  
In light of all the research pointing to the MET receptor’s role in drug resistance, its 
potential as a biomarker of drug resistance is investigated in this chapter. 
 
HYPOTHESES TESTED IN THIS CHAPTER 
 
 The expression of the MET receptor is increased in drug-resistant cells compared 
to parental (drug-sensitive) cells. 
 The inhibition of the MET receptor increases drug sensitivity of drug-resistant cells.  
 Combination treatment involving a MET receptor inhibitor and a platinum drug 
results in a synergistic apoptotic effect.   
 Silencing the MET proto-oncogene reverses drug resistance in a cellular model of 
ovarian cancer.   
 Downstream signalling pathways of the MET receptor are actively involved in 
mediating drug resistance in ovarian cancer.  
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4.2 Methods 
 
To investigate receptor protein levels as well as levels of the downstream signalling 
effectors of the MET receptor, western blotting techniques (section 2.2.2) were employed. 
The Annexin V-FITC assay (section 2.2.5) assessing cell viability (as the non-apoptotic cell 
population) was employed to investigate effects of receptor inhibition on cell viability. MTT 
assays (section 2.2.6) were used to investigate effects of combination treatment (inhibitor 
and platinum drug) and gene silencing assays (section 2.2.7) combined with the Annexin 
V-FITC assays were used to investigate the effect silencing the gene encoding the MET 
receptor will have on drug resistance.  
 
4.3 Results 
4.3.1 MET receptor activation in drug-resistant cells 
Total MET protein levels were expressed differently in the two drug-resistant cell lines 
examined. With the SKOV3 CR cells, total MET protein levels were increased significantly 
compared to the parental cells (P<0.001). In the OVCAR3 EMT-induced cells, total MET 
protein levels were decreased significantly compared to the parental cells (P<0.01) (Figure 
4.2).  
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The expression of the activated form of the MET receptor, phosphorylated MET (P-MET) 
protein, was determined in the two cell lines. The drug-resistant variants of both cell lines 
had significantly increased levels of P-MET compared to the parental cells (P<0.0001) 
(Figure 4.3).  
 
 
 
S
K
O
V
3
 C
o
n
tr
o
l
S
K
O
V
3
 C
R
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
N
o
r
m
a
li
s
e
d
 b
a
n
d
 d
e
n
s
it
y
* * *
O
V
C
A
R
3
 C
o
n
tr
o
l
O
V
C
A
R
3
 E
M
T
-i
n
d
u
c
e
d
0
2 0 0
4 0 0
6 0 0
8 0 0
N
o
r
m
a
li
s
e
d
 b
a
n
d
 d
e
n
s
it
y
* *
 Figure 4.2 MET protein levels in drug-resistant cell lines 
MET protein levels were analysed through western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging 
System.  ** P<0.01; *** P<0.001 between indicated groups (Unpaired T-test) 
n=3. 
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4.3.2 Effect of MET receptor inhibition on drug sensitivity 
4.3.2.1 Effect of carboplatin with MET receptor inhibition on cell viability 
Due to increased receptor activation in drug-resistant cells, the next aim was to examine 
the effect of inhibiting the MET receptor on drug sensitivity. For this, foretinib, a potent 
inhibitor of the MET receptor, was selected. Annexin V-FITC assays indicated that drug 
treatment with either carboplatin or foretinib or in combination together effectively reduced 
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 Figure 4.3 P-MET protein levels in drug-resistant cell lines 
P-MET protein levels were analysed through western blotting. Proteins were 
electrophoresed on 7% Tris-acetate gels and transferred onto nitrocellulose 
membranes. The membranes were then blocked and probed for primary and 
secondary antibodies and visualised with the LiCOR Odyssey CLx Imaging 
System.  *** P<0.001 between indicated groups (Unpaired T-test) n=3. 
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cell viability compared to untreated cells in parental cells (control adjusted to 100%, 
carboplatin-treated: 93.3% ± 0.3, foretinib-treated: 54.2% ± 1.3 and combination treatment: 
65.5% ± 0.2). Foretinib was significantly more effective on its own (P<0.0001). When 
combined with carboplatin, the efficacy seen with foretinib-only treatment was reduced. 
However, the combination treatment was more effective than carboplatin treatment on its 
own (P<0.0001) (Figure 4.4).  
 
 
The same effect was observed with drug-resistant cells treated in the same manner. Being 
drug-resistant cells, they were less sensitive to carboplatin treatment than parental cells 
were to carboplatin treatment. Foretinib treatment or combination treatment of both 
carboplatin and foretinib reduced cell viability significantly in these drug-resistant cells 
(control adjusted to 100%, carboplatin-treated: 96.8% ± 0.1, foretinib-treated: 37.1% ± 0.2 
and combination treatment: 38.5% ± 0.9). Both these treatments were more effective 
compared to carboplatin treatment alone (Figure 4.5). 
 
Figure 4.4 Effect of treating parental 
cells with a combination of drug and 
inhibitor  
Cells incubated with the appropriate 
treatment (no drug, 50µM of 
carboplatin, 0.6µM of foretinib or with 
both) for 48 hours were treated with 
Annexin-FITC and propidium iodide 
and analysed through flow cytometry 
for cell viability. All cell viability values 
of untreated cells were corrected to 
100% and the values for treated cells 
were normalised to the untreated cells’ 
values. *** P<0.001; **** P<0.0001 
between indicated groups (One-way 
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In both the parental and drug-resistant cell lines, foretinib worked more effectively on its 
own and it worked better in the drug-resistant cell line (Figure 4.6), which expresses 
significantly more MET receptor (Figure 4.2), the target of the foretinib inhibitor. Cell 
viability was 54.2% ± 1.3 with SKOV3 control cells and 37.1% ± 0.2 with SKOV3 CR cells 
(P<0.001). 
 
 
Figure 4.5 Effect of treating drug-
resistant cells with a combination of 
drug and inhibitor 
Cells incubated with the appropriate 
treatment (no drug, 50µM of 
carboplatin, 0.6µM of foretinib or with 
both) for 48 hours were treated with 
Annexin-FITC and propidium iodide 
and analysed through flow cytometry 
for cell viability. All cell viability 
values of untreated cells were 
corrected to 100% and the values for 
treated cells were normalised to the 
untreated cells’ values. ** P<0.01; **** 
P<0.0001 between indicated groups 
(One-way ANOVA) n=4. 
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Figure 4.6 Effect of foretinib 
treatment between parental and 
drug-resistant cell lines 
Cells incubated with 0.6µM of 
foretinib for 48 hours were 
treated with Annexin-FITC and 
propidium iodide and analysed 
through flow cytometry for cell 
viability. *** P<0.001 between 
indicated groups (Unpaired t-
test) n=4.   
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4.3.2.2 Activity profile of combination treatment with cisplatin and MET receptor inhibition 
If carboplatin and foretinib worked synergistically, a more marked decrease in cell viability 
would be observed with combination treatment compared to single treatment of either 
carboplatin or foretinib. However, this was not seen. Therefore, to determine the type of 
activity displayed by the two drugs when in combination, combination index (CI) values 
were obtained through combination studies via MTT assays. For the drug, we initially used 
carboplatin. However, after initial tests to assess cell viability, we decided to switch to 
cisplatin as carboplatin failed to give suitable dose-response profiles in the cell lines 
tested. Cisplatin has a better cytotoxic activity profile compared to carboplatin, which can 
be assessed better via MTT assays. They are both platinum drugs with the same 
mechanism of action differing only in its structure (which gives cisplatin its more cytotoxic 
activity, whilst carboplatin has a more of a growth inhibitory effect). In order to determine 
CI values, we first assessed apoptosis with each agent alone and then carried out 
combination treatment to assess whether combination treatment was more synergistic or 
antagonistic.   
4.3.2.2.1 Effect of single treatment with cisplatin 
Treatment with cisplatin indicated a dose-dependent decrease in cell viability for both 
parental and drug-resistant cell lines (Figure 4.7). The drug-resistant cell line displayed 
higher levels of cell viability than the parental cell line (with a drug-resistant factor of 1.4 at 
50% cell survival) displaying its drug-resistant phenotype (Figure 4.9). The maximum dose 
of 6.4 µM was incapable of killing all cells (100% apoptosis) with either the parental or the 
drug-resistant cell lines (Figure 4.7).   
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4.3.2.2.2 Effect of single treatment with foretinib 
Same as with cisplatin, treatment with foretinib displayed a dose-dependent reduction in 
cell viability with parental and drug-resistant cell lines (Figure 4.8). The drug-resistant cell 
line displayed better cell survival compared to the parental cell line with a resistant factor 
of 2.9 (at 50% cell survival) (Figure 4.9). A dose of 0.2µM was capable of reducing cell 
viability by 50% for parental cells whilst a dose of 0.7µM was required to produce the same 
effect in the drug-resistant cell line. The maximum dose of 3.2µM was incapable of 
producing a 100% apoptotic effect with either the parental or the drug-resistant cell lines 
(Figure 4.8).   
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 Figure 4.7 Responses of parental and drug-resistant cell lines towards 
cisplatin exposure 
Responses of parental and drug-resistant cells towards increasing doses of 
cisplatin were obtained via MTT assays. Cells plated in 96-well plates were 
incubated with increasing doses of cisplatin (0-6.4µM) for 72 hours. Cells 
were then incubated with MTT solution for four hours and the crystals formed 
were solubilised with DMSO. Absorbance readings were taken from wells at 
570nm with a plate reader n=4.   
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 Figure 4.9 Identification of dose 
values required for 50% cell 
apoptosis in parental and drug-
resistant cell lines exposed to 
cisplatin and foretinib 
Responses of parental and drug-
resistant cells towards increasing 
doses of cisplatin and foretinib 
were obtained via MTT assays. 
Cells plated in 96-well plates were 
incubated with increasing doses 
of cisplatin (0-6.4µM) or foretinib 
(0-3.2µM) for 72 hours. Cells were 
then incubated with MTT solution 
for four hours and the crystals 
formed were solubilised with 
DMSO. Absorbance readings 
were taken from wells at 570nm 
with a plate n=4.   
Dose-response curve – log 
(inhibitor) vs. normalised 
response – variable slope. 
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 Figure 4.8 Responses of parental and drug-resistant cell lines towards 
foretinib exposure 
Responses of parental and drug-resistant cells towards increasing doses of 
foretinib were obtained via MTT assays. Cells plated in 96-well plates were 
incubated with increasing doses of foretinib (0-3.2µM) for 72 hours. Cells were 
then incubated with MTT solution for four hours and the crystals formed were 
solubilised with DMSO. Absorbance readings were taken from wells at 570nm 
with a plate n=4.   
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4.3.2.2.3 Effect of combination treatment with both cisplatin and foretinib 
Following analyses of parental and drug-resistant cells’ responses towards cisplatin and 
foretinib individually, cells were then treated with foretinib and cisplatin (1:2 dose ratio). 
Combination treatment evoked a more antagonistic effect in both the parental and drug-
resistant cell lines at the chosen dose ratio. The graphs show that the drug combination of 
foretinib and cisplatin at the selected dose ratio displayed antagonistic activity for both 
parental and drug-resistant cell lines as the plotted line remains above CI=1. CI values 
over 1.0 display antagonistic activity (Figure 4.10). 
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Figure 4.10: Combination drug treatment effect on cell survival 
Responses of parental and drug-resistant cells towards increasing doses of 
cisplatin and foretinib were obtained via MTT assays. Cells plated in 96-well 
plates were incubated with increasing doses of foretinib (0-3.2µM) and 
cisplatin (0-6.4µM) in a 1:2 ratio for 72 hours. Cells were then incubated with 
MTT solution for four hours and the crystals formed were solubilised with 
DMSO. Absorbance readings were taken from wells at 570nm with a plate n=4.    
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4.3.3 Knocking down MET receptor expression does not reverse the drug-resistant 
phenotype 
Higher levels of P-MET exist in the drug-resistant cell lines (Figure 4.3) and when the MET 
receptor was inhibited, there was a greater decrease in cell viability in the drug-resistant 
cell line compared to the parental cell line (Figure 4.6). The next aim was to determine 
whether knocking down the receptor could increase the sensitivity of the drug-resistant cell 
lines towards drug treatment. Knocking down Met gene expression led to increased cell 
viability of SKOV3 carboplatin-resistant cells.  Mean percentage cell viability was 80.8% ± 
1.0 for SKOV3 CR cells with no Met knockdown (scramble control – NC) and 87.8% ± 1.2 
for SKOV3 CR cells with Met knockdown (P<0.05) (Figure 4.11). 
 
 
Parental and drug-resistant cells were exposed to carboplatin treatment (100µM) after Met 
gene knockdown to determine drug sensitivity of cells. With Met gene knockdown, parental 
cells displayed more resistance when exposed to carboplatin treatment (87.6% ± 0.4 vs. 
84.5% ± 1.8) (Figure 4.12).  
 
Figure 4.11: Knocking down Met  gene 
expression enhanced cell survival in 
drug-resistant ovarian cancer 
Cells plated in 6-well plates were 
subjected to scrambled siRNA (NC) or 
Met siRNA treatment for 72 hours. 
Cells were treated with Annexin-FITC 
and propidium iodide and cell viability 
was analysed through flow cytometry. 
* P<0.05 (unpaired t-test) n=3.   
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Drug treatment significantly decreased cell viability without the knockdown of the Met gene 
in drug-resistant cells. Mean percentage cell viability was 88.6% ± 0.8 for SKOV3 CR NC 
cells without drug treatment and 74.8% ± 1.2 for SKOV3 CR NC with drug treatment 
(P<0.001). However, knocking down the Met gene appeared to bring about a protective 
effect indicated by the increased cell viability levels (as measured by the non-apoptotic cell 
population) of drug-treated cells with Met gene knockdown in comparison to drug-treated 
cells with no Met gene knockdown. Mean percentage cell viability was 74.8% ± 1.2 for 
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Figure 4.12: Knocking down MET expression enhances cell survival in 
ovarian cancer parental cells 
Cells plated in 6-well plates were subjected to scrambled siRNA (NC) or Met 
siRNA treatment for 72 hours. Cells were then incubated with carboplatin 
(100µM) for 48 hours. After 48 hours, cells were treated with Annexin-FITC 
and propidium iodide and cell viability was analysed through flow cytometry.  
A and C) Flow cytometry analysis of viability of parental cells with and 
without Met gene knockdown with carboplatin treatment. All NC and Met 
siRNA control results were corrected to 100% and all drug-treated NC and Met 
siRNA results were normalised according to their respective controls. B) 
Complete knockdown of Met was confirmed through western blotting. **** 
P<0.0001 between indicated groups (One-way ANOVA) n=3. 
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SKOV3 CR NC with drug treatment and 92.9 ± 2.7 for SKOV3 CR Met siRNA with drug 
treatment (P<0.01) (Figure 4.13). 
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B) 
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Figure 4.13: Knocking down MET expression exhibits more resistance to drug 
treatment in drug-resistant cells 
Cells plated in 6-well plates were subjected to scrambled siRNA (NC) or Met 
siRNA treatment for 72 hours. Cells were then incubated with carboplatin 
(100µM) for 48 hours. After 48 hours, cells were treated with Annexin-FITC and 
propidium iodide and cell viability was analysed through flow cytometry.  A 
and C) Flow cytometry analysis of viability of drug-resistant cells with and 
without Met gene knockdown with carboplatin treatment. All NC and Met 
siRNA control results were corrected to 100% and all drug-treated NC and Met 
siRNA results were normalised according to their respective controls. B) 
Complete knockdown of Met was confirmed through western blotting. ** 
P<0.01; *** P<0.001 between indicated groups (One-way ANOVA) n=3. 
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4.3.4 Analyses of downstream signalling proteins of the activated MET receptor 
Knocking down the MET receptor did not enhance the sensitivity of cells towards drug 
treatment. Given its increased activated state in drug-resistant cell lines (section 4.3.1) and 
the fact that inhibiting the receptor led to a decrease in cell viability (section 4.3.2.1), we 
examined the downstream signalling pathways activated by the receptor in order to better 
understand the lack of sensitivity exhibited towards drug treatment on knocking down the 
MET receptor.   
4.3.4.1 STAT3 signalling  
There was an increased amount of total STAT3 protein in the drug-resistant cell lines 
compared to their parental counterparts.  Whilst the difference was not significant in the 
SKOV3 cell line (P>0.05), it was significant in the OVCAR3 TaxR and OVCAR3 EMT-
induced cell lines (P<0.0001). The phosphorylated form of the protein (P-STAT3) was 
significantly reduced in two of the drug-resistant cell lines (SKOV3 CR and OVCAR3 EMT-
induced) compared to their parental counterparts (SKOV3: P<0.05 and OVCAR3 EMT: 
P<0.0001). However, in the paclitaxel-resistant cell line, there was more phosphorylated 
STAT3 compared to the parental control (P>0.05) (Figure 4.14).  
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4.3.4.2 RAC1 signalling 
There was an increase in total RAC1 protein in two of the drug-resistant cell lines 
(OVCAR3 TaxR and OVCAR3 EMT-induced) compared to their parental counterparts 
(P<0.05). In contrast, the amount of total RAC1 protein was decreased in the carboplatin-
resistant cell line compared to its parental cell line (P<0.01). The phosphorylated form of 
the protein (P-RAC1) was significantly increased in all three drug-resistant cell lines 
compared to their parental counterparts (OVCAR3 TaxR and OVCAR3 EMT: P<0.01 and 
SKOV3 CR: P<0.001) (Figure 4.15).   
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Figure 4.14: STAT3 expression in drug-resistant cells 
STAT3 expression levels in the cell lines were analysed through western 
blotting. Proteins were electrophoresed on 7% Tris-Acetate and transferred to 
nitrocellulose membranes. Membranes were blocked and probed for primary 
and secondary antibodies and visualised with the LiCOR Odyssey CLx 
Imaging System. * P<0.05; **** P<0.0001 between indicated groups (unpaired 
t-test) n=3. 
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4.3.4.3 ERK signalling 
Total ERK expression was reduced in two of the drug-resistant cell lines. Carboplatin-
resistant cells have significantly reduced levels of ERK when compared to its parental cell 
line (P<0.0001). The EMT-induced drug-resistant cell line also displayed decreased levels 
of ERK expression compared to its parental counterpart (P<0.05). In contrast, levels of 
total ERK in paclitaxel-resistant cells were significantly increased compared to the parental 
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 Figure 4.15: RAC1 expression in drug-resistant cells 
RAC1 expression levels in the cell lines were analysed through western 
blotting. Proteins were electrophoresed on 10% Bis-Tris gels and transferred 
onto nitrocellulose membranes. Membranes were blocked and probed for 
primary and secondary antibodies and visualised with the LiCOR Odyssey 
CLx Imaging System. * P<0.05; ** P<0.01; *** P<0.001 between indicated 
groups (unpaired t-test) n=3. 
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cell line (P<0.0001) (Figure 4.16). Similar to its total ERK levels, phosphorylated ERK 
levels were significantly reduced in the SKOV3 carboplatin-resistant cells compared to its 
parental cell line (P<0.05). However, phosphorylated ERK levels were significantly 
increased in the paclitaxel-resistant and EMT-induced drug-resistant cell lines compared to 
the parental cell line (OVCAR3 TaxR: P<0.05; OVCAR3 EMT: P<0.01) (Figure 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.16: ERK expression in drug resistant cells 
Total ERK expression levels in the cell lines were analysed through western 
blotting. Proteins were electrophoresed on 10% Bis-Tris gels and transferred 
onto nitrocellulose membranes. Membranes were blocked and probed for 
primary and secondary antibodies and visualised with the LiCOR Odyssey CLx 
Imaging System. * P<0.05; ** P<0.01; **** P<0.0001 between indicated groups 
(unpaired t-test) n=3.    
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4.3.4.4 AKT signalling 
Total AKT expression was increased in all the drug-resistant cell lines compared to their 
respective parental cell lines (all P>0.05). The phosphorylated form of the protein (P-AKT) 
was undetectable in the OVCAR3 cell lines, but levels were increased in the carboplatin-
resistant cell line compared to its parental cell line (P>0.05) (Figure 4.18) 
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 Figure 4.17: AKT expression in drug-resistant cells 
Total AKT expression levels in the cell lines were analysed through western 
blotting. Proteins were electrophoresed on 7% Tris-acetate gels and 
transferred onto nitrocellulose membranes. Membranes were blocked and 
probed for primary and secondary antibodies and visualised with the LiCOR 
Odyssey CLx Imaging System (unpaired t-test – P>0.05) n=3.    
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4.4 Discussion 
In this chapter, the MET receptor was investigated to identify its potential as a biomarker of 
drug resistance. Whilst the inactivated form of the receptor differed in the drug-resistant 
cells examined (one having decreased amount of the receptor protein), both the drug-
resistant cell lines had increased levels of the phosphorylated form of the receptor. An 
increase in the activated form of the receptor in drug-resistant cells is reported by other 
studies (Ozasa et al., 2014, Kim et al., 2016b, Moschetta et al., 2013) and a wide literature 
search indicates that this is the common consensus.  
The amount of activated protein in the EMT-induced drug-resistant cell line was even more 
than that seen in the carboplatin-resistant cell line probably due to the added effects 
contributed to by the presence of the EMT inducers in it. All three EMT inducers (EGF, IL-6 
and TGF-β) are known to play a role in MET receptor activation. EGF binds to EGFR 
which is capable of activating the MET receptor (Jo et al., 2000). Jo et al. (2000) showed 
that inhibition of EGFR resulted in a marked decrease in the activation of the MET receptor 
highlighting the effect of EGF on the MET receptor. Such an effect is also seen in another 
study which indicated that EGFR, when activated, is capable of activating the MET 
receptor (Guo et al., 2008). IL-6 is capable of augmenting MET protein expression (Hov et 
al., 2009). The study by Hov et al. (2009) examining IL-6 effects in MET signalling in 
myeloma cells found that the addition of IL-6 enhanced MET expression. A study using 
proximal tubule cells of the kidney found that MET expression was reduced in the absence 
of TGF-β signalling (Khodo et al., 2016). However, TGF-β was found to negatively regulate 
MET receptor activation in another study (Papa et al., 2017). The study by Papa et al. 
(2017) was done with glioblastoma cells and therefore the different regulatory activities 
may be due to the different cell types involved in the two studies. Nevertheless, the 
combined effects of IL-6 and EGF signalling should overtake any negative regulation of the 
receptor and be responsible for the enhanced receptor activation seen in the cell line.  
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Due to the increased presence of the phosphorylated form of the MET receptor in the 
drug-resistant cells, the Annexin V-FITC assay was used to observe cells’ response 
towards drug treatment on inhibition of the MET receptor. Results here showed inhibition 
of the receptor by foretinib in drug-resistant cells led to a drastic decrease in cell viability. 
Foretinib has been shown to reduce invasive, growth, proliferative and survival abilities of 
ovarian cancer cells (Zillhardt et al., 2011) which explains the cell viability effect seen here. 
However, it is an inhibitor with several other targets besides the MET receptor: RON, 
VEGFR2, AXL, PDGFR, Flt-1, -3, -4, KIT and Tie-2 (Kataoka et al., 2012). Given the many 
targets, many of which play a role in drug resistance (Prislei et al., 2010, Ning et al., 2001, 
Shen et al., 2018, Martin et al., 2008), the enhanced reduction in cell viability is perhaps to 
be expected. Furthermore, PDGFR, KIT, VEGFR2 and RON are known to be expressed in 
ovarian cancer (Schmandt et al., 2003, Spannuth et al., 2009, Maggiora et al., 2003). 
However, the fact that foretinib has many targets makes it difficult to gauge the degree of 
influence of foretinib on the MET receptor. Interestingly, when foretinib was combined with 
carboplatin, there was better cell viability compared to treatment with foretinib alone. To 
this author’s knowledge, there does not appear to be any studies looking at foretinib in 
combination with carboplatin in any cancer including ovarian cancer. Results from the 
annexin assay point towards possible antagonistic activity between the two agents. In 
order to determine if the two agents behaved antagonistically, combination drug treatment 
was carried out via MTT assays. Loewe’s combination index analysis was used to test the 
drug-drug interaction. A combination index value lower than one indicates synergism, 
equal to one indicates additivity and greater than one indicates antagonism. Combination 
treatment can be both informative and help. It can help to minimise serious side effects of 
a particular drug by combining it with another or enhance the expected effect by the 
presence of an extra drug. Combination index values obtained and isobologram analysis 
supported the results seen in the Annexin V-FITC assay indicating possible antagonism at 
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the selected 1:2 dose ratio. Cisplatin has previously shown better growth inhibitory 
properties at lower doses and was more cytotoxic compared to carboplatin (Fanning et al., 
1990) and was therefore, chosen as the platinum agent for use in combinations studies 
with MTT assays. Both are platinum compounds only differing in their structural form and 
they both work using the same mechanism, which made the change from carboplatin to 
cisplatin not a major issue. Results from the combination studies indicated that a larger 
proportion of cells were affected at higher CI values (drug antagonism). Drug antagonism 
may not necessarily mean an unfavourable drug combination in therapy (Yeh et al., 2009). 
Drugs that show antagonistic behaviour could be useful in suppressing the induction of 
drug resistance. Antagonism here possibly indicates that the two drugs do not work 
together effectively. However, even though they do not work together effectively, they each 
will select for cells that are sensitive to each drug alone. This means cells resistant to one 
drug may respond well to the other effectively slowing down the induction of drug 
resistance. Even with this antagonistic activity, adding carboplatin to foretinib was more 
effective than carboplatin alone in both the parental and drug-resistant cell lines. 
Nevertheless, it must be noted that the combination treatment did reduce cell viability 
significantly especially in the drug-resistant cell line despite the possible antagonistic 
activity between the two drugs.  
Cell viability was increased when the met gene was silenced in ovarian cancer cells. 
Studies show silencing the Met gene leads to reductions in cell survival and growth rates 
(Corso et al., 2008, Li et al., 2011). The lack of MET receptor signalling did not enhance 
cell sensitivity in the present study towards carboplatin treatment either. The Annexin V-
FITC assays did show foretinib treatment causes a significant decrease in cell viability, but 
as the gene silencing assay shows no significant effect with Met gene silencing, it could be 
that the foretinib results possibly arise from the inhibition of proteins besides the MET 
receptor. As mentioned previously, foretinib targets other proteins besides the met 
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receptor (Kataoka et al., 2012). Furthermore, the knockdown of the MET receptor could 
have resulted in the upregulation of other associated receptor tyrosine kinase signalling 
leading to enhanced drug resistance. Such a possibility is discussed by Logan-Collins et 
al. (2010) in respect to the RON receptor. They found that some drug-resistant cells are 
capable of expressing other receptor tyrosine kinases (kinase switching) in the presence of 
RON gene silencing allowing these cells to avoid drug treatment effects (Logan-Collins et 
al., 2010). In light of all this evidence, this could perhaps make the MET receptor not an 
ideal biomarker of drug resistance at least in ovarian cancer.  
The identification of signalling pathways activated in drug-resistant cell lines can provide 
useful information about which pathways contribute to the anti-apoptotic and enhanced 
growth features of the drug-resistant phenotype. This information can then be used to 
improve existing targeted therapy as well as help identity possible future targets of interest. 
The activation of the MET receptor leads to the activation of several downstream signalling 
pathways (Hov et al., 2009).  Analysis of four downstream targets (STAT3, RAC1, ERK 
and AKT) of the MET receptor revealed very different information. It has been established 
the MET receptor is highly active in drug-resistant cells. However, not all of its downstream 
signalling pathways appeared to be phosphorylated because of MET receptor activation.  
In the carboplatin-resistant cell line phosphorylated ERK and STAT3 expression levels 
were both less compared to the parental cell line. However, the AKT and RAC1 signalling 
proteins were increasingly phosphorylated in the carboplatin-resistant cell line compared to 
its parental counterpart. In contrast, in the paclitaxel-resistant cell line, STAT3, ERK and 
RAC1 phosphorylations were observed whilst the EMT-induced drug-resistant cell line had 
increased levels of phosphorylated ERK and RAC1.   
The expression of the RAC1 protein was increased in all the three drug-resistant cell lines. 
RAC1 expression has been associated with increased invasion and metastasis 
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(characteristics of drug resistance) and increased levels correlated to poor prognosis (Lou 
et al., 2018). RAC1 is a Rho GTPase, which due to its role in actin cytoskeletal 
reorganisation plays an important role in cell migration and invasion (Cardama et al., 
2018). Furthermore, RAC1 appeared to repair DNA strand damage in cardiomyocytes 
(Huelsenbeck et al., 2012) highlighting another mechanism by which its activation can lead 
to drug resistance. RAC1 inhibition was suggested as a possible therapeutic strategy in 
non-small cell lung cancer by Kaneto et al. (2014). RAC1 inhbition was found to have 
affected both cell migration and growth (Kaneto et al., 2014) though drug sensitivity was 
not tested in the study. Due to its increased activation across all three drug-resistant cell 
line, it could perhaps be an interesting biomarker for drug resistance in ovarian cancer that 
requires further investigation.  
STAT3 signalling is associated with cell proliferation, apoptosis and metastasis (Johnston 
and Grandis, 2011). However, STAT3 signalling was downregulated in two of the drug-
resistant cell lines. This could indicate that it does not play a central role in the drug 
resistance of these two cell lines, but it does appear to play a role in paclitaxel resistance. 
Paclitaxel treatment can activate the STAT3 signalling pathway (Abubaker et al., 2014b), 
which corroborates the increased activated form of STAT3 seen in the paclitaxel-resistant 
cell line, whose drug resistance was developed through repeated doses of paclitaxel being 
administered to the cell line.  
ERK signalling is associated with cell proliferation, adhesion, migration, differentiation and 
survival (Buscà et al., 2016). In studying the ERK signalling pathway, western blot analysis 
revealed increased phosphorylated ERK protein in the two drug-resistant OVCAR3 cell 
lines. These results are supported by other studies. Paclitaxel treatment was found to  
activate the ERK signalling pathway in oesophageal cancer cells (Okano and Rustgi, 
2001) and the three EMT inducers used were also found capable of activating the ERK 
signalling pathway (Lee et al., 2007, Takahashi-Niki et al., 2015, Klemm et al., 2017). ERK 
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signalling has been associated with resistance towards platinum drugs (Achkar et al., 
2018, Lim and Song, 2017, Song et al., 2018a), but the results in the present study 
indicate otherwise with decreased expressions of both total ERK and phosphorylated ERK 
in the carboplatin-resistant cell line. In this particular carboplatin-resistant cell line, ERK 
signalling may not be contributing to the drug-resistant characteristics of cell proliferation 
and survival among others.  
AKT signalling was increased in the carboplatin-resistant cell line. AKT signalling is 
associated with cell survival, proliferation and growth (Avan et al., 2016), all characteristics 
of drug resistance. However, the activated form of the protein was undetectable in the 
OVCAR3 cell line. This could mean that the protein is not activated in this particular cell 
line but a study by Lee et al. (2005) says otherwise. Therefore, it could perhaps be the 
phosphorylation target of the AKT antibody that has resulted in a lack of phosphorylated 
AKT protein in the cell line as there are several phosphorylation points on the AKT protein.  
Overall, the MET protein plays an important role in drug resistance due to its enhanced 
expression levels in the drug-resistant cell line and the downstream signalling pathways 
activated are associated with drug-resistant characteristics of cell survival and motility. 
Inhibition of the receptor did show a significant decrease in cell viability, but there is a 
possibility that the decrease cannot be fully attributed to the inhibition of the MET receptor 
alone. In addition, silencing the gene for the receptor did not show effective drug re-
sensitisation. Therefore, though it may mediate downstream signalling proteins involved in 
drug-resistant characteristics of cell proliferation and survival, the receptor itself may not 
be an ideal biomarker for drug resistance in ovarian cancer.   
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CHAPTER 5 
Identification of novel biomarkers of 
drug resistance using a PCR array 
approach 
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5.1 Introduction 
Having reviewed the use of EMT-related proteins as biomarkers of drug resistance and the 
MET receptor, the final aim of this study was to identify novel genes that could be possible 
biomarkers of drug resistance in ovarian cancer. For this, a PCR array with 84 genes 
associated with EMT was used. The EMT-induced drug-resistant cell line had similar 
protein expression levels and migratory behaviour characteristic of the drug-induced drug-
resistant cells. Hence, the process of EMT was further explored to identify biomarkers for 
the identification of a drug-resistant phenotype in ovarian cancer.  
 
5.2 Methods 
qPCR arrays (section 2.2.8) and western blotting (section 2.2.2) techniques were 
employed for the work done in this chapter. The methods are described in full detail in 
chapter 2.   
 
5.3 Results 
5.3.1 PCR analysis of drug-resistant cell lines to identify significantly upregulated 
EMT-related genes  
In the SKOV3 carboplatin-resistant cell line, there were 13 significantly upregulated genes 
compared to the parental cell line. In the OVCAR3 paclitaxel-resistant cell line, there were 
33 significantly upregulated genes compared to the parental cell line. In the OVCAR3 
EMT-induced drug-resistant cell line, there were 22 significantly upregulated genes 
compared to its parental cell line (Appendix 7.3). Of these, only one gene was commonly 
upregulated in all three drug-resistant cell lines: TCF4.  
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Four genes were significantly upregulated in both the carboplatin-resistant and paclitaxel-
resistant cell lines: TGFβ1, TGFβ2, TMEM132A and WNT5A. In the same cell line, but 
with drug resistance induced in two different ways (continuous drug treatment and EMT 
induction), 14 genes were significantly upregulated (Table 5.1). 
 
Table 5.1 Commonly upregulated genes between the paclitaxel-resistant and EMT-
induced drug-resistant cells 
Upregulated Genes 
CTNNB1 
ESR1 
FN1 
ITGAV 
KRT7 
MAP1B 
MST1R 
RAC1 
RGS2 
SNAI2 
STAT3 
VCAN 
WNT5B 
ZEB1 
 
  
From these data, several upregulated genes common to two or more cell lines were picked 
out for further analysis through western blotting: TCF4 (common to the carboplatin-
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resistant, paclitaxel-resistant and EMT-induced cell lines), WNT5A (common to 
carboplatin-resistant and paclitaxel-resistant cell lines) and STAT3 and ZEB1 (common to 
both drug-resistant OVCAR3 cell lines). 
Western blotting analyses showed that the gene expression levels did not correlate to the 
protein expression levels in the carboplatin-resistant cell line. The protein expression of 
TCF4 and WNT5A were both decreased in the drug-resistant cell line compared to the 
parental cell line (TCF4: P<0.01 and WNT5A: P>0.05) (Figure 5.1).  
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In the OVCAR3 paclitaxel-resistant cell line, western blotting analysis showed that the 
gene expression levels did correlate to the protein expression levels with one exception: 
TCF4. Even though the gene expression was increased in the drug-resistant cells, its 
protein expression was decreased compared to the parental cells (P>0.05). For all the 
other three genes, their protein expression levels were significantly increased in the drug-
resistant cells compared to the parental cells (STAT3 and ZEB1: P<0.0001, WNT5A: 
P<0.05) (Figure 5.2).  
Figure 5.1 Gene and protein expression of chosen genes in the carboplatin-
resistant cell line 
A. Gene expression levels of chosen genes in the carboplatin-resistant cells. 
B. Protein expression levels of the chosen genes in the carboplatin-resistant 
cells. ** P<0.1 between indicated groups (Unpaired T-Test) n=3. 
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In the OVCAR3 EMT-induced drug-resistant cell line, western blotting analysis showed 
that the gene expression levels did correlate to the protein expression levels with one 
exception: TCF4. Even though the gene expression was increased in the drug-resistant 
cells, its protein expression was decreased compared to the parental cells (P>0.05). For all 
the other three genes, their protein expression levels were significantly increased in the 
drug-resistant cells compared to the parental cells (STAT3: P<0.001 and ZEB1: P<0.0001) 
(Figure 5.3).  
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Figure 5.2 Gene and protein expression of chosen genes in the paclitaxel-
resistant cell line 
A. Gene expression levels of chosen genes in the paclitaxel-resistant cells. B. 
Protein expression levels of the chosen genes in the paclitaxel-resistant cells. 
* P<0.05; **** P<0.0001 between indicated groups (Unpaired T-Test) n=3. 
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5.4 Discussion 
In this chapter, the focus was on identifying novel genes that could be possible biomarkers 
of drug resistance in ovarian cancer. With EMT’s association with drug resistance, a PCR   
array containing primer assays for 84 EMT-related genes was used.   
Gene expression analyses did not always correlate to its protein expression levels. This 
can be due to differences in regulation of transcription and translation of the mRNA, but 
could also be related to the inefficiency of current metholodolgies to accurately represent 
the gene and protein levels in a sample under investigation. A review by Maier et al. 
(2009) discusses this lack of correlation between mRNA and protein levels in detail.   
A gene encoding TCF4 (Transcription factor 4) was upregulated across all three drug-
resistant cell lines. However, in contrast, its protein expression levels were downregulated 
across the same three drug-resistant cell lines. Immunoglobulin transcription factor 2 
(ITF2) (also known as TCF4) expression was found increased in drug-resistant cancers 
(Hur et al., 2017). TCF4 possibly contributes to drug resistance via EMT induction as well 
as the induction of anti-apoptotic mechanisms. E2-2 (otherwise known as TCF4) is 
capable of regulating EMT (Sobrado et al., 2009). Cells transfected with E2-2 displayed a 
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Figure 5.3 Gene and protein expression of 
chosen genes in the EMT-induced drug-
resistant cell line 
A. Gene expression levels of chosen genes 
in the EMT-induced drug-resistant cells. B. 
Protein expression levels of the chosen 
genes in the EMT-induced drug-resistant 
cells. * P<0.05; *** P<0.001; **** P<0.0001 
between indicated groups (Unpaired T-Test) 
n=3. 
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mesenchymal phenotype with decreased E-cadherin levels and increased levels of 
mesenchymal markers such as vimentin. The contribution of such markers to drug 
resistance was discussed previously (section 3.4).  Hur et al. (2017) showed that when 
ITF2 was silenced, there was an increase in activated caspase 3 with enhanced cell 
apoptosis. Furthermore, ITF2 is a downstream target of the Wnt/β-catenin signalling 
pathway and increased nuclear β-catenin expression was seen in these drug-resistant cell 
lines. This may be why there was an increased gene expression level of ITF2 as there was 
increased β-catenin and Wnt expression in drug-resistant cell lines seen in the work 
undertaken in this study even though regulatory effects on translation of the protein results 
in decreased protein levels of TCF4. 
WNT5A was upregulated in the paclitaxel-resistant cell line and supported the work by Yin 
et al. (2016). Upregulated WNT5A gene expression was observed in the gefitinib-resistant 
NSCLC as well as the EMT-induced NSCLC. Yin et al. (2016) also found this gene 
upregulated in their CXCR4-positive cell population. CXCR4 upregulation is associated 
with stemness in drug-resistant NSCLC (Jung et al., 2012). WNT5A could play a role in 
inducing stem cell-like nature and contributing to drug-resistance.  
Furthermore, the association of WNT5A with drug resistance in ovarian cancer itself is 
supported by a study by Peng et al. (2011). An increased drug-resistant capacity was 
observed in ovarian cancer cell line, SKOV3, where WNT5A was overexpressed with the 
downregulation of the gene leading to an enhanced positive response to drug treatment 
(Peng et al., 2011). Hung et al. (2014) found upregulated gene and protein expression 
levels of WNT5A in drug-resistant cancer cell lines. The increased gene expression was 
attributed to the hypomethylation of the gene in the drug-resistant cells (Hung et al., 2014). 
Furthermore, the increased WNT5A expression was also associated with an increased 
expression level in the β-CATENIN protein. In Chapter 3 (section 3.3.1.2), it was reported 
that drug-resistant cells did have increased β-CATENIN protein expression levels.  Hung 
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et al. (2014) showed that knocking down WNT5A expression led to decreased β-CATENIN 
expression highlighting the regulatory effect of WNT5A on β-CATENIN expression.  
Increased WNT5A expression was accompanied with an increase in the expression level 
of the multi-drug transporter, ABCB1 and the knockdown of WNT5A led to a decreased 
expression level of ABCB1 (Hung et al., 2014). ABC transporters are well established as 
important factors in drug resistance (section 1.4.13). The results from the present research 
suggests that WNT5A could be contributing to drug-resistance in the paclitaxel-resistant 
cell line through increased drug efflux mechanisms. 
In gemcitabine-resistant bladder cancer, increased expression of mIR-129-5p increased 
sensitivity to drug-treatment with enhanced cell apoptosis (Cao et al., 2018). The same 
study revealed that WNT5A was a target gene of mIR-129-5p as the use of a mIR-129-5p 
inhibitor led to increased WNT5A expression levels.  Whilst the levels of mIR-129-5p in 
ovarian cancer were not analysed in this thesis, a study by Tan et al. (2015) showed that 
expression of mIR-129-5p in ovarian cancer cells made the cells more sensitive to cisplatin 
(Tan et al., 2015). There is a lack of reported studies currently examining the role of 
WNT5A in drug-resistant ovarian cancer. Therefore, even though WNT5A levels are 
increased in the drug-resistant ovarian cancer cells in the present study, further research 
in to this protein is required to determine its value as a drug-resistant biomarker in ovarian 
cancer.  
ZEB1 was found upregulated in both drug-resistant cell lines of OVCAR3. ZEB1 is an 
EMT-inducing transcription factor capable of repressing epithelial markers such as those 
involved in cell junctional complexes and promoting mesenchymal markers such as those 
involved in cytoskeletal rearrangement (Caramel et al., 2018). Increased ZEB1 expression 
has also been observed in drug-resistant cancers (Zou et al., 2017a, Yoshida et al., 2016, 
Zhang et al., 2018).  
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ZEB1 is involved in the regulatory networks of several miRNAs, which have been 
associated with drug resistance: mIR-27b, mIR-34a, mIR-429 and members of the miR-
200 family (Zou et al., 2017b, Burk et al., 2008, Zhang et al., 2018).  
mIR-429 in particular has been shown to play a role in drug resistance in ovarian cancer in 
association with ZEB1 (Zou et al., 2017b, Chen et al., 2011). Cisplatin-resistant ovarian 
cancer cells expressed lower levels of mIR-429 and transfecting these cells with mIR-429 
led to decreased cell proliferation and increased cell apoptosis (Zou et al., 2017b).  
Increased expression of ZEB1 was observed in the drug-resistant cells and this expression 
was downregulated when the cells were transfected with mIR-429 pointing to its inhibitory 
effect on ZEB1. mIR-429 was also found to be downregulated in expression in chemo-
resistant ovarian cancer patients with a significant association being found between mIR-
429 expression and chemotherapy response. As ZEB1 has shown increased expression in 
drug-resistant ovarian cancer in this thesis and it is affected by mIR-429 actions (which in 
turn have been associated with negative chemotherapy response), it emerges as a 
possible protein of interest in drug resistance in addition to levels of mIR-429.  
Furthermore, Chen et al. (2011) showed that mIR-429 is capable of regulating EMT. 
Mesenchymal cells expressed lower levels of mIR-429 with increased ZEB1 expression. 
When mIR-429 was overexpressed in these cells, they adopted a more epithelial 
phenotype with increased expression of E-CADHERIN and decreased expression of 
mesenchymal markers such as ZEB1, VIMENTIN and N-CADHERIN.  
ZEB1 is a repressor of E-CADHERIN expression (Park et al., 2008). Consistent with this, 
in chapter 3 (sections 3.3.3.1), both the drug-resistant cell lines of OVCAR3 displayed 
decreased levels of E-CADHERIN. Therefore, ZEB1 could be responsible for the 
downregulation of E-CADHERIN in these two drug-resistant OVCAR3 cell lines. In 
contrast, however, even though the SKOV3 carboplatin-resistant cells also displayed 
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decreased levels of E-CADHERIN, its ZEB1 gene expression levels were downregulated. 
As the protein expression levels of ZEB1 were not probed for this cell line, it remains to be 
seen whether despite the low gene expression levels, there is increased protein 
expression levels, which could have then contributed to E-CADHERIN downregulation or 
whether E-CADHERIN downregulation in this cell line is not influenced by ZEB1 
expression.  Nevertheless, the association of ZEB1 with drug resistance and EMT shows 
its potential as a marker of drug resistance in ovarian cancer and therefore, requires 
further investigation to determine its biomarker potential. 
STAT3 is another gene found to be upregulated in both the drug-resistant forms of the 
OVCAR3 cell line. The increased gene expression levels correlated with protein 
expression levels in the two cell lines. Despite the downregulated gene expression of 
STAT3 in the carboplatin-resistant SKOV3 cell line, in chapter 4 (section 4.3.4.1), it was 
seen that the protein expression of STAT3 was higher in the drug-resistant SKOV3 cell 
line. Increased STAT3 expression levels have been associated with drug-resistance (Barré 
et al., 2007, Song et al., 2018b). STAT3 could contribute to drug-resistance by the 
increased expression of drug efflux plumps (Seo et al., 2017). Blocking STAT3 activity led 
to a downregulation of p-glycoprotein levels enhancing sensitivity towards Adriamycin 
treatment (Zhang et al., 2011). P-glycoprotein is a drug efflux pump encoded by the 
ABCB1 gene which when inhibited resulted in sensitivity towards paclitaxel in ovarian 
cancer cells (Zhang et al., 2016, Vaidyanathan et al., 2016). However, STAT3 could also 
contribute to drug resistance through its effects on proteins related to the apoptotic 
pathways such as BCL-2, BCL-xL, SURVIVIN and P53 (Poli and Camporeale, 2015). 
Increased transcription of anti-apoptotic proteins, BCL-2, MCL-1 and c-IAP2 by STAT3 
was observed in intestinal epithelial cells, which made them resistant to apoptotic effects 
induced by tumour necrosis factor-α (Bhattacharya et al., 2005). P53 inhibits cell growth 
arresting cells in the G1 phase of cell cycle just before the stage of mitosis (Levine et al., 
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1991). STAT3 binds to the p53 promotor supressing its transcription and the reduction in 
STAT3 activity led to increased p53 expression and increased cell apoptotic and 
decreased cell growth activities (Niu et al., 2005). Furthermore, STAT3 regulates the 
WNT/β-catenin signalling axis with the knockdown of STAT3 resulting in the reduced 
signalling of this pathway (Chen et al., 2017). Increased STAT3 (sections 4.3.4.1. and 
5.3.1), WNT (section 5.3.1)  and β-catenin (section 3.3.1.2) expression levels have been 
observed in the drug-resistant cell lines in this thesis indicating a possible role for this 
network of proteins in inducing drug resistance in ovarian cancer. STAT3, therefore, 
emerges as another biomarker of interest in drug-resistant ovarian cancer.  
The overall aim of this chapter was to identify genes that could be possible biomarkers of 
drug resistance in ovarian cancer and through the PCR array, upregulated genes related 
to EMT and therefore, drug resistance were identified. From this list of genes, only several 
upregulated genes were analysed for their protein expression levels in this chapter due to 
time-constraints. However, in order to determine their potential as biomarkers of drug 
resistance, further work beyond protein analyses is required. This is a significant drawback 
for the work in this chapter as further work such as gene silencing or gene overexpression 
combined with drug sensitivity testing could have further helped to determine their 
potential as biomarkers of drug resistance.  
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CHAPTER 6 
Discussion and Future work 
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6.1 Discussion 
The main aim of this study has been to identify biomarkers capable of determining a drug-
resistant phenotype in ovarian cancer.  As a starting point on how to identify which 
proteins to consider as biomarkers of drug resistance, proteins associated with the 
process of EMT were chosen. EMT-associated proteins are commonly found upregulated 
in drug-resistant cancers (Arumugam et al., 2009, Işeri et al., 2011). The role EMT plays in 
drug resistance is discussed in several of the published literature (Du and Shim, 2016, 
Shibue and Weinberg, 2017, Singh and Settleman, 2010). Using this EMT-led approach, 
five EMT-associated proteins commonly used in EMT-related drug resistance studies in 
cancer were chosen: E-CADHERIN, β-CATENIN, VIMENTIN, SLUG and TWIST. The use 
of four drug-resistant cell lines allowed to determine the proteins that have similar 
expression across the four drug-resistant cell lines. This made them more reliable as 
possible biomarkers of drug resistance rather than relying on a single drug-resistant cell 
line. 
E-CADHERIN levels were downregulated in three drug-resistant cell lines as well as in the 
EMT-induced cell line. E-CADHERIN, being an epithelial marker, would be expected to be 
downregulated if the association of EMT with drug resistance is considered. Published 
studies do point to the downregulation of E-CADHERIN in drug-resistant cancers (Chen et 
al., 2012, Berezhnaya et al., 2009, Lu et al., 2012), which agrees with the result observed 
in the present study. E-CADHERIN is a cell junctional protein involved in anchoring the cell 
to the basement membrane and neighbouring cells resulting in the immobile state of the 
cell (Serrano-Gomez et al., 2016). The downregulation allows the transition of the cell from 
an immobile to a mobile state as attachments with neighbouring cells and basement 
membrane cease to exist. A study on ovarian cancer cells showed that E-CADHERIN loss 
is accompanied by an increase in ERK signalling activity (Sawada et al., 2008) involved in 
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cell proliferation and anti-apoptosis (Li et al., 2016), characteristics of drug-resistant cells, 
and the present study does reflect this with increased phosphorylated expression of ERK 
in the paclitaxel-resistant and EMT-induced cell lines. The expression of ERK in the 
carboplatin-resistant cell line could indicate that E-CADHERIN and the ERK signalling do 
not associate in them. E-CADHERIN downregulation is also mediated by AKT signalling 
(Lau and Leung, 2012) and this is confirmed by the increased phosphorylated expression 
of the protein in the carboplatin-resistant cell line in the present study. AKT signalling is 
involved in cell proliferation and survival (Avan et al., 2016), characteristics of drug-
resistant cells. Furthermore, E-CADHERIN expression is transcriptionally repressed by the 
activity of SLUG and ZEB1 (Vergara et al., 2016). In this regard, the present study showed 
upregulation of SLUG in all three of the drug-resistant cell lines with downregulation of E-
CADHERIN. In the CaOV3 carboplatin-resistant cell line, the increased E-cadherin 
expression was accompanied with downregulated SLUG expression, which indicates that 
SLUG expression plays an important role in the regulation of E-CADHERIN expression in 
drug-resistance. Furthermore, ZEB1 expression was also upregulated in the OVCAR3 
paclitaxel-resistant cell line as well as the EMT-induced cell line in the present study 
pointing to another transcriptional factor, which may play an important role in the regulation 
of E-CADHERIN. In light of all this, the downregulation of E-CADHERIN protein could 
serve as a possible biomarker of drug resistance in ovarian cancer, though further 
investigation is required.  
β-CATENIN was significantly elevated in all four drug-resistant cell lines including the 
EMT-induced cell line in the present study. β-CATENIN links junctional protein, E-
CADHERIN, to the cytoskeleton of the cell allowing for the structural stability of the cell 
(Tian et al., 2011). With E-CADHERIN downregulation, β-CATENIN cytoplasmic 
concentrations increase and Wnt signalling can regulate β-CATENIN resulting in the 
translocation of β-CATENIN to the nucleus (Reya & Clevers, 2005). To this effect, WNT5A 
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protein expression was found upregulated in the paclitaxel-resistant cell line in the present 
study. The expression of genes related to Wnt/β-catenin signalling is enhanced in drug-
resistant lung cancer (Nakata et al., 2015).  Whilst increased phosphorylated AKT protein 
was only detectable in the carboplatin-resistant cell line, total AKT protein levels were 
enhanced in the paclitaxel-resistant, carboplatin-resistant and the EMT-induced cell lines 
in the present study. AKT is capable of phosphorylating GSK3, which prevents the 
ubiquitination of cytoplasmic β-CATENIN allowing it to translocate to the nucleus 
(McCubrey et al., 2014; Reya & Clevers, 2005). In the carboplatin-resistant cell line, the 
phosphorylated AKT protein could be regulating the deactivation of GSK3 activity allowing 
for β-CATENIN-related transcriptional activity. β-CATENIN regulates the expression of 
various proteins such as CYCLIN D, JUN and MYC (Shang et al., 2017). CYCLIN D 
overexpression was associated with cisplatin-resistance in pancreatic cancer (Biliran et al., 
2005). The contribution of CYCLIN D towards cisplatin-induced apoptosis was related to 
enhanced expression of anti-apoptotic proteins: BCL2 and BCL-xL. Expression of Jun 
protein is associated with increased cell migration and decreased cell apoptosis in drug-
resistant melanoma cell lines (Ramsdale et al., 2015). MYC protein is capable of anti-
apoptotic activity through the upregulation of SURVIVIN protein contributing to drug 
resistance in leukaemia cells (Zhang et al., 2015). SURVIVIN expression is associated 
with paclitaxel-resistance in ovarian cancer (Zaffaroni et al., 2002). Therefore, in the 
paclitaxel-resistant cell line in the present study with its enhanced β-CATENIN expression, 
SURVIVIN may play a role in the contribution to the drug-resistant phenotype through its 
anti-apoptotic effects. In light of all this information, upregulated β-CATENIN levels could 
serve as a possible biomarker of drug resistance in ovarian cancer, though further 
investigation is required. 
SLUG showed significantly elevated expression in three of the drug-resistant cell lines as 
well as in the EMT-induced cell line in the present study.  This association of SLUG with 
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resistance towards platinum and taxane in ovarian cancer is supported by other studies 
(Haslehurst et al., 2012; Kurrey et al., 2009). As mentioned earlier, SLUG is responsible 
for the repression of E-CADHERIN expression (Vergara et al., 2016). The decreased E-
cadherin expression resulting in a breakdown of cell junctions could be aiding in the 
increased migratory capacities observed by Haslehurst et al. (2012), which was also 
replicated in the present study through scratch assays, which showed increased migratory 
capacities of paclitaxel-resistant, carboplatin-resistant and EMT-induced cell lines. 
Furthermore, WNT signalling prevents the degradation of SLUG by GSK3 (Wu et al., 
2012). Vallin et al. (2001) showed that the Xenopus slug promotor consisted of binding 
sites for β-CATENIN further highlighting the role Wnt/β-catenin signalling plays in drug 
resistance. In the paclitaxel-resistant OVCAR3 cell line in the present study, SLUG, WNT 
and β-CATENIN expression levels were increased suggesting possible interacting 
pathways contributing to drug resistance. SLUG was also found to increase the expression 
of VIMENTIN in breast cancer cells (Wu et al., 2012) and it could also be responsible for 
the increased expression of VIMENTIN observed in the present study with the paclitaxel-
resistant, carboplatin-resistant and the EMT-induced cell lines. SLUG contribution to drug-
mediated apoptosis has been attributed to the repression of genes associated apoptosis 
such as PTEN (Kurrey et al., 2009). The AKT protein is a target of PTEN and the 
repression of the PTEN protein allows AKT signalling, which is involved in cell survival 
processes (Xu and Mo, 2012). Furthermore, in the present study, subsequent gene 
silencing work targeting the SNAI2 gene led to increased sensitivity towards drug 
treatment. In light of all this information, elevated SLUG expression levels can serve as a 
possible biomarker of drug resistance in ovarian cancer.     
VIMENTIN expression levels vary across the drug-resistant cell lines examined with no 
particular dominant expression. This was surprising because being a common 
mesenchymal marker, VIMENTIN levels were expected to be increased in the drug-
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resistant cell lines. However, this was only true of the OVCAR3 paclitaxel-resistant cell line 
and the SKOV3 carboplatin-resistant cell line. Both the PEO1 and CaOV3 carboplatin-
resistant cell lines displayed downregulated expression levels of VIMENTIN. VIMENTIN is 
an intermediate filament involved in the regulation of the cell cytoskeleton that leads to cell 
motility (Mendez et al., 2010) and the metastatic phenotype is associated with drug 
resistance (Liang et al., 2002). In addition, the gene encoding the VIMENTIN protein 
contains binding sites in its promotor for β-CATENIN (Gilles et al., 2003). As mentioned 
previously, the two drug-resistant cell lines with upregulated VIMENTIN expression also 
had upregulated β-CATENIN in the present study. Therefore, the upregulated levels 
observed in two of the drug-resistant cell lines was understandable. Nevertheless, though 
the decreased VIMENTIN levels in the present study were not what was expected, there 
was one study in ovarian cancer, which also described downregulated VIMENTIN levels in 
drug-resistant cancer cells (Huo et al., 2016). The study by Huo et al. (2016) showed that 
VIMENTIN downregulation led to an increase in stem cell markers, increase in drug 
exocytosis and arrested cells in G2 phase allowing the repair of drug-mediated DNA 
damage contributing to drug resistance. This is possibly the mechanism of drug resistance 
mediated by VIMENTIN in the PEO1 and CaOV3 carboplatin-resistant cell lines. However, 
due to the focus of this present study being on reliable biomarkers of drug resistance and 
the fact that the present study showed varying expressions of VIMENTIN across the four 
drug-resistant cell lines, it was not deemed a possible biomarker of drug resistance in 
ovarian cancer. 
TWIST expression was found downregulated in three of the drug-resistant cell lines 
including the EMT-induced cell line. This appears to be a novel finding and does not agree 
with current published studies, which associate upregulated TWIST expression with drug 
resistance (Li et al., 2018; Roberts et al., 2016; Wang et al., 2018). Roberts et al. (2016) 
found that TWIST mediates drug resistance in ovarian cancer through the upregulation of 
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cell survival-associated AKT protein. However, in the present study, though upregulated 
AKT expression has been observed in the carboplatin-resistant, paclitaxel-resistant and 
EMT-induced cell lines, TWIST is not mediating this upregulation. TWIST is an EMT 
transcription factor and mediates drug resistance through the regulation of cell survival and 
anti-apoptosis-related proteins (Kwon et al., 2017) and in the absence of any supporting 
data from other published studies, TWIST cannot be considered a biomarker of drug 
resistance in ovarian cancer without further investigation. 
The present study used the process of EMT and proteins associated with it as a starting 
point to look for possible biomarkers of ovarian cancer. The drug-resistant cell lines 
(resistant towards carboplatin or paclitaxel) used were established with repeated exposure 
of parental forms of the cell lines to the particular drug. In order to see whether drug-
resistance could instead be established through the induction of EMT, three EMT inducers 
were used. When the expression of E-CADHERIN, β-CATENIN, VIMENTIN, SLUG and 
TWIST were compared between the OVCAR3 paclitaxel-resistant cell line and the EMT-
induced cell line, the similar protein expression patters pointed towards the induction of 
drug resistance in the EMT-treated cell line. In order to establish the drug-resistant 
phenotype further, after inconclusive MTT assays, scratch assays were employed. The 
use of scratch assay analyses on carboplatin-resistant and paclitaxel-resistant cell lines 
indicated that drug-resistant cells had an increased capacity for migration. On this basis, 
the scratch assay was employed to analyse the migratory capacity of the EMT-treated 
cells compared to its parental cell line. The assay revealed that the EMT-treated cells did 
have increased migratory capacity establishing a drug-resistant phenotype in these cells. 
During protein expression analyses of the above mentioned five proteins in the present 
study, all mesenchymal markers (VIMENTIN, SLUG and TWIST) were not upregulated in 
all the drug-resistant cell lines considered. VIMENTIN was downregulated in two drug-
resistant cell lines, SLUG was downregulated in one drug-resistant cell line and TWIST 
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was downregulated in three drug-resistant cell lines, including the EMT-induced cell line. If 
we associated the complete state of EMT with drug resistance, these three mesenchymal 
markers should have been upregulated in all the drug-resistant cell lines. Yet, such an 
upregulation was not common even though the cell lines had been analysed and 
established to be drug-resistant. This brings about the idea that perhaps drug resistance 
does not necessarily have to involve the completion of EMT. This idea is supported in a 
study by Jolly et al. (2016). This 2016 study associates drug resistance with a partial state 
of EMT where cells express both epithelial and mesenchymal markers, which is more 
reflective of the protein expression analyses conducted in the present study. This perhaps 
makes it incorrect to refer to the cell line treated with EMT as an EMT-induced cell line. 
However, this author does not find it completely incorrect to do so. EMT has been induced 
in the cell line. It no longer presents a protein expression profile similar to its parental cell 
line, but perhaps the process of EMT has not come to completion in the cell line. There are 
limited studies exploring the concept of a partial EMT and drug resistance, but in light of 
what is observed in the present study, this author is inclined to agree that a partial state of 
EMT and its association with drug resistance may be worth the consideration.  
The MET receptor protein was examined during the MSc dissertation of this author and 
upregulation of the phosphorylated protein was found in drug-resistant ovarian cancer cell 
lines. Therefore, examination of this receptor as a possible biomarker of drug resistance in 
ovarian cancer was included in the present study. The MET receptor was phosphorylated 
in the carboplatin-resistant and EMT-induced drug resistant ovarian cancer cell lines. 
Though the inhibition of the MET receptor resulted in decreased cell viability, the silencing 
of the MET gene showed an increased resistance towards carboplatin treatment. 
Therefore, there is the possibility that the cell viability reduction observed with the foretinib 
inhibitor could be due to the added effects of the other targets of the inhibitor such as RON 
and VEGFR2, leading to the possibility that the results may not be a true reflection of the 
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inhibitor’s effects on the MET receptor alone. Furthermore, the MET receptor is a tyrosine 
kinase receptor and the lack of input from the MET receptor could lead to an enhance in 
the signalling of other tyrosine kinase receptors. In light of this, the MET receptor protein 
may not be ideal as a biomarker of drug resistance in ovarian cancer.  
Looking at the downstream signalling proteins of the MET receptor, phosphorylated RAC1 
was observed in all three drug-resistant cell lines (carboplatin-resistant, paclitaxel-resistant 
and EMT-induced drug-resistant) examined. Increased expression of RAC1 has been 
associated with drug resistance in head and neck squamous cell carcinoma (Skvortsov et 
al., 2014) and gastric cancer (Yoon et al., 2017). RAC1 signalling is involved in cell 
metastasis and invasion (Lou et al., 2018), which are characteristics of drug resistance. 
RAC1 increases cell proliferation activity (characteristic of drug-resistant cells) through the 
activation ERK signalling (Arai et al., 2005). This could be true for both the drug-resistant 
forms of the OVCAR3 cell line (paclitaxel-resistant and EMT-induced cell lines), which 
displayed increased levels of both phosphorylated ERK and phosphorylated RAC1.  Given 
the significantly increased expression levels of RAC1 in the three drug-resistant cell lines 
examined, this protein may be of interest as a biomarker of drug resistance in ovarian 
cancer. 
In the last chapter, a PCR array approach was used to analyse a large number of genes 
associated with EMT in the carboplatin-resistant, paclitaxel-resistant and EMT-induced 
drug-resistant cell lines. From the results obtained, several genes were analysed for their 
protein expression. WNT5A, STAT3 and ZEB1 protein expression levels were increased in 
at least one drug-resistant cell line examined. However, due to time constraints, further 
examination of these proteins was not possible, but they should be considered as possible 
candidates for biomarkers of drug resistance in ovarian cancer pending further 
investigation. Effects of WNT, ZEB1 and STAT3 activity have been described before with 
regards to their relation to drug resistance and therefore, a discussion is not made here on 
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the proteins.  As this last chapter of work was targeting the production of a list of several 
genes that could be used for further investigation as biomarkers of drug resistance, the full 
list of all the upregulated genes in each drug-resistant cell line examined is provided in 
Appendix 7.3.    
This piece of work was limited to the analyses of markers related to EMT. However, there 
are other biological markers, which could also be potential candidates as biomarkers of 
drug resistance in ovarian cancer. A study by Munoz-Galvan et al. (2019) examined 
ovarian tumours and found that many of the identified dysregulated genes were associated 
with the stem cell phenotype (Muñoz-Galván et al., 2019). As discussed in section 1.5.1.7, 
the stem cell phenotype is associated with drug resistance. The genes examined in the 
study were not in the PCR array used in this present study indicating other possible 
avenues of research for the identification of biomarkers of drug-resistance in ovarian 
cancer. Munoz-Galvan et al. (2019) observed that inhibiting the stem cell-related proteins 
resulted in a better response to platinum therapy highlighting the importance of the stem 
cell phenotype in drug resistance in ovarian cancer.  
Other potential biomarkers can be found by looking at processes that contribute to drug 
resistance (extensively described in section 1.5.1). Proteins involved in DNA methylation, 
histone acetylation and DNA repair pathways are possible processes that may yield useful 
biomarkers of drug resistance in ovarian cancer (Zyl et al., 2018). The use of decitabine, 
which inhibited DNA methyltransferase enzymes, for example, resulted in decreased 
methylation rates and restored platinum sensitivity in high grade serous carcinoma 
patients (Fang et al., 2010), which points to DNA methyltransferase enzymes as possible 
biomarkers.  
The biomarkers discussed in this study cannot be located in the blood and therefore, the 
clinical application of such biomarkers to determine a drug-resistant phenotype in ovarian 
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cancer patients will have to be through the examination of biopsy samples. The presence 
of such biomarkers could inform the clinician on the best chemotherapeutic route for the 
patient. The recent discovery of a panel of proteins detectable in the blood with the 
potential to detect ovarian cancer earlier than current diagnostic mechanisms (Russell et 
al., 2019)allow leads to the hope that perhaps one day, such a blood test could also inform 
a clinician of the drug-resistant phenotype of a patient.  
 
6.2 Further work 
E-CADHERIN was downregulated in three of the drug-resistant cell lines including the 
EMT-induced cell line. Witta et al. (2006) have shown that expression of E-CADHERIN 
resulted in sensitivity towards gefitinib in a gefitinib-resistant lung cancer cell line (Witta et 
al., 2006). Therefore, perhaps the decreased expression of E-CADHERIN could serve as a 
biomarker of drug resistance in ovarian cancer. Further work to experiment the effect of 
overexpressing the gene encoding E-CADHERIN on drug resistance could help determine 
the reliability of E-CADHERIN as a biomarker of drug resistance.  
β-CATENIN was a protein that was upregulated significantly across all four drug-resistant 
cell lines including the EMT-induced cell line. Due to time constraints, this protein was not 
further examined for its potential as a biomarker of drug resistance. Downregulation of β-
CATENIN expression restored Gefitinib sensitivity in a  drug-resistant lung cancer cell line 
(Nakata et al., 2015) and therefore, further exploration of β-CATENIN with gene silencing 
work may provide further evidence of the reliability of the protein as a possible biomarker 
of drug resistance in ovarian cancer.  
SLUG, significantly elevated in three drug-resistant cell lines as well as the EMT-induced 
cell line, showed that knocking down its expression restored sensitivity towards drug 
treatment.  Haslehurst et al. (2012) examined both cell lines and drug-resistant tumour 
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samples and found increased SLUG expression in both (Haslehurst et al., 2012). 
However, due to the very low number of drug-resistant tumours (11) examined, further 
work is required with a larger tissue sample group to ensure the reliability of SLUG as a 
biomarker of drug resistance in ovarian cancer.  
Despite the examination of the MET receptor through protein analysis the receptor and its 
downstream signalling effectors, effects of receptor inhibition and receptor knockdown, it 
was not possible to determine whether it could be a possible biomarker of drug resistance. 
Perhaps, the use of an inhbitior whose target is only the MET receptor may help determine 
its importance in drug resistance better. Another possible avenue of research would be to 
examine the expression levels of the downstream signalling effectors in cells subjected to 
knockdown or inhibition of the receptor.   
Looking at downstream signalling proteins of the MET receptor, in the paclitaxel-resistant 
cell line, increased expression of phosphorylated STAT3, phosphorylated RAC1 and 
phosphorylated ERK were observed. In the carboplatin-resistant cell line, increased 
expression of phosphorylated RAC1 and phosphorylated AKT were observed. In the EMT-
induced drug-resistant cell line, phosphorylated RAC1 and phosphorylated ERK1 
expressions were observed. STAT3 signalling is mediates drug-resistant characteristics 
such as cell proliferation, apoptosis and metastasis (Johnston & Grandis, 2011). RAC1 
signalling is involved in the drug-resistant characteristics of metastasis, invasion and cell 
proliferation (Arai et al., 2005; Lou et al., 2018). AKT signalling is involved in the drug-
resistant characteristics of cell survival, proliferation and growth (Avan et al., 2016). ERK 
signalling mediates drug resistance through regulation of cell proliferation, migration, 
differentiation and survival (Buscà et al., 2016). Though all the signalling proteins mediate 
drug-resistant mechanisms, not all are active in each drug-resistant cell line examined. 
Therefore, when determining biomarkers to identify a drug-resistant phenotype, perhaps 
their expression must be considered across at least 10 various drug-resistant ovarian 
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cancer cell lines and the expression of the most commonly upregulated proteins then 
analysed in tumour tissues.  
Appendix 7.3 gives the full list of all upregulated genes for each drug-resistant cell line 
examined and this could be the next step in the identification of biomarkers of drug 
resistance in ovarian cancer. The examination of the protein expression levels and the 
effect of knocking down the expression of upregulated proteins on drug sensitivity could 
provide useful information about their potential as biomarkers of drug resistance in ovarian 
cancer.  
All the work done in this study was based on 2D cell culture models. Cellular processes 
such as cell proliferation, migration and survival are, however, better protrayed in 3D 
culture models, which can mimic in-vivo conditions better than 2D culture models (Duval et 
al., 2017). Therefore, the work done in this study should be replicated when translated to 
3D culture models and clinical tissue samples to ensure the reliability of these biomarkers.  
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7.1 Data from the epithelial antigen staining assay 
 SKOV3 
CONTROL 
SKOV3 
CR 
OVCAR3 
CONTROL 
OVCAR3 
TaxR 
OVCAR3 
EMT-
induced 
PEO1 
CONTROL 
PEO1 
CR 
 1 TEST 5.1 3.7 17 23.8 17.5 30.9 37.4 
BLANK 1.2 1 9.6 6.5 12.8 1 1 
CHANGE 3.9 2.7 7.4 17.3 4.7 29.9 36.4 
 2 TEST 8 3.3 
 
17.8 24.5 17.1 29.9 35.5 
BLANK 1.1 1 9.4 6.7 11.9 1.1 1.1 
CHANGE 6.9 2.3 8.4 17.8 5.2 28.8 34.4 
 3 TEST 6.7 3.6 16.9 23.9 17.2 30.5 36.8 
BLANK 1.2 1.1 9.6 7 12.5 1 1.1 
CHANGE 5.5 2.5 7.3 16.9 4.7 29.5 35.7 
 
 
7.2 Data from scratch assays 
7.2.1 SKOV3 
 Mean distance moved (µm) (from three wells) 
SKOV3 Control SKOV3 Control 
- 100µM 
SKOV3 CR SKOV3 CR - 
100µm 
Assay 1 733.3 
 
508.6 
 
1087.2 
 
824.1 
 
Assay 2 969.2 
 
897.9 
 
1020.3 
 
923.8 
 
Assay 3 952.3 
 
748.7 
 
1269.3 
 
1161 
 
 
7.2.2 OVCAR3 
 Mean distance moved (µm) (from  at least two 
wells) 
OVCAR3 Control OVCAR3 TaxR 
Assay 1 401.6 
 
1042.0 
 
Assay 2 290.3 
 
674.8 
 
Assay 3 260.2 
 
518.2 
 
Assay 4 630.1 
 
812.7 
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 Mean distance moved (µm) (from at least two wells) 
OVCAR3 Control OVCAR3 Control – 
5nM 
OVCAR3 Control – 
10nM 
Assay 1 463 
 
242.9 
 
201.3 
 
Assay 2 509.7 
 
242.1 
 
238.4 
 
Assay 3 791.2 
 
501.4 
 
478.4 
 
Assay 4  649.4 536.1 
 
 Mean distance moved (µm) (from at least two wells) 
OVCAR3 TaxR OVCAR3 TaxR – 5nM OVCAR3 TaxR – 10nM 
Assay 1 1248.1 729.2 
 
698.8 
 
Assay 2 982.6 
 
865.1 
 
488.4 
 
Assay 3 1054.9 799.7 713.1 
 
 Mean distance moved (µm) (from at least two wells) 
OVCAR3 Control OVCAR3 TaxR OVCAR3 EMT-induced 
Assay 1 463 
 
1248.1 
 
889.7 
 
Assay 2 279.7 
 
620.3 
 
840.5 
 
Assay 3 295.3 
 
706.8 
 
924.5 
 
Assay 4 318 
 
686 
 
984.1 
 
Assay 5 156.1 911.7 901.3 
 
 Mean distance moved (µm) (from at least two wells) 
OVCAR3 EMT-
induced 
OVCAR3 EMT-induced 
– 5nM 
OVCAR3 EMT-induced 
– 10nM 
Assay 1 889.7 
 
712.4 
 
652.2 
 
Assay 2 840.5 
 
669.4 
 
643.4 
Assay 3 924.5 
 
818.6 
 
472.5 
 
Assay 4 984.1 
 
747.9 567.9 
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Assay 5 901.3 866.3 
 
834.9 
 
Assay 6   791.2 
 
 
7.3 All significantly upregulated genes identified in the microarray analyses 
SKOV3 carboplatin-
resistant 
OVCAR3 paclitaxel-
resistant 
OVCAR3 EMT-induced 
COL5A2 MMP3 MMP2 
TGFβ2 MST1R FN1 
SERPINE1 COL1A2 BMP7 
TFP1 DSC2 ITGAV 
TSPAN13 MAP1B TFP12 
STEAP1 TGFβ1 PTP4A1 
TMEM132A TGFβ2 VCAN 
PLEK2 VCAN WNT5B 
TGFβ1 WNT5B MAP1B 
SNAI1 WNT11 FZD7 
MMP9 KRT7 KRT7 
 ZEB2 PLEK2 
 ACTB RGS2 
 VPS13A EGFR 
 SMAD2 MST1R 
 NOTCH1 RAC1 
 RAC1 ESR1 
 RGS2  
 B2M  
 GSC  
 TMEM132A  
 ESR1  
 OCLN  
 GSK3β  
 ITGAV  
 IGFBP4  
 TMEFF1  
 FN1  
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